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Outline of the thesis 
At the end of the past century, cardiovascular diseases accounted for nearly half of deaths in 
the developed world and 25 percent in the developing world. Among cardiovascular disease 
deaths, approximately 43 percent are due to coronary artery disease, and by 2020 coronary 
artery disease will eventually become the world's number one cause of death and disability1. 
Currently, coronary revascularization is recommended to alleviate symptoms caused by 
myocardial ischemia, improve the likelihood of long-term survival and reduce the risk of 
future non-fatal cardiac events2• Approximately 60 percent of patients with symptomatic 
coronary artery disease have multivessel disease that could be treated by either percutaneous 
coronary intervention or coronary artery bypass graft surgery3. Therefore, given the 
magnitude of the problem, a better understanding of the invasive management and clinical 
outcome of patients with coronary artery disease is of critical public health importance. 
The initial description of the saphenous vein graft technique for the surgical treatment of 
coronary artery disease by Favaloro4 paved the way for a number of studies that compared 
coronary artery bypass graft surgery versus medical treatment in the 1970s. The results of 
these studies were consistent and found survival advantage only in patients with multiple risk 
factors or left main disease. Percutaneous coronary intervention was introduced into clinical 
practice by Gruentzig in 197i and compared to medical treatment in various clinical settings. 
As the procedure gained acceptance and safety, its use was also extended to many different 
groups of patients with coronary artery disease. Finally, in the late 1980s and early 1990s, 
randomized trials comparing percutaneous coronary intervention with coronary artery bypass 
graft surgery were planned and executed. The results from these studies found a similar 
prognosis and symptomatic relief for the two initial revascularization strategies. Documented 
differences between the two procedures include a lower rate of repeat revascularization in 
patients initially treated with coronary artery bypass graft surgery. 
The use of coronary stents, initially introduced by Puel and Sigwart6•7 in the late 1980s, 
rapidly gained acceptance among the interventional community. Coronary stenting was 
associated with superior and predictable angiographic results. Coronary stents also improved 
the safety of the procedure and significantly reduced the incidence of angiographic restenosis. 
This background made it necessary to re-evaluate the relative benefits of surgery and 
percutaneous coronary intervention in the stent era and second-generation trials that compared 
percutaneous coronary intervention with multiple stenting versus coronary artery bypass graft 
surgery in patients with multi vessel disease were designed and carried out8-11 . 
This thesis presents an overview of clinical trials and observational studies on coronary 
revascularization and evaluates the results obtained with revascularization in different subsets 
of patients treated with percutaneous coronary intervention or coronary artery bypass graft 
surgery. The lessons learned from these studies are presented in three parts. 
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Introduction 
Part 1: Clinical trials and observational studies on coronary revascularization 
Chapter 1 of this thesis critically investigates the clinical and angiographic outcome of 
patients with mild coronary lesions treated with balloon angioplasty or coronary stenting 
(Coronary plaque sealing, i.e. dilatation of angiographically nonsignificant lesions) compared 
to moderate and severe stenoses. 
In Chapter 2, we provide an updated quantitative analysis of the clinical outcomes of patients 
with multivessel coronary artery disease (CAD) enrolled in four contemporary trials of PCI 
with multiple stenting versus Coronary Artery Bypass Surgery (CABO): The Arterial 
Revascularization Therapies Study (ARTS)9, Stentor Surgery (SoS)10, Argentine Randomized 
Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in Multivessel 
Disease (ERACI-2)8 and Medicine, Angioplasty or Surgery Study for Multivessel Coronary 
Artery Disease (MASS-2)11 . 
Chapter 3 of this thesis provides an extensive clinically relevant description of the major 
observational studies and randomized clinical trials of coronary stenting versus bypass surgery 
carried out over the past two decades. 
In Chapter 4, we describe the 6-month clinical outcome of patients with multi vessel CAD 
and complete angiographic data enrolled in PURSUIT (Platelet Glycoprotein IIb/IIIa in 
Unstable Angina: Receptor Supression Using Integrilin Therapy) stratified according to the 
treatment strategy applied early during hospitalization (Medical treatment - PCI (Balloon) -
PCI (Stent)- CABO). 
Part 2: Predictors of adverse angiographic and clinical outcome 
In Chapter 5, we sought to assess whether coronary stents have modified the predictive value 
of demographic, clinical and quantitative coronary angiographic predictors of coronary 
restenosis identified during the balloon era. 
In Chapter 6, we evaluate the treatment of in-stent restenosis with six different modalities 
(Stent-in-stent, rotational atherectomy, balloon angioplasty, laser angioplasty, directional 
atherectomy and vascular brachytherapy) and its clinical outcome. We also pool all the 
available data from the radiation (Beta and gamma) studies for the treatment of in-stent 
restenosis. Finally, we describe preliminary data on drug eluting stents for the treatment of in-
stent restenosis. 
Restenosis and consequent adverse cardiac events are increased in diabetic patients 
undergoing percutaneous coronary intervention (PCI). Use of intracoronary stents may 
ameliorate such risks. In Chapter 7, we investigate the clinical and angiographic factors 
influencing the likelihood of restenosis following stent deployment in this high-risk patient 
subgroup. 
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Part 3: Special subgroups on coronary revascularization 
Obesity is considered one of the major modifiable risk factors for coronary heart disease. 
However, the impact of BMI on the outcomes after coronary artery revascularization remains 
controversial. In Chapter 8, we describe the impact of body mass index on the long-term 
outcomes in patients with multivessel coronary artery disease randomized to either stenting or 
coronary artery bypass surgery (CABG). 
Chronic renal insufficiency (CRI) is associated with adverse outcomes after CABG and PCL 
In Chapter 9, using data from the Arterial Revascularization Therapies Study (ARTS), we 
evaluate the effect of CRI on outcomes after coronary revascularization and we compare the 
outcomes of patients with CRI who were randomly assigned to CABG or PCL 
In Chapter 10, we assess the effect offluvastatin on the outcome of patients with or without 
renal dysfunction in the Lescol Intervention Prevention Study (LIPS). Additionally, we 
evaluate the effect of fluvastatin on renal function and the relation between changes in renal 
function on the incidence of adverse cardiovascular events. 
Finally, Chapter 11 evaluates the impact of the extent of angiographic coronary artery disease 
(single- or multivessel) and of fluvastatin treatment on the incidence of late cardiac 
atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS). 
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Aims To investigate the clinical and angiographic outcome of patients with mild 
coronary lesions treated with balloon angioplasty or coronary stenting (coronary 
plaque sealing, i.e. dilatation of angiographically non-significant lesions) compared to 
moderate and severe stenoses. 
Methods and results Patients with chronic stable angina and a single de novo lesion in 
a native coronary vessel scheduled to undergo percutaneous coronary intervention 
(PCI) were selected from 14 different studies. Off-line analysis of angiographic 
outcomes was assessed in all patients using identical and standardised methods of 
data acquisition, analysis and definitions. Clinical endpoints were adjudicated by 
independent clinical events committees. All quantitative coronary angiographic (QCA) 
analyses were performed in the same core laboratory. Stenosis severity prior to PCI 
was categorised into three groups: <50% diameter stenosis (DS), 50-99%DS and >99%DS 
pre. A total of 3812 patients were included in this study; 1484 patients (39%) were 
successfully treated with balloon angioplasty (BA) only and stented angioplasty was 
performed in 2328 patients (61%). 
One-year mortality and rate of non-fatal myocardial infarction (MI) (Kaplan-Meier) 
did not differ between BA and stented angioplasty for any of the stenosis severity 
categories. Following BA, the combined event rate (death and non-fatal Ml) was 4.8, 
4.6 and 0% in the <50, 50-99 and >99%DS categories, respectively. Following stented 
angioplasty, the combined event rate was 3.1, 4.4 and 4.8% in the same categories. 
The need for repeat revascularisation corrected for stenosis severity in the Cox 
proportional-hazards regression model was reduced by 20% after stented angioplasty 
(hazard ratio (HR) 0.80, 95%CI 0.69-0. 93). 
* Corresponding author. Clinical Epidemiology Unit, Room H-543, Department of Cardiology, Thoraxcentre, University Hospital 
Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. Tel.: +31-10-463-3909; fax: +31-10·4089484 
E-mail address: boersma@thch.azr.nl (E. Boersma). 
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Chapter 7 
Conclusion The concept of plaque sealing is appealing from the theoretical point of 
view. However, with current technology, plaque sealing cannot prevent death and 
future non-fatal Mls in the long-term because 1-year event rates after PCI of 
non-significant stenoses remain unacceptably elevated when compared with the 
estimated 1-year probability of a non-fatal Ml in lesions with a <50%DS. Moreover, 
major adverse cardiac events at 1-year after PCI are not directly related to the degree 
of pre-procedural stenosis severity. 
© 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All 
rights reserved. 
Introduction 
Revascularisation by percutaneous coronary inter-
vention (PCI) is performed to relieve symptoms in 
patients with coronary artery disease and angie-
graphically significant coronary stenosis. However, 
coronary stenoses vary in severity and even mild 
stenoses harbour an unpredictable risk of acute 
occlusion that may cause myocardial infarction (MI) 
and sudden death. Balloon angioplasty typically 
induces plaque splitting which engenders a tissular 
reaction covering the plaque. The smooth muscle-
rich neointima later transforms into a collagen-rich 
layer, which results in plaque sealing. Thus, once 
the acute effect of vessel trauma with its inherent 
risk of abrupt occlusion has passed, the subsequent 
risk of acute occlusion of a sealed plaque should be 
markedly reduced thanks to the repaired fibrous 
cap, which has overgrown the inflicted wound. 1•2 
Therefore, plaque sealing by balloon angioplasty 
has been advocated to prevent acute cor-
onary events in patients with angiographically 
non-significant coronary lesions. 3 
Endorsing this concept and recommending PCI for 
angiographically non-significant lesions would mean 
a potentially large increase in procedures that needs 
sound justification. So far, the plaque-sealing con-
cept has not been tested in prospective randomised 
clinical trials. A few observational case series from 
single centre experiences4•5 have cautioned against 
the use of BA in non-significant lesions. We there-
fore aimed to investigate the clinical and angie-
graphic outcome of coronary plaque sealing, i.e. 
dilatation of angiographically non-significant 
lesions compared to moderate and severe stenoses, 
selected from a large cohort of registries and clinical 
trials of patients undergoing PCI. 
Methods 
Patient selection 
Patients with chronic stable angina and a single de 
novo lesion in a native coronary vessel scheduled to 
undergo PCI were selected from 14 different 
studies: two placebo-active randomised trials 
22 
aimed at coronary restenosis prevention after bal-
loon angioplasty (BA) alone or with additional 
stenting (FLARE6 and TRAPIST7), nine stent regis-
tries (BENESTENT-2 Pilot, 8 WEST-1 ,9 WEST-2, 10 
Wellstent Native, 11 ROSE, 12 DUET, 13 EASI, 14 
SOPHOS15 and MAGIC 5-L16), two randomised trials 
comparing coronary stenting against BA alone 
(BENESTENT-1 17 and BENESTENT-218) and the intra-
vascular ultrasound (IVUS) substudy of a ran-
demised clinical trial that evaluated the safety and 
efficacy of long-term treatment with an oral GP 
lib/Ilia inhibitor in patients undergoing PCI 
(EXCITE19). A general description of these studies 
and the individual contribution of each clinical trial 
and registry, in terms of the number of single-lesion 
patients with chronic stable angina selected for this 
analysis is depicted in Table 1. 
These studies are considered representative of 
the current practice of PCI but antedated the use 
of intracoronary brachytherapy and drug-eluting 
stents. Off-line analysis of angiographic outcomes 
was assessed in all patients using identical and 
standardised methods of data acquisition, analy-
sis and definitions of the variables in the same 
core laboratory (Cardialysis, Rotterdam, The 
Netherlands) using the Cardiovascular Angiogra-
phy Analysis System II (CAAS II) (Pie Medical, 
Maastricht, The Netherlands). 
Patients were included if they had three 
adequate angiograms, one immediately before the 
intervention, one immediately after and one at 
6-month follow-up. Patients with an unsuccessful 
procedure or patients with treated saphenous vein 
grafts were excluded. 
Clinical endpoint definition 
Clinical endpoints were uniformly defined across 
the different trials and registries as follows. Death 
was defined to include all deaths, regardless of 
cause. However, for the purposes of this study, only 
cardiac deaths were considered in the analysis of 
clinical events and any death was considered of 
cardiac origin unless unequivocally proven other-
wise. Non-fatal Ml was diagnosed if there were new 
Table 1 General overview of randomised clinical trials and device registries 
Acronym-year Study Type of study Treatment for Objective 
single-lesion patients 
BA Coronary 
stenting 
BENESTENT-1-1994 BElgian NEtherlands STENT Randomised PTCA vs Stent 258 262 Evaluation of long-term angiographic and clinical 
outcomes of coronary stenting compared to standard 
PTCA 
BENESTENT-2 BElgian NEtherlands STENT-2 Pilot Stent registry 1 202 Determine the safety of elective implantation of a 
Pilot-1996 heparin-coated Palmaz-Schatz stent in patients with a 
single de novo lesion in a native coronary artery 
WEST-1-1997 West European Stent Trial Stent registry 2 85 Safety and efficacy of ACS Multi-Link coronary stenting 
in patients with chronic stable angina due to a single 
lesion in a native coronary artery 
WEST-2-1998 West European Stent Trial2 Stent registry 0 165 Assess the use of aspirin alone following successful 
implantation of an ACS Multllink-Stent under IVUS and 
QCA guidance in patients with chronic stable or 
unstable angina 
BENESTENT-2-1998 BElgian NEtherlands STENT-2 Randomised PTCA vs Stent 379 276 Compare event-free survival in patients after 
heparin-coated stent implantation plus antiplatelet 
therapy with standard balloon angioplasty 
FLARE-1999 Fluvastatin Angiographic REstenosis Randomised active treatment vs 713 0 Evaluate the ability of Fluvastatin to reduce restenosis 
placebo after successful PTCA 
Wellstent Wellstent native study Stent registry 0 55 Assess the safety and efficacy of the self-expanding 
Native-1999 Wallstent in patients with stable or unstable angina 
ROSE-2000 Registry for Optimal beStent Stent registry 0 66 Assess the procedural safety of beStent Brava 
Evaluation implantation, 6-month angiographic and 12-month 
clinical outcomes of this population 
DUET-2000 Evaluation of the ACS-Multi-Link DUET Stent registry 0 113 Assess the safety and efficacy of the ACS Multi-Link 
coronary stent system DUET coronary stainless steel balloon-expandable stent 
SOPHOS-2000 Study Of Phosphorylcholine coating On Stent registry 0 241 Assess the safety and efficacy of the BiodivYsio stent 
Stents 
EXCITE-2000 Evaluation of oral Xemilofiban in Randomised active treatment vs 131 430 To evaluate whether long-term Administration of a 
Controlling Thrombotic Events placebo glycoprotein lib/lila receptor antagonist would provide 
sustained protection from death, Ml, and the need for 
urgent revascularisation 
EASI-2001 European Antiplatelet Stent Stent registry 0 113 Assess event-free survival after implantation of the 
Investigators Cordis coil cross-flex stent 
MAGIC-5L-2001 MAGIC-5L Study Stent registry 0 136 Assess the safety and efficacy of 5 different lengths of 
the self-expanding Magic Wallstent 
TRAPIST -2001 Trapidil on restenosis after stenting Randomised active treatment vs 0 184 Assess the safety and efficacy of Trapidil (PDGF and 
placebo Thromboxane A2 synthetase inhibitor) in restenosis 
prevention after coronary stenting 
N 
0:l 
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pathologic Q waves (>0.04 s) with a depth of more 
than one quarter of the corresponding R-wave 
amplitude in two or more contiguous leads con-
sidered by the investigator as not present at study 
inclusion20 or if there was an increase in serum 
creatine kinase (CK) to more than twice the normal 
value, together with a pathological increase in 
muscle brain creatine kinase (CK-MB) iso-enzyme. If 
CK-MB data were not available, CK values were 
accepted as sufficient evidence of MI. These 
enzymes were measured per protocol at screening, 
6 h before and 12 h after intervention. Repeat 
revascularisations (by CABG or repeat PCI) were 
defined as those involving a previously treated 
vessel between the initial procedure (considered 
complete when the guiding catheter was removed 
from the arterial sheath) and 1-year. 
The primary clinical endpoint of this study was 
cardiac death and the combined rate of death 
and non-fatal MI. Secondary combined endpoint 
included the rate of repeat revascularisation. 
QCA analysis and angiographic endpoints 
The standard definitions used in this study for QCA 
variables: vessel size, pre-procedural minimal lumi-
nal diameter (MLD pre), post-procedural minimal 
luminal diameter (MLD post), minimal luminal 
diameter at 6-month follow-up (MLD f-up), 
diameter stenosis greater than 50% at 6-month 
follow-up (DS >50% at 6-month), acute gain, late 
loss and loss index have been described else-
where. 21 •22 The pre-procedural reference diameter 
(RD pre) was the diameter obtained by an inter-
polated method and the lesion length was defined 
by the curvature analysis. 21 
Data analysis 
Data was divided into quintiles according to the 
degree of severity of pre-procedural diameter 
stenosis (DS pre) as assessed by QCA and based on 
the definitions used in the CASS registry study.23 
Separate baseline, QCA and clinical endpoint analy-
ses were performed in patients treated with 
balloon angioplasty only (BA group) and patients in 
whom coronary stents were implanted (stent 
group). Because the event rates for BA and stent 
groups were similar for patients in the middle three 
quintiles (50-69, 70-89 and 90-99%DS), we com-
bined the middle three quintiles into a single group 
(50-99%DS). Therefore, stenosis severity was cat-
egorised into three groups as follows: <50, 50-99 
and >99%DS pre. 
The statistical analysis was performed using the 
SAS 8.0 software package (SAS Institute, Cary, NC). 
24 
Quantitative values were given as median (25th, 
75th percentiles) or mean±standard deviation. To 
test for differences in categorical variables the 
Fisher's exact test was applied and to test for 
differences in continuous baseline variables across 
the studies, the Kruskal-Wallis test was used. 
Event rate curves were constructed by means of 
Kaplan-Meier methods, and event rate differences 
between the three groups of stenosis severity were 
compared with the use of the log-rank testY The 
Cox proportional-hazards regression model was 
used to examine the effect of coronary stenting on 
the primary and secondary clinical endpoints of this 
study, corrected for stenosis severity (<50, 50-99 
and >99%DS pre). Statistical significance was 
inferred at P<0.05. 
Results 
A total of 3812 patients with chronic stable angina 
and a single coronary lesion in a native vessel were 
included in this study; 1484 patients (39%) were 
successfully treated with BA only and stented 
angioplasty was performed in 2328 patients (61%). 
Comparisons between the three groups of stenosis 
severity (<50, 50-99 and >99%DS pre) were sum-
marised for baseline characteristics, angiographic 
and clinical outcomes for BA and Stent groups in 
Tables 2--4 and Figs. 1-3. 
Baseline clinical characteristics 
BA group 
The three groups of patients with varying degrees 
of stenosis severity were similar with regard to age, 
gender, height, weight, history of hypertension, 
diabetes mellitus, peripheral vascular disease, pre-
vious bypass surgery (CABG), smoking status and 
treated vessel. 
Baseline comparisons between the three groups 
that were statistically different included: history of 
prior Ml, previous PCI and multiple vessel disease 
(MVD). History of prior Ml was more frequent in the 
<50%DS category, whereas MVD occurred more 
often in the intermediate and highest categories of 
stenosis severity. A significant decreasing trend in 
the percentage of patients with a previous angio-
plasty was observed in 12.4, 7.5 and 2.4% in the 
<50, 50-99 and >99%DS categories, respectively 
(Table1). 
Stent group 
The three different groups of patients with varying 
degrees of stenosis severity were similar with 
regard to age, gender, height, weight, history of 
1\.) 
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Table 2 Baseline characteristics 
Balloon angioplasty population Stent population 
<50% DS pre 50-99% DS pre >99% DS pre P-value <50% DS pre 50-99% DS pre 
(n=124) (n=1266) (n=94) (n=96)) (n=2128) 
Age, 60 (52, 68) 60 (52, 67) 59 (51,65) 0.356 60 (52, 69) 60 (52, 66) 
Men,% 78 81 85 0.458 78 80 
Height, em 170 (164, 175) 170 (165, 176) 170 (165, 180) 0.355 170 (164, 177) 171 (165, 176) 
Weight, kg 76 (69, 84) 78 (70, 85) 80 (74, 89) 0.096 77 (70, 85) 78 (70, 86) 
History 
Hypertension, % 37 36 34 0.914 37 37 
Diabetes mellitus, % 6.6 7 9.7 0.593 14 12 
Ml,% 40 27 34 0.009 30 29 
PVD,% 7.4 5.6 4.8 0.659 3.2 6.5 
Angioplasty, % 12.4 7.5 2.4 0.029 11 10 
Bypass surgery, % 2.4 3.4 0 0.258 3.2 2.8 
Smoking status, % 
Current 26 28 27 0.835 30 28 
Prior history 49 48 46 0.874 41 48 
MVD,% 2.5 8 3.6 0.035 26 23 
Vessel treated, % 
RCA 26 27 28 0.936 21 36 
LAD 52 47 36 0.086 63 46 
LCx 21 26 35 0.061 15 17 
Data presented are median (25th, 75th percentiles) or percentages. 
Ml=prlor history myocardial infarction; PVD=peripheral vascular disease; MVD=multiple vessel disease; DS pre= pre-procedural diameter stenosis. 
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Table 3 Pre-procedural, post-procedural and 6-month follow-up QCA analysis of treated lesions 
Balloon angioplasty population Stent population 
<50% DS pre 50--99% DS pre >99% DS pre P-value <50% DS pre 50--99% DS pre >99% DS pre P-value 
(n=124) (n=1266) (n=94) (n=96) (n=2128) (n=104) 
Vessel size, mm 2.61 (2.3, 2.85) 2.78 (2.47, 3.14) 2.47 (2.23, 2.79) <0,0001 2.75 (2.52, 3.14) 2. 91 (2.64, 3.25) 2.96 (2.7, 3.37) 0.006 
Lesion length, mm 6.89 (5. 59, 8.03) 7.48 (6.01, 9.48) 7.86 (6.33, 9.79) 0.009 6.74 (5.55, 8.81) 8.15 (6.48, 10. 3) 17.4 (12, 25.8) <0,0001 
MLDpre, mm 1.4 (1.24, 1.62) 1.01 (0.85, 1.18) 0 (0, 0) <0,0001 1.53 (1.36, 1.68) 1.01 (0.86, 1.18) 0 (0, 0) <0.0001 
MLD post, mm 1.86 (1.61, 2.16) 1.93 (1.68, 2.22) 1.7 (1.47, 1.89) <0.0001 2.62 (2.3, 2.93) 2.64 (2.39, 2.91) 2.46 (2.2, 2.7) 0.0002 
MLDf-up, mm 1.7 (1.35, 2) 1.62 (1.25, 1. 98) 1.24 (0.73, 1.73) <0.0001 1.89 (1.52, 2.37) 1.88 (1.44, 2.27) 1.6 (1, 1.98) <0.0001 
DS >50% at 6-month f-up, % 24 30 44 0.008 19 21 32 0,005 
Acute gain 0.45 (0.29, 0.6) 0.9 (0.67, 1.14) 1.7 (1.47, 1.89) <0.0001 1.1 (0.88, 1.28) 1.6(1.35, 1.86) 2.46 (2.2, 2.69) <0.0001 
Late loss 0.19 (-0.09, 0.5) 0.25 (-0.02, 0.6) 0.41 (0.04, 1.03) 0.002 0.69 (0.42, 1.1) 0.74 (0.42, 1.1) 0.9 (0.54, 1.34) 0.024 
Loss index 0.44 (-0.1 5, 1.07) 0.28 (-0.02, 0.67) 0.25 (0.02, 0.58) 0.171 0.59 (0.42, 1.01) 0.46 (0.26, 0.72) 0.37 (0.21, 0.5) <0,0001 
Data presented are median (25th, 75th percentiles) or mean±standard deviation. 
MLD pre=pre-procedural minimal luminal diameter; MLD post=post-procedural minimal luminal diameter; MLD f-up=minimalluminal diameter at 6-month follow-up; acute gain= 
MLD post-MLD pre; late loss=MLD post-MLD f-up; loss index=acute gain/late loss± DS pre=pre-procedural diameter stenosis. 
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Clinical and angiographic outcome of patients with mild coronary lesions 
Table 4 Frequency of clinical end-points in descending order of severity 
Balloon angioplasty population 5tent population 
<50%05 pre 50-99%05 pre >99%05 pre <50%05 pre 50-99%05 pre >99%05 pre 
(n=124) (n=1266) (n=94) (n=96) (n=2128) (n=104) 
Cardiac death 3 (2.4) 12 (0.9) 0 (0) 0 (0) 19 (0.9) 1 (1) 
Non-fatal Ml 3 (2.4) 48 (3.8) 0 (0) 3 (3.1) 79 (3.7) 4 (3.8) 
Repeat revascularisation (CABG 23 (18.5) 268 (20.7) 28 (29.7) 18 (18.7) 308 (14.5) 20 (19.2) 
or Re·PCI) 
Cardiac death or non-fatal Ml 6 (4.8) 59 (4.6) 0 (0) 3 (3.1) 95 (4.4) 5 (4.8) 
Cardiac death, non-fatal Ml or 26 (21) 301 (24) 28 (29.7) 18 (18.7) 365 (17) 23 (22) 
repeat revascularisation 
Any event 29 (23) 328 (26) 28 (29.7) 21 (22) 406 (19) 25 (24) 
Ml, acute myocardial infarction; repeat revascularisation includes coronary artery bypass graft (CABG) surgery and 
percutaneous coronary intervention (PCI). Log-Rank test comparing the three categories of stenosis severity at 1·year was: 
cardiac death (BA, 3.41; P=0.18; stent, 0.78; P=0.67); non-fatal Ml (BA, 4.65; P=0.9; stent, 0.01, P=0.99) and cardiac death 
or non-fatal Ml (BA, 4. 97; P=0.83; stent, 0.197; P=O. 90). OS pre= pre-procedural diameter stenosis. 
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Fig. 1 One-year event rate curves for patients treated with balloon angioplasty and varying degrees of stenosis severity measured by 
QCA. Left: event rate curves for repeat revascularisation (CABG or Re·PCI). Right: event rate curves for death, non·fatal Ml or repeat 
revascularisation (CABGIRe-PCI). <50%05 pre=<SO% pre-procedural diameter stenosis; 50-99%05 pre=50-99% pre-procedural diameter 
stenosis, >99%05 pre=>99% pre-procedural diameter stenosis. QCA=quantitative coronary angiography; Ml=myocardial infarction; 
PCI= percutaneous coronary intervention; CABG=coronary artery bypass graft surgery. 
hypertension, diabetes mellitus, peripheral vascu· 
lar disease, previous PCI, CABG, smoking status and 
treated vessel. Baseline comparisons between the 
three groups that were statistically different 
included: previous Ml and a treated lesion located 
in the LAD. A previous Ml was more frequent in the 
>99%DS category whereas mild lesions where most 
often treated while located in the LAD (Table 2). 
Baseline, post-procedural and 6-month 
follow-up QCA 
Several angiographic variables were highly corre· 
lated with the degree of stenosis severity (Table 3). 
Lumen and vessel dimensions were smaller as 
the stenosis severity progressed. The acute gain 
increases with increasing stenosis severity as does 
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Stent population 
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Fig. 2 One-year event rate curves for patients treated with coronary stenting and varying degrees of stenosis severity measured by 
QCA. Left: event rate curves for repeat revascularisation (CABG or Re-PCI). Right: event rate curves for death, non-fatal Ml or repeat 
revascularisation (CABG/Re-PCI). <50%DS pre=< 50% pre-procedural diameter stenosis, 50-99%05 pre=S0-99% pre-procedural diameter 
stenosis, 99%DS pre=>99% pre-procedural diameter stenosis. QCA=quantitative coronary angiography; Ml=myocardial infarction; 
PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft surgery. 
the late loss, but the loss index diminished with 
increased stenosis severity. A significant and direct 
relationship between stenosis severity, lesion 
length and 05>50% at 6-month follow-up was 
observed across the three categories (<50, 50-99 
and >99%05) for both BA and stented patients. 
Clinical endpoints at 1 year 
BA group 
The incidence of cardiac death and non-fatal Ml was 
not different between the <50, 50-99 and >99%05 
groups (Table 4). Repeat revascularisation (CABG or 
Re-PCI) occurred in 18.5% of patients in the <50%05 
group, 20.7% patients in the 50-99%05 group and 
29.7% patients in the >99%05 group (Table 4). 
Stent population 
The incidence of cardiac death and non-fatal Ml did 
not differ with stenosis severity (Table 4). Repeat 
revascularisation (CABG or Re-PCI) occurred in 
18.7% of patients in the <50%05 group, 14.5% 
patients in the 50-99%05 group and 19.2% patients 
in the >99%05 group (Table 4). 
Event-rate analysis for BA and stent populations 
The log-rank test did not reveal a statistically 
significant difference in the event-rates over time 
among the subgroups of increasing stenosis severity 
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(Table 4, Figs. 1 and 2). The primary event rate 
(cardiac death, death or Ml) following BA or stent-
ing of angiographically non-significant stenoses was 
equivalent to the event rate observed after BA or 
stenting of angiographically significant stenoses. 
Irrespective of stenosis severity, death or non-fatal 
Ml at 1 year occurred in nearly 5% of both BA and 
stent cases. A significant difference (Fig. 3) in 
favour of coronary stenting (corrected for stenosis 
severity) was observed with respect to the need for 
repeat revascularisation (HR 0.80; 95% Cl 0.69-
0. 93) and the combined clinical end-point of 
cardiac death, non-fatal infarction or repeat 
revascularisation (HR 0.83; 95% Cl 0.72-0.96). 
Discussion 
Our findings indicate that event rate at 1 year is 
substantial (over 20%) when angiographically non-
significant stenoses (<50%05) are treated by BA or 
stenting. In fact, the event rate after PC! was not 
related to stenosis severity. Originally, the concept 
of plaque sealing was intended to be applied with 
BA, which is no longer realistic since current 
practice involves stent implantation in over 70% of 
PCI procedures. 25 Therefore, the concept was 
extended to the use of stents, hoping this would 
improve the outcome. Even after implantation of 
Clinical and angiographic outcome of patients with mild coronary lesions 
Cardiac Death 
Non fatal myocardial infarction 
Repeat revascularisation 
(CABG or repeat PCI) 
Cardiac Death or non fatal 
myocardial infarction 
Cardiac Death, non fatal 
Myocardial infarction or repeat 
revascularisation 
0 0.5 
Stent 
---
--
1 1.5 2 2.5 
Ballon Angioplasty 
Fig. 3 HR for clinical endpoints. HR are shown with 95% CJ. HR with upper confidence limits that are less than 1 represent a benefit 
with the use of coronary stents. Point estimates and CJ have been corrected for pre-procedural stenosis severity (<50, 50-99 and 
>99%DS pre). 
currently available stainless steel stents, the event 
rate remained as high as 22% at 1 year. The present 
data argue against the performance of PCI on angie-
graphically non-significant stenoses because high 
short-term event rates outweigh any hypothetical 
long-term benefit that might be derived from this 
type of intervention. 
Similar conclusions could be drawn from previ-
ously published studies. Based on the Coronary 
Artery Surgery Study (CASS) registry data,23 the 
estimated 1-year probability of an anterior Ml in 
LAD lesions with a <SO%DS is 0.6% and 2.2% in lesions 
between 50 and 70%DS. In the present study, the 
observed non-fatal Ml rate after PCI of non-
significant stenoses was four- to fivefold greater 
than the estimated spontaneous risk in the first and 
two-fold in the latter group. 
The first report of BA in mild lesions was 
published 19 years ago by lschinger et aL4 Patients 
with chronic stable angina pectoris poorly control-
led by previous medical treatment in whom <60%DS 
were dilated (n=64) were compared with a random 
sample of patients in whom >60%DS were dilated. 
After a mean follow-up of 7 months, these investi-
gators cautioned against the application of BA in 
patients with mildly diseased vessels due to the 
high incidence of periprocedural Ml (6.2% vs 0% in 
>60%DS, P<O.OS) and restenosis (29%). 
A decade later, data from Hamon et aL 5 pro-
vided additional evidence for this point of view. 
Angiographic outcome from 26 patients in whom 
dilated lesions were <50%DS (n=29) was disappoint-
ing compared to lesions >50%DS (n=32). When mild 
stenoses were treated by BA, the DS at follow-up 
(40%) was the same as the DS prior to BA (42%). No 
net angiographic benefit was obtained because 
some non-significant lesions became significant at 
6 months. 
In the DEFER trial,26 patients with chest pain and 
an angiographic stenosis but without objective 
documentation of ischaemia by non-invasive test-
ing, were randomised to deferral or performance of 
PCI based on the results of the fractional flow 
reserve (FFR) of the target lesion prior to interven-
tion. Two-year event rates for death, non-fatal Ml, 
and repeat revascularisation were 1.1, 3.3 and 7.8% 
in the perform group, which was not different from 
2.2, 0 and 5.6% in the defer groups. This proved 
that there is no clinical benefit of PCI for non-
significant stenoses at 2 years. It remains possible 
that a benefit will develop later and that deferred 
intervention needs to be performed subsequently, 
thereby reducing the percentage of patients spared 
the procedure. 
The incidence of hard endpoints (cardiac death 
and Ml) is comparable between our series and 
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the performance group of the DEFER trial. The 
increased rate of repeat revascularisation in our 
series is due to the fact that protocol-driven angi-
ography was applied in all patients at 6 months. 27 
This is obvious from Figs. 1 and 2 in which most 
revascularisation events occurred at 6 months. It 
has been well documented that when repeat 
angiography is guided by clinical symptoms rather 
than per protocol, the rates of repeat revascular-
isation decrease. 18 
Limitations 
It should be stressed that the present results were 
gathered from multiple, high-performance, inter-
national sites and that the data collection was 
performed under rigorous control (common defini-
tions, use of individual case record forms, inde-
pendent data monitoring and source verification). 
The observed event rates may still represent a 
biased underestimation of the results obtainable in 
the 'real world'. 
In this retrospective analysis, event rates were 
limited to a 1-year follow-up period. We also lack 
data from a control group, patients with <50% DS 
medically treated and followed over time. Further-
more, all these studies were conducted before the 
introduction of glycoprotein lib-lila inhibitors, 
which could have decreased event rates in the 
study groups. 
We realize that any potential benefit of plaque 
sealing will only become evident in the long-term. 
However, the trade-off between high short-term 
event rates and long-term benefit appears to be 
unfavourable. This balance may be reverted with 
improved procedural and short-term results. The 
introduction of glycoprotein lib-lila inhibitors has 
significantly decreased the incidence of non-fatal 
periprocedural Ml. 28 Likewise, restenosis could be 
virtually eliminated in the near future with the use 
of drug-eluting stents, as suggested by recently 
published data. 29 The evaluation of plaque vulner-
ability by IVUS imaging30 or temperature measure-
ments31 may help to identify which patients are at 
increased risk and may benefit the most from 
mechanical plaque sealing. 32 When this new thera-
peutic armamentarium is at hand, the concept of 
plaque sealing will need to be revisited and may 
become clinically viable. Until such evidence 
eventually becomes available, one should refrain 
from dilating non-significant stenoses. 
Conclusion 
The concept of plaque sealing is appealing from 
the theoretical point of view. However, with the 
30 
currently available technology, its clinical goals 
(prevention of death and Ml in the long-term) 
cannot be reached because 1-year event rates 
after PCI of non-significant stenoses still are 
unacceptably high. 
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ABSTRACT: 
Background: The combined evidence comparing percutaneous coronary intervention 
(PCI) with coronary artery bypass graft (CABG) surgery suggest a similar prognosis for 
these two initial revascularisation strategies. Documented differences between the two 
procedures include a lower rate of angina and repeat revascularisation in patients initially 
treated with CABG. Our aim was to provide an updated quantitative analysis of the 
clinical outcomes of patients with multivessel coronary artery disease (CAD) included in 
contemporary trials ofPCI with multiple stenting versus CABG. 
Methods: We composed an individual patient database on 3051 patients of four trials 
(ARTS, SoS, ERACI-2 and MASS-2) that compared PCI with multiple stenting (n=l518) 
versus CABG (n=l533). The primary clinical endpoint of this study was the combined 
rate of death, non-fatal MI or stroke at one year. Secondary combined endpoints included 
death and the rate of repeat revascularisation at one year. All analyses were based on the 
intention to treat principle. 
Results: After one year of follow-up, 132 (8.7%) ofthose randomised to stenting versus 
140 (9 .1%) of those randomised to CABG reached the primary clinical endpoint 
(Adjusted Hazard Ratio=0.95 [95%CI 0.74-1.23], p=0.71). Mortality was similar in both 
groups (PCI 3% [n=46], CABG 2.8% [n=43]; Adjusted HR=1.02 [95%CI 0.64-1.60], 
p=0.93). Repeat revascularisation procedures occurred more frequently in the PCI as 
compared to the CABG group (PCI 18% [n=272], CABG 4.4% [n=68]; Adjusted 
HR=4.42 [95%CI 3.33-5.87], p<O.OOOl). 
Conclusions: After one year of the initial procedure, PCI with multiple stenting and 
CABG provided a similar degree of protection against death, non-fatal MI or stroke for 
patients with multivessel CAD. Repeat revascularisation procedures remain higher in PCI 
with stenting as compared to CABG. 
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INTRODUCTION 
At the end of the past century, cardiovascular disease (CVD) accounted for nearly half of 
deaths in the developed world and 25 percent in the developing world. Among CVD 
deaths, approximately 43% are due to coronary artery disease (CAD), and by 2020 CAD 
will eventually become the world's number one cause of death and disability1. 
Approximately 60 percent of patients with CAD have multivessel disease that could be 
treated by either percutaneous coronary intervention (PCI) or coronary artery bypass graft 
(CABG) surgeif. Therefore, given the magnitude of the problem, a better understanding 
of the invasive management and clinical outcome of patients with CAD is of critical 
public health importance. 
The last two decades witnessed major advances in coronary revascularisation techniques 
for CAD and several randornised clinical trials compared percutaneous transluminal 
coronary angioplasty (PTCA) against CABG surgery for the treatment of CAD3-10. 
Additionally, three systematic overviews of these trials, one11 with information gathered 
in a standard proforma from every principal investigator and two with data extracted 
from the published literature with intermediate12 and long term follow-up outcomes13, 
have also been reported. However, these studies were designed in the late 80s, conducted 
and reported in the early 90s and since then, major technological advances have been 
achieved in both PCI and CABG surgery. The results from trials that antedated the stent 
era are not reflective of the current practice of coronary revascularisation since coronary 
stents are implanted in approximately 80% of all percutaneous coronary interventions 
nowadays14. 
A systematic overview with individual patient data from contemporary clinical trials 
comparing PCI with multiple stenting against CABG surgery will provide the clinician 
caring for patients with multivessel CAD with precise treatment effect estimates and 
more robust and reliable data regarding the advantages and drawbacks of each treatment 
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strategy. The timing of this analysis is also advantageous, as it provides baseline data for 
comparisons with the results of drug-eluting stents in similar patients. 
METHODS 
There are substantial differences between meta-analyses of the literature and meta-
analyses of individual patient data15•16. The most important reason for these differences is 
that meta-analyses of individual patient data are based on a time to event analysis, 
whereas meta-analyses of the literature are based on endpoint analysis at a specific point 
in time17. Results obtained from meta-analyses of individual patient data offer least 
biased and more reliable treatment effect estimates due to the flexibility and extent of 
analyses that can be done in subgroups and whenever possible, should be preferred over 
meta-analyses of the literature. 
Selection of patients and data management 
We intended to include all major contemporary randomised clinical trials that compared 
PCI with stenting versus CABG in patients with multiple vessel CAD. To identify 
eligible trials we did a MEDLINE search using the keywords "coronary stenting", 
"coronary artery bypass surgery" and "multivessel disease". Furthermore, we examined 
the reference lists of identified articles, as well as the scientific sessions abstracts in 
Circulation, Journal of the American College of Cardiology and European Heart 
Journal. Five trials were identified: ARTS (Arterial Revascularisation Therapies 
Study)18, SoS (Stent or Surgery)19, ERACI-2 (Argentine Randomised Study: Coronary 
Angioplasty with Stenting versus Coronary Bypass Surgery in Multivessel Diseasei0, 
MASS-2 (Medicine, Angioplasty or Surgery Study for Multivessel Coronary Artery 
Disease )21 and A WE SOME (Angina With Extremely Serious Operative Mortality 
Evaluation) triaf2 . There were substantial differences in trial design. ARTS and SoS were 
multinational studies, ERACI-2 was multicentre and MASS-2 was single centre. The 
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patient population of these trials also differed in terms of comorbidity, coronary anatomy 
and periprocedural risk. In ARTS, high-risk patients were excluded and approximately 
two thirds of the patients enrolled had two-vessel disease. SoS had fewer restrictions on 
case selection, few rules on how the procedure was to be performed, and little 
specifications regarding adjunctive therapy. In ERACI-2, the study population was 
composed predominantly by patients with unstable angina and patients with left main 
stenosis judged to be good candidates for stenting were included (approximately 5%). 
Finally, MASS-2 trial included a slightly higher number of diabetics and patients with 3-
vessel disease than the other 3 trials. We excluded the medical treatment arm from 
MASS-2 and specifically, did not include the AWESOME trial22, a major study that 
compared long-term survival among patients assigned to either CABG or PCI with 
medically refractory myocardial ischaemia and high risk of adverse outcomes. 
Approximately 80% of the patients enrolled in this study had multiple vessel disease. 
Patients with prior heart surgery, ongoing or very recent MI and left ventricular ejection 
fraction <35% were included in A WE SOME and this type of patients is clearly different 
from the patient population of the four other trials included in this meta-analysis in which 
all previously mentioned variables were considered as exclusion criteria. 
Each principal investigator was contacted and individual patient data was requested 
regarding baseline demographics, clinical characteristics, use of cardiac medications at 
screening, status of coronary anatomy at baseline angiography, ejection fraction, 
allocated treatment strategy (coronary stenting or CABG), date of randomisation, dates of 
scheduled and actual end of treatment, total number of successfully dilated lesions per 
patient, total number of stents implanted in each patient, total number of anastomoses and 
conduits per patient, completeness of revascularisation, use of platelet glycoprotein 
IIb!IIIa inhibitors as adjuncts to PCI, outcome events of interest limited to one year 
follow-up included death, myocardial infarction (MI), stroke, repeat revascularisation 
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(PCI or CABG); and anginal status at one-year. Data was transferred in electronic format 
to the coordinating centre, Clinical Epidemiology Unit, Thoraxcenter, Rotterdam, the 
Netherlands. Rigorous checks for data completeness, consistency and agreement with the 
main published reports were performed and finally an electronic database was composed 
consisting of individual patient data of all four trials. Table 1 shows the design 
characteristics of the four trials included in this meta-analysis. 
Definitions of variables and clinical end points 
We found substantial heterogeneity in clinical endpoint definitions in ARTS, SoS, 
ERACI-2 and MASS-2. However, when pooling the data and with the knowledge that 
heterogeneity in endpoint definitions across trials will not lead to biased results23 , we did 
not attempt to retrospectively reclassify clinical endpoints and we retained the original 
trial-specific definition for each clinical endpoint. 
The primary clinical endpoint ofthis study was the combined rate of death, non-fatal MI 
or stroke at one year. Secondary combined endpoints included death and the rate of 
repeat revascularisation (PCI or CABG). Major adverse cardiac and cerebrovascular 
(MACCE) events were death, non-fatal myocardial infarction, cerebrovascular events or 
repeat revascularisation by PCI or CABG. 
Statistical analysis 
The statistical analysis was performed using the SAS 8.0 software package (SAS 
Institute, Cary, North Carolina). Quantitative values were given as median (25th, 75th 
percentiles) or mean± standard deviation. To test for differences in categorical variables 
the Fisher's exact test was applied and to test for differences in continuous baseline 
variables, the Kruskal-Wallis test was used. Event rate curves were constructed by means 
of Kaplan-Meier methods, and event rate differences between the two groups were 
compared with the use of the log-rank test24 . The Cox proportional-hazards regression 
model was applied to determine the pooled HR for the effect of CABG or coronary 
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stenting on the primary and secondary clinical endpoints of this meta-analysis. Results 
are presented as hazard ratios (HR) and 95% confidence intervals (CI). Statistical 
significance was inferred at p < 0.05. To check for statistical evidence of heterogeneity, 
we fitted different unadjusted and adjusted (Adjusted for trial outcome differences and 
important patient baseline characteristics: Age, gender, previous myocardial infarction, 
diabetes mellitus, peripheral vascular disease, hypertension, enrolment diagnosis, ejection 
fraction, smoking status, aspirin use, B-blocker use, calcium channel blocker use, long 
acting nitrates use and statin use) models introducing interactions terms (trial*allocated 
treatment [CABG or coronary stenting]) into the Cox model and compared the full model 
(Interaction term for treatment) with the reduced model (No interaction term for 
treatment) with the x2 test. Furthermore, subgroup analyses of treatment effects (CABG 
versus coronary stenting) were also evaluated with Cox regression modelling (including a 
subgroup*allocated treatment [CABG or coronary stenting] interaction arm), with 
adjustment for trial. 
RESULTS 
Between June 1995 and June 2000, 3051 patients at 113 participating centres were 
randomly allocated to undergo multiple stent implantation (1518 patients) or CABG 
(1533 patients). Patient baseline profile, medications and periprocedural characteristics 
according to the revascularisation strategy applied are presented in table 2. The average 
interval between randomisation and treatment was 15 ± 22 days (range, 0 to 243) for 
patients in the stenting group and 20 ± 29 days (range, 0 to 362) for patients in the CABG 
group. A total of 98 percent of the patients in the stenting group (1487 patients) and 96 
percent of those in the CABG group (1467 patients) received the assigned treatment. 
Among the patients in the PCI group, a mean (±SD) 2.4±l.llesions with stenosis of more 
than 50 percent of the luminal diameter were successfully revascularised, and 2.3±1.1 
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lesions had stents implanted (79%). The median number of stents implanted per patient 
was 2 (2, 3), and five or more stents were implanted in 3% (66) patients. 6.7% (102) of 
patients received platelet glycoprotein IIb/IIIa inhibitors at the index procedure. Among 
the patients in the CABG group, a mean of2.7±0.8 anastomoses were performed with the 
use of a mean of 2.5±0.7 conduits. In 90% of the patients in the surgery group, at least 
one arterial conduit was used. Complete revascularisation was achieved in 82% of the 
patients in the CABG group as compared to 54% of the patients in the PCI group 
(p<O.OOOl). 
30-day clinical outcomes 
The 30-day composite endpoint of death, myocardial infarction or stroke occurred in 122 
patients. 48 (3.1 %) of those randornised to stenting versus 74 (4.8%) of those randomised 
to CABG reached this composite clinical endpoint (Adjusted HR=0.61 [95%CI 0.42-
0.89], p=0.01). As shown in table 3, there were no significant differences in mortality 
(Adjusted HR=0.89 [95%CI 0.42-1.87], p=0.77), stroke (Adjusted HR=0.32 [95%CI 
0.10-1.03], p=0.05) or myocardial infarction (Adjusted HR=0.69 [95%CI 0.44-1.08], 
p=0.11) between the two initial revascularisation strategies at 30 days. However, repeat 
revascularisation procedures were performed more frequently in those initially treated 
with PCI with multiple stenting (Adjusted HR=7.79 [95%CI 3.32-18.29], p<0.0001). 
One-year clinical outcomes 
As shown in Figure 1, the cumulative event rates for the primary clinical endpoint of 
death, non-fatal MI or stroke after one year of follow-up were 8.7% (132) for those 
randomised to stenting (n=1518) versus 9.1% (140) for those randornised to CABG 
(n=1533). The log-rank test did not reveal a statistically significant difference between 
the event rates over time (p=0.63). Further investigation with Cox proportional hazard 
regression analysis did not demonstrate any difference between the two revascularisation 
strategies and the primary endpoint of this study (Unadjusted HR=0.94 [95%CI 0.74-
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1.19], p=0.61; Adjusted HR=0.95 [95%CI 0.74-1.23], p=0.71). Mortality (Figure 2) was 
also similar in both groups (PCI 3% [n=46], CABG 2.8% [n=43]; Adjusted HR=1.01 
[95%CI 0.64-1.60], p=0.93). However, repeat revascularisation procedures occurred 
more frequently in the PCI with multiple stenting as compared to the CABG group (PCI 
18% [n=272], CABG 4.4% [n=68]; Adjusted HR=4.42 [95%CI 3.33-5.87], p<0.0001); 
and fmally the combined rate of MACCE events (Figure 3) also occurred more often in 
the PCI compared with the CABG group (PCI 24% [n=363], CABG 13% [n=201]; 
Adjusted HR=1.94 [95%CI 1.61-2.34], p<0.0001). As shown in table 4, anginal status at 
one year assessed with the Canadian Cardiovascular Society (CCS) functional class 
demonstrated a significant difference in terms of freedom from angina (CCS 0) in the 
CABG group compared with the PCI group (CABG 82% [n=1230], PCI 77% [n=1145], 
p=0.001). 
Heterogeneity 
In unadjusted and adjusted analysis, we found global quantitative evidence of 
heterogeneity between the four trials for the primary clinical endpoint of this study (r!"; p 
< 0.001); we also found heterogeneity when ERACI-2 (r!"; p < 0.01), MASS-2 (r!"; p < 
0.01) and SoS (r!"; p < 0.001) were removed from the model but there was no 
heterogeneity when ERACI-2 and MASS-2 where both excluded (X2 ; Unadjusted p > 0.2, 
adjusted p > 0.1). However, the heterogeneity was limited to the first 30 days (x2 ; p < 
0.001) and no longer present from 30-days to one year (x2 ; p > 0.2). Moreover, the 
adjusted hazard ratio at one-year of ARTS and SoS was similar to the pooled hazard ratio 
of ARTS, SoS, ERACI-2 and MASS-2 for the primary (HR=0.97 [95%CI 0.71-1.32], 
p=0.85 vs. HR=0.95 [95%CI 0.74-1.23], p=0.71) and secondary endpoints ofthis study 
like mortality (HR=1.30 [95%CI 0.66-2.57], p=0.44 vs. HR=l.02 [95%CI 0.64-1.60], 
p=0.94) and repeat revascularisation procedures (HR=5.46 [95%CI 3.82-7.80], p<0.0001 
vs. HR=4.42 [95%CI 3.33-5.87], p<0.0001). 
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Subgroup analyses 
The two revascularisation strategies did not differ with regard to rates of death, non-fatal 
MI or stroke across various prognostically important subpopulations, including those 
grouped by age, gender, status with regard to diabetes mellitus, smoking and number of 
diseased vessels (Figure 4). We also carried out a specific sub-analysis on mortality in 
diabetic patients. Mortality occurred at one-year in 15 (5.6%) of 266 diabetics in the PCI 
group versus 10 (3.5%) of 283 diabetics in the CABG group (HR=l.61 [95%CI 0.72-
3.61], p=0.245). 
DISCUSSION 
To our knowledge, this is the first by patient systematic overview of PCI with multiple 
stenting versus CABG in patients with multivessel disease undergoing coronary 
revascularisation. The 30-day event rates indicate that both PCI with stenting and CABG 
are procedures still associated with relatively high event rates and that short-term 
mortality (1.2% and 1% for PCI with stenting and CABG, respectively), even with the 
advent of newer surgical and interventional techniques, remain similar to those in-
hospital mortality rates reported in the BARI10 trial (1.1% and 1.3% for PCI and CABG, 
respectively). Our findings are also in accordance with previous reports that compared 
PCI with CABG10- 12, indicating that the two revascularisation strategies are associated 
with similar rates of death, non-fatal MI or stroke at a follow-up of one year. However, 
the widespread use of coronary stenting had significantly decreased the need for 
emergency CABG to approximately 1% among patients treated with PCL The observed 
gap between CABG and PCI in terms of MACCE at one-year, has narrowed from 32% 
reported in the pre-stent era9 to 11% in the present report, representing the stent era. This 
gap will continue to narrow with the newly introduced drug-eluting stents that have been 
shown to remarkably reduce restenosis and repeat revascularisation rates25 . Preliminary 
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data from the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam 
Cardiology Hospital) registrY6 have shown a 91.2% 6-month MACCE-free survival in 
307 consecutive patients with multivessel disease treated with sirolimus-eluting stents 
compared to 81.4% in 427 patients treated with bare metal stents (p<O.Ol). In this 
scenario, the adoption of measures aiming to modify the natural course of the 
atherosclerotic disease itself (i.e. non restenosis-related complications) becomes the main 
focus of attention after percutaneous or surgical treatment of multivessel disease. In this 
regard, statins could decrease perioperative mortalitT7 and reduce the risk of coronary 
atherosclerotic events in patients undergoing PCrZ8 . 
The fact that we found statistical evidence of heterogeneity present after adjustment for 
important patient characteristics is not surprising. In ARTS and SoS, PCI and CABG had 
similar event rates for the primary endpoint. In ERACI-2, PCI was better and finally in 
MASS-2, CABG was better. ERACI-2 was the first randomised trial to report a 
significant survival advantage with PCI versus CABG in any subset. These results could 
be attributed to the fact that 28% of ERACI-2 patients had angina at rest with ST-
segment changes in the 48 hours prior to revascularisation and 27% of patients 
randomised to CABG had also peripheral vascular disease, an additional risk factor for 
adverse outcomes with CABG29. Taken together, these demographic data suggest that the 
surgical mortality in ERAC-2 was not unreasonably high for this type of population. The 
survival advantage with CABG versus PCI found in MASS-2 for the primary endpoint 
could be explained by the occurrence of each individual endpoint. At one year, 
complications in the PCI group included death in 4.5%, myocardial infarction in 8.3% 
and stroke in 1% as compared to death in 4%, myocardial infarction in 2% and stroke in 
3% in the CABG group. 
The BARI trial demonstrated a higher mortality rate at five30 (34.5% versus 19.4%, 
p=0.003) and seven31 years (44.3% versus 23.6%, p=O.OOI) among diabetic patients with 
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multivessel disease treated with PCI compared with CABG. In this meta-analysis, CABG 
did not provide any survival advantage over PCI at one-year among the 549 diabetics 
studied. One-year mortality in the diabetic patients assigned to PCI was higher as 
compared to those assigned to CABG (5.6% versus 3.5%, p=NS). However, this 
difference was not statistically significant. Similar mortality rates among diabetics have 
been reported in the ARTS trial at one32 (6.3% versus 3.1%, p=NS) and three33 years 
(7 .1% versus 4.2%, p=NS). We cannot exclude that with a longer follow-up, the survival 
advantage will achieve statistical significance. The hypothesis that late lesion progression 
in nontreated coronary segments is an important cause of mortality in diabetic patients 
with multivessel disease34 may explain the difference in results observed with shorter-
term (<3 years) versus longer-term (>5 years) follow-up. Moreover, the periprocedural 
use of platelet glycoprotein lib/Ilia inhibitors in the PCI group may have played a role in 
decreasing the mortality associated with PCI35 in our patient population. Ongoing studies 
(FREEDOM36, ARTS-2 and BARI-2D37) will provide further insights on the optimal 
management of multi vessel disease in diabetic patients. 
The main limitation of this meta-analysis is the relatively short follow-up period limited 
to one year. Long term (5 year) follow-up of this cohort of patients is planned. Another 
potential limitation is inherent to the fact that a highly selected population was included 
into these studies, limiting the generalizability of the results to more complex subsets of 
patients. 
CONCLUSIONS 
After one year of the initial procedure, PCI with multiple stenting and CABG provided a 
similar degree of protection against death, non-fatal MI or stroke for patients with 
multivessel CAD. Repeat revascularisation procedures remain higher in PCI with stenting 
as compared to CABG. 
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FIGURE 1 
One-year cumulative risk of death, non-fatal myocardial infarction or cerebrovascular 
events of patients with multivessel disease randomised to percutaneous coronary 
intervention or coronary artery bypass graft (CABG) surgery in ARTS, SoS, ERACI-2 
and MASS-2 trials 
*Adjusted for age, gender, previous myocardial infarction, diabetes mellitus, peripheral 
vascular disease, hypertension, enrolment diagnosis, ejection fraction, smoking status, 
aspirin use, 13-blocker use, calcium channel blocker use and long acting nitrates use 
FIGURE 2 
One-year cumulative risk of death 
FIGURE3 
One-year cumulative risk of death, non-fatal myocardial infarction, cerebrovascular 
events or repeat revascularisation 
FIGURE4 
Hazard ratio of one-year death, non-fatal myocardial infarction or cerebrovascular events 
in subgroups of patients according to important baseline characteristics. The areas of the 
black squares are proportional to the amount of statistical information 
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TABLE 1. DESIGN CHARACTERISTICS OF TRIALS ON PCI WITH STENTING VERSUS CABG 
ARTS SoS ERACI-2 MASS-2 
Enrolment period March 1997 to Junel998 November 1996 to October 1996 to June 1995 to June 2000 
December 1999 October 1998 
Number of screened NA NA 2759 18692 
patients 
Number of eligible NA NA 1076 2076 
patients 
Number of randomized 1205 988 450 611 (408§) 
patients 
Major inclusion criteria Stable, unstable angina or Stable or unstable Stable, unstable angina Stable angina or 
silent ischemia angina or asymptomatic patients asymptomatic patients with 
with myocardium at risk objective evidence of 
(> 2 areas with perfusion myocardial ischemia 
defects) 
Angiographically Angiographically Angiographically Angiographically 
proven multivessel proven multivessel proven multivessel proven multivessel 
disease with one or more disease with one or more disease with one or more disease with one or more 
significant stenoses in at significant stenoses in at significant stenoses in at significant stenoses in at 
least 2 major epicardial least 2 major epicardial least 2 major epicardial least 2 major epicardial 
coronary arteries coronary arteries coronary arteries coronary arteries 
Equivalent degree of Equivalent degree of Complete functional Equivalent degree of 
revascularization was revascularization was Revascularization# revascularization was 
Mandatory# not mandatory# mandatory# 
Major exclusion criteria Previous CABG or PCI Previous CABG or PCI Previous CABG or PCI Previous CABG or PCI 
(In the last year) 
Need for concomitant Need for concomitant Concomitant severe Concomitant valvular 
major cardiovascular major cardiovascular valvular heart disease heart disease 
surgerJ1[ surgel11[ 
Left main stenosis Left main stenosis 
Transmural MI within the AMI in the 48 h before AMI in the 48 h before AMI or unstable angina 
Previous week the revascularization the revascularization requiring emergency 
procedure procedure revascularization 
Primary endpoint 12-month MACCE*-free Rate of repeat MACEt rate within 30 Composite endpoint of 
survival Revascularisation days and need for cardiac death, nonfatal 
emergency or elective myocardial infarction, 
repeat revascularisation and refractory angina 
procedures at 30 days requiring revascularisation 
Mean LV ejection 60% 57% 53% 68% 
Fraction 
NA ~Not available 
*MACCE =Major adverse cardiac or cerebrovascular events. defined as death~ stroke. transient ischaemic attacks. and reversible 
ischaemic neurologic deficits~ documented nonfatal myocardial infarction~ and repeated revascularisation by percutaneous coronary 
intervention or surgery 
~MACE= Major adverse cardiac events defined as death, Q-wave MI or stroke 
§Patients randomized to percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery 
#All these trials included patients in which coronary revascularization was indicated and appropriate by either strategy (PCI with 
multiple stenting or CABO by consensus agreement between the interventionalist and cardiac surgeon 
~efined as valve surgery, resection of aortic or left ventricular aneurysm, carotid endarterectomy or abdominal aortic aneurysm 
surgery 
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TABLE 2. BASELINE PROFILE, MEDICATIONS AND PERIPROCEDURAL 
CHARACTERISTICS OF THE PATIENTS INCLUDED IN THE INTENTION TO 
TREAT ANALYSIS* 
Male gender (% of patients) 
Age (yr) 
Previous myocardial infarction 
Diabetes Mellitus 
Hypertension 
H ypercholesterolaernia 
Family History of CAD 
Peripheral vascular disease 
Current smoker (% of patients) 
Cardiac medications (%) 
Aspirin 
B-blockers 
Calcium channel blockers 
Nitrates 
Statins 
Enrollment diagnosis 
Stable angina(% of patients) t 
Unstable angina(% of patients) § 
Silent ischaemia (% of patients) 
Ejection fraction(%) 
No of segments with stenosis> 50% of 
luminal diameter 
Number of diseased vessels (% of 
patients) 
2 
3 
Vessel territory with stenosis (% of 
patients) 
Right coronary artery 
Left anterior descending artery 
Left circumflex artery 
Left main coronary artery 
Length ofhospital stay (days) 
STENTING 
(n=1518) 
76.5 
61 (53, 68) 
43 
17.5 
50.4 
53.8 
40 
7 
20 
93.5 
73.3 
37.3 
68 
49 
66.5 
28.5 
5 
59±11 
2.74±0.98 
59 
41 
74 
90.5 
62.7 
1 
2 (1, 4) 
BYPASS 
SURGERY 
(n=l533) 
76.6 
61 (54, 68) 
41 
18.4 
50.6 
52.7 
39 
8.2 
26 
90 
75.3 
40.2 
70.3 
47 
69 
27 
4 
59±11 
2.79±0.95 
54 
46 
76 
91.2 
67.4 
0.6 
8 (6, 10) 
*Data presented as the median value (25th, 75th percentiles) or as the mean value± SD. 
tStable angina was defined according to the system of the Canadian Cardiovascular 
Society. §Unstable angina was defined according to the Braunwald classification 
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TABLE 3. 30-DAY CLINICAL END POINTS 
STENTING BYPASS UNADJUSTED ADJUSTED 
SURGERY HAZARD RATIO HAZARD RATIO 
(95% Cl) (95%CI) 
OUTCOME EVENTS AT 30 DAYS {N=l518) {N=1533) 
Death, myocardial infarction or 48 (3.1%) 74 (4.8%) 0.64 (0.45-0.93) 0.61 (0.42-0.89) 
Stroke 
Death 18 (1.2%) 16 {!%) 1.13 (0.57-2.21) 0.89 (0.42-1.87) 
Cerebrovascular accident 5 (0.3%) 11 (0.7%) 0.46 (0.16-1.32) 0.32 (0.10-1.03) 
Myocardial infarction 34(2.2%) 51 (3.3%) 0.67 (0.43-1.03) 0.69 (0.44-1.08) 
Repeated revascularization 51 (3.3%) 8 (0.5%) 6.56 (3.11-13.83) 7.79 (3.32-18.29) 
CABG 26 (1.7%) 5 (0.3%) 5.31 (2.04-13.83) 8.81 (2.64-29.41) 
PCI 28 (1.8%) 3 (0.2%) 9.52 (2.89-31.33) 7.91 (2.38-26.28) 
Event-free survival 1434 (94.5%) 1452 (94.7%) 
Any event 84 (5.5%) 81 (5.3%) 1.05 (0.77-1.42) 1.01 (0.73-1.39) 
*Adjusted for age, gender, previous myocardial infarction, diabetes mellitus, peripheral vascular disease, hypertension, enrolment 
diagnosis, ejection fraction, smoking status, aspirin use, B-blocker use, calcium channel blocker use, long acting nitrates use and stalin 
use 
TABLE 4. CLINICAL ENDPOINTS AND FUNCTIONAL STATUS AT ONE YEAR 
STENTING BYPASS UNADJUSTED ADJUSTED 
SURGERY HAZARD RATIO HAZARD RATIO 
(95% Cl) (95% Cl) 
OUTCOME EVENTS AT ONE-YEAR {N=l518) (N=1533) 
Death, myocardial infarction or 132 (8.7%) 140(9.1%) 0.94 (0.74-1.19) 0.95 (0.74-1.23) 
Stroke 
Death 46(3%) 43 (2.8%) 1.07 (0.70-1.62) 1.02 (0.64-1.60) 
Cerebrovascular accident 17 (1.1%) 23 (1.5%) 0.75 (0.40-1.40) 0.74 (0.37-1.51) 
Myocardial infarction 88 (5.8%) 85 (5.5%) 1.04 (0.77-1.41) 1.07 (0.78-1.47) 
Repeated revascularization 272 (18%) 68 (4.4%) 4.36 (3.34-5.69) 4.42 (3.33-5.87) 
CABG 94(6.2%) 21 (1.4%) 4.64 (2.89-7.44) 4.57 (2.77-7.57) 
PCI !96 (13%) 48 {3%) 4.36 (3.18-5.98) 4.42 (3.16-6.18) 
Event-free survival 1155 (76%) 1332 (87%) 
Any event 363 (24%) 201 (13%) 1.90 (1.60-2.26) 1.94 (1.61-2.34) 
Canadian Cardiovascular Society p- value 
functional class at one year 
0 1145 (77%) 1230 (82%) 0.001 
I 199 (13%) 107 (7%) <0.0001 
II 114(8%) 146 (9.6%) 0.048 
ill 24 (1.6%) 20 (1.3%) 0.515 
IV 4 (0.4%) 2 (0.1%) 0.404 
*Adjusted for age, gender, previous myocardial infarction, diabetes mellitus, peripheral vascular disease, hypertension, enrolment 
diagnosis, ejection fraction, smoking status, aspirin use, B-blocker use, calcium channel blocker use, long acting nitrates use and stalin 
use 
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Numbers at risk 
PCI 
CABG 
10% 
8% 
2% 
Adjusted HR* (95% CI) = 0.95 (0.74 -1.23) 
~+-------~--------~------~ 
0 
1518 
1533 
120 
1427 
1422 
240 
1398 
1404 
360 
1387 
1393 
FIGURE 1 
Prevalence 
Gender Male 77% 
Female 23% 
Age <65 year 62% 
;o,65 year 38% 
Diabetes Yes 18% 
No 82% 
Smoking Never 30% 
Former 47% 
Current 23% 
Vessel disease Two 57% 
Three 43% 
All patients 
0 
Event rate 
8.7% 
9.3% 
7.3% 
11.3% 
11.1% 
8.4% 
8.7% 
9.5% 
7.8% 
8.2% 
9.9% 
8.9% 
Stenting better 
0.5 
• 
Ill 
1.0 
CABGbetter 
1.5 2.0 
FIGURE4 
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Introduction 
The extent of the atherosclerotic disease has been shown to be one of the most important factors 
affecting the outcomes of patients with coronary heart disease 1-5. In medically treated patients, the 
presence of angiographic multifocal disease, together with reduced ventricular function, reliably 
predicts late-term mortality 4. Shortly after the introduction of coronary artery bypass graft surgery 
(CABG), several randomized trials demonstrated the benefit of surgical treatment on the mortality 
of patients with multivessel coronary heart disease. A metanalysis has been performed with 
individual patient data from seven randomized studies comparing CABG with medical treatment in 
stable patients treated between 1972 and 1984 6• Although at 10 years of follow-up 41% of the 
patients initially assigned to medical treatment had undergone CABG, the initial strategy of surgical 
treatment was associated with a 42% risk reduction of mortality for patients with 3-vessel disease. 
This body of evidence convincingly establishes the role of invasive treatment as an important 
therapeutic measure for patients with multivessel disease. 
Percutaneous coronary intervention (PCI) was first introduced in the clinical scenario in the late 
1970's. As initially applied, angioplasty was addressed to treat highly selected coronary lesions in 
patients with single-vessel disease. However since then, interventional methods and technology 
have evolved with improved success in more complex clinical and anatomic settings, including 
multivessel coronary disease. 
Annually, it is estimated that over 1,0000,000 percutaneous coronary interventions and 500,000 
surgical revascularizations are performed worldwide, and patients with multivessel disease account 
for the majority of cases treated. Commonly, both modalities, either PCI or CABG, are technically 
feasible for an individual patient with multivessel disease and selection of the most appropriate 
revascularization method may constitute a challenging clinical problem. Several randomized studies 
have addressed this question in the late 80's and early 90's, emolling over 4000 patients in total 7"15. 
The results are consistent among these trials (Table 1). Overall, post-procedure myocardial 
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infarction was higher for CABG-treated patients, while no difference was observed between both 
treatments in late occurrence of myocardial infarction. Short- and long-term survival was similar 
between both strategies in all trials, except in the BARI trial, in which surgically treated patients 
showed a better survival at 7.8 years (80.9% for PCI vs. 84.4% for CABG; p=0.04). However, this 
difference was largely explained by a greater mortality among diabetics treated with PCI (survival 
55.7% in PCI vs. 76.4% in CABG; p = 0.001). Among non-diabetics, survival was identical 
between both treatments (survival86.8% in PCI vs. 86.4% in CABG; p = 0.72) 15• Nevertheless, the 
most striking difference between percutaneous and surgical treatment for multivessel disease in 
these first studies was the evident higher need for repeat revascularization among those treated with 
angioplasty 7' 10•12•13•15 (Table 1 ). In-hospital (commonly due to early vessel occlusion) and late 
repeat revascularization (directly associated with restenosis) were both significantly higher after 
treatment with percutaneous techniques. Emergent early re-intervention occurred in 8.4% of 
patients treated with angioplasty in the BARI trial 15, and as much as 65.3% ofPCI-treated patients 
have had a new revascularization procedure after 8 years in the EAST trial 10• 
Both surgical and percutaneous treatments, and especially PCI techniques, have been substantially 
improved in the last years. It is of note that several of these implementations were not available at 
the time of the early comparative studies. In particular, coronary stent implantation was performed 
in only a minority of patients enrolled in these "pre-stent era" trials 7•8•10•12·13•15 (Table 1). As 
compared to balloon angioplasty, the main technique applied in the fust randomized trials of PCI 
vs. CABG, stents have been proven to reduce the incidence of acute complications and the need of 
further revascularization in a broad range of clinical and anatomical settings. Due to the significant 
change in safety and clinical efficacy consequent of coronary stent utilization, the fmdings of the 
first randomized CABG vs. balloon angioplasty trials for multivessel disease cannot be extrapolated 
to the current clinical scenario, in which a widespread use of stenting accounts for more than 80% 
63 
Chapter3 
of all PCI. In this regard, the impact of multivessel coronary stenting has been evaluated in the 
several observational and randomized trials in the last years. 
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Multivessel Stenting- Observational Studies 
Several non-randomized studies evaluating the impact of coronary stenting on patients with 
multivessel disease have been recently published 16-23 (Tables 2 and 3). In most studies, the included 
patient population had preserved left ventricular function, approximately 20% were diabetics, and 
3-vessel disease was present in only a minority of patients. Overall, procedural success rates and in-
hospital complications after multivessel stenting were notably favorable. At long-term follow-up (1 
to 3 years), multivessel stenting was associated with a low mortality rate (0% to 5.1 %) and 10% to 
30% of cases required additional revascularization procedures during the observation period. 
Consistently among these studies, at least 70% of patients remained free of any events. 
In one study, patients treated with multivessel stenting were reported to have similar early and late 
outcomes as compared to patients with single vessel-disease treated with stenting 17. At 1 year, there 
was no difference in death (0.7% vs. 1.4% respectively; p=0.6), Q-wave myocardial infarction (0% 
vs. 1.5% respectively; p=0.6), or target lesion revacularization (15% vs. 16% respectively; p=0.5), 
with a similar proportion of patients remaining free of events at the end of follow-up (78% for both 
groups). 
In a large observational study comparing stenting with surgery, similar mortality rates at 2.5 years 
were observed between both strategies in patients with double-vessel disease (93% vs 92% 
respectively for those with proximal left anterior descending artery disease; p=NS) or triple-vessel 
disease (80% vs 85% respectively for those with proximal left anterior descending artery disease; 
p=NS)16_ 
For single-lesion treatment, coronary stenting has virtually eliminated the occurrence of acute 
vessel occlusion shortly after the procedure, a complication seen in up to 16% of complex lesions 
after balloon angioplasty 24. Accordingly, in-hospital urgent re-revascularization has been reported 
in a negligible number of patients, commonly less than 1% of cases. In addition to the benefit in the 
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early outcomes, stent implantation has been demonstrated to reduce restenosis and the need of 
repeat revascularization in single-lesion dilatation 25-27• The process of restenosis formation is a 
local phenomenon triggered by the vascular trauma imposed by coronary dilatation and stent 
deployment. However, several systemic, or patient-related factors may significantly modulate the 
ultimate vascular response after angioplasty. Indeed, in patients treated with multistent 
implantation, a clear intra-patient predisposition has been demonstrated to affect the occurrence of 
restenosis, since the occurrence of restenosis in one lesion appeared to significantly increase the 
likelihood of restenosis in another lesion in the same patient 28. The restenosis rate was observed to 
increase with the number of lesions treated, from 24.4% for single-lesion stenting (per patient 
analysis) to 63.1% for those with 3 or more lesions treated (p<0.001) 28 . However, even considering 
an eventual increased risk of restenosis, multivessel stenting represents an evident improvement in 
the long-term efficacy of multi-lesion percutaneous interventions, as compared to the historical 
series with non-stent techniques (i.e. balloon dilatation). 
Srinivas et aL have compared the outcomes of multivessel patients treated in the "pre-stent era" 
with those treated more recently 19 (Tables 2 and 3). From 915 patients randomized to percutaneous 
treatment in BARl trial, a total of 904 had attempted angioplasty and were analyzed as a "pre-stent 
era" group. These patients were enrolled from 1988 and 1991 and actual stent utilization was 
performed in only 1% of cases. For comparison, a group of 857 patients treated from 1997 to 1999 
and included in the National Heart, Lung and Blood Institute Dynamic Registry was selected based 
on the same BARl eligibility criteria (i.e. angiographically documented multivessel disease 
amenable to percutaneous treatment in the absence of left main disease, recent acute myocardial 
infarction, or previous revascularization). Stents were utilized in 76% of cases and glycoprotein 
lib lila inhibitors were used in 24% (not available at the time of BARl trial). Several baseline and 
procedural differences were observed between both populations, however, after multivariable 
adjustment, treatment in the "stent era" was associated with better short- and long-term outcomes. 
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More recently treated patients had an 82% reduction in the risk of in-hospital surgery (p<O.OOl) and 
a 55% reduction in the risk of either in-hospital death, myocardial infarction, or surgery (p<O.OOl). 
Moreover, at 1-year patients treated in the "stent era" had significantly less re-interventions (risk 
reduction 59%; p<O.OOl) and a strong trend towards less death or myocardial infarction (risk 
reduction 26%; p<0.07). 
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Multivessel Stenting- Randomized Trials 
To date, 5 randomized trials have been completed comparing percutaneous coronary intervention 
with stent implantation and surgical revascularization for patients with multivessel disease 
[Rodriguez, 2001 #589;Serruys, 2001 #27;, 2002 #649;Hueb, 2001 #671]. The individual results of 
these studies and the findings of a metanalysis with the pooled patient population are presented 
below. 
ARTS- The Arterial Revascularization Therapies Study 29 
The ARTS randomized 1205 elective patients with multivessel disease (without left main disease) 
to treatment with PCI or CABG. The study design and main results are summarized in Tables 4 to 
7. High-risk patients were excluded and approximately two thirds of the patients enrolled in the trial 
had two-vessel disease. In both groups, a mean of 2.8 lesions per patient were identified in the pre-
procedure angiogram. In the stent group, 2.6 lesions were treated per patient (89% with stents). In 
the surgery group, 2.6 distal anastomoses were performed per patient. However, complete 
anatomical revascularization was achieved in only 71% vs. 84% after PCI or CABG respectively 
(p<O.Ol) 30. 
In the stent group, 40% of all events occurring at 30 days were due to stent thrombosis (2.8% of 
patients and 1.1% of stented lesions). At 1 year, patients treated with PCI had significantly more 
adverse cardiac and cerebrovascular events than patients treated with CABG (26.2% vs. 12.2% 
respectively; p<O.Ol). However, this difference in outcomes was exclusively due to a higher rate of 
repeat revascularization in the stent group. The incidence of death, MI, or cerebrovascular accident 
was similar between patients treated percutaneously or surgically (9.3% vs. 8.8% respectively; 
p=NS). Overall, 21.0% of the patients in the PCI group received an additional revascularization, as 
compared with 3.8% of those in the CABG group. An elevated periprocedural CKMB level was the 
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only multivariable predictor of adverse events in the surgical group (creatine kinase values > 5 
times the normal limit were found in 12.6 % of the surgical patients and in 6.2 %percent of stenting 
patients [p<O.OOI]). The presence of diabetes was the only predictor of events among patients 
treated with PCI. 
SoS trial- The Stent Or Surgery trial[, 2002 #649] 
The SoS trial randomized 988 patients with symptomatic multivessel disease to treatment with PCI 
or CABG. The study design and main results are summarized in Tables 4 to 7. There were few 
restrictions on case selection, few rules on how the procedure was to be performed, and little 
specifications regarding adjunctive therapy. Patients were considered for enrollment if the 
revascularization was judged to be clinically indicated and appropriate by either invasive strategy. 
At least one lesion had to be suitable for stent implantation. Included patients had predominantly 2-
vessel disease and preserved left ventricular function. Diabetes was present in approximately 15%. 
In the patients actually treated with PCI as randomized, 94% of all attempted lesions were 
successfully dilated (2. 7 lesions and 2.0 mean epicardial vessels successfully treated per patient). At 
least 1 stent was implanted in 78% of lesions (median 2.0 stents per patient). Glycoprotein IIb/IIIa 
inhibitors were utilized in 8% of patients. In patients treated with CABG as allocated, the mean 
number of grafts was 2.8 per patient. Internal mammary grafts were utilized in 93% 
The incidence of death or myocardial infarction was similar between both groups. However, 
mortality at 1 year was lower in CABG than PCI patients (0.8% vs. 2.5%; p = 0.05), and the 
difference at two years was even greater (2% vs. 5%; p = 0.01). This was in large part due to a 
difference in non-cardiac mortality; there were 8 cancer deaths among the PCI patients versus one 
among the CABG patients, a difference most likely explained by chance. Clearly, the remarkably 
low mortality in the CABG group further contributed to the significant difference in mortality 
between the two groups. Among patients allocated to PCI, 21% had one or more repeat 
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interventions (PCI or CABG) after 2 years of follow-up, compared with 6% in the CABG group 
(p<O.Ol). Most of the additional revascularization procedures occurred in the first year. 
MASS 2 trial - The Medicine, Angioplasty or Surgery Study for 
Multivessel Coronary Artery Disease-2 31 
In the MASS 2 trial, 611 patients were randomized to either medical therapy (n = 203), PCI (n = 
205), or CABG (n = 203). The primary endpoint was the combined frequency of cardiac death, 
myocardial infarction or unstable angina at one year. The trial included a slightly higher number of 
diabetics and patients with 3-vessel disease than the other 3 studies. At 1 year, the mortality rate 
was similar in all three arms: 4.5% with CABG, 4.0% with PCI and 2.0% with medical therapy. 
However, the frequency of myocardial infarction was 2% among CABG patients, 2% among 
medically treated patients, and 8% among PCI patients (p = 0.015). The frequency of stroke was 
3%, 1% and 2% in the CABG, PCI and medical arms, respectively. Patients treated with PCI 
presented a significantly higher incidence of repeat revascularization or crossover at 1 year than 
those included in the other 2 arms (0% for the CABG group vs. 8% for the medical group vs. 14% 
for PCI; p<O.Ol for all). 
ERACI2 trial- The Argentine Coronary Angioplasty With Stenting 
Versus Coronary Bypass Surgery in Patients With Multiple-Vessel 
Disease-2 32 
The ERACI 2 trial randomized 450 patients with symptomatic multivessel disease to treatment with 
stenting or CABG. The study design and main results are summarized in Tables 4 to 7. Patients 
with left main stenosis judged to be good candidates for stenting were included (approximately 
5%). The study population was composed predominantly of patients with unstable angina 
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(Braunwald class lib, Illb, and C in 91.1% ). Diabetes mellitus was present in 17% of patients and 
glycoprotein Ilbiiia inhibitors were administered to 28% of the PCI group. The Gianturco-Roubin II 
stent was the primary stent used (mean stent utilized per patient= 1.4) and approximately 90% of 
patients received a LIMA graft. At 30 days, the combined frequency of death, Q-wave myocardial 
infarction, need for repeat revascularization procedures, and stroke (primary endpoint of the study) 
was significantly lower in patients treated with PCI than in those treated with CABG (3.6% vs. 
12.3% respectively; p < 0.01). Similarly, mortality alone was lower for PCI than for CABG at 30 
days (0.9% vs. 5.7% respectively; p = 0.01). Although patients with unstable angina were observed 
to have a higher surgical risk, CABG was identified as the only multivariable predictor of 30-day 
adverse events (odds ratio 3.91; 95% confidence interval: 1.71- 8.89; p<O.Ol). Even though no 
further difference was observed in the incidence of death between both groups after 30 days, at 18 
months the total mortality rate was still lower for the percutaneous group (3.1% vs. 7.5% 
respectively; p = 0.02). In contrast, the need of repeat revascularization during the follow-up was 
significantly worse in the PCI group (16.8% vs. 4.8% respectively; p<O.Ol). Moreover, after 18 
months, patients allocated to CABG were more frequently free of angina than those treated with 
PCI (92% vs. 84.5%, respectively, p = 0.01). 
A separate analysis of the ERACI 2 was performed only with patients presenting significant 
stenosis in the proximal left anterior descending (LAD) artery (113 patients treated with PCI and 
117 with CABG) 33. Although no major differences were observed between both treatment groups, 
when compared to the overall population of ERACI 2, patients included in this substudy had 
significantly less 3-vessel disease (36% vs. 62%; p=0.008) and peripheral vascular disease (15% vs. 
27%; p=0.04). Patients with proximal LAD lesions had a strong trend towards more in-hospital 
death or myocardial infarction when treated surgically (7.6% vs. 1.8%; p=0.089). However, at 2 
years the incidence of death or myocardial infarction was similar between the CABG and stenting 
groups (89% vs. 92% respectively; p=0.9). 
71 
Chapter3 
Stenting versus coronary surgery for multivessel disease - a pooled 
analysis of ERACI-2, SoS, ARTS, and MASS-2 randomized trials 
A metanalysis has been performed with the individual data of all patients treated with PCI or CABG 
enrolled in the four randomized trials described above (ERACI 2, ARTS, SoS, and MASS 2 trials). 
The main results of this metanalysis are presented in Table 8 and Figure 1. In total, more than 3000 
patients have been randomized, with 1518 being treated with stenting and 1533 with surgery. 
Baseline characteristics were well balanced between both groups. Overall, relatively non-complex 
patients have been included, generally with preserved left ventricular function (mean ejection 
fraction 59%) and a diabetes rate of 18%. As a rule, patients were treated electively with only 
approximately 30% with unstable angina. Stenting was associated with a significantly shorter in-
hospital stay as compared to CABG (5±29 vs. 10±26 days; p<0.0001). Both treatments were 
associated with virtually similar in-hospital outcomes (Table 8). Notably, coronary stent 
implantation improved considerably the safety of percutaneous treatment for patients with 
multivessel disease. The incidence of periprocedural repeat revascularization was approximately 
3% in the pooled analysis of patients treated with multivessel stenting in the 4 randomized trials, 
while rates were as high as 13% in the BARI trial 15 had been previously observed in the first series 
with balloon angioplasty. In the ARTS trial, 40% of all events occurring in the first month after 
stenting were due to stent thrombosis, a complication that could be potentially reduced with 
utilization of heparin-coated stents or a more liberal use of glycoprotein IIbiiia inhibitors 29 . 
At 1 year, multivessel stenting and CABG were associated with similar rates of death as well as of 
death, myocardial infarction or cerebrovascular accident (Table 8 and Figure 1). As depicted in 
Figure 1, the corresponding event curves were observed to almost overlap between both treatment 
modalities during the entire observation period. Interestingly, as historically compared to the early 
balloon versus CABG trials, the 1-year death rate remained grossly constant across both the "pre-
stent" and the "stent" eras for both treatments (range from 3-4%) (Figure 2A) 34. 
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However, the incidence of major events after 1 year was significantly higher for patients treated 
with multivessel stenting (23.9% vs. 13.1 %; p<O.Ol), which was almost entirely explained by the 
increased rate ofre-intervention in this group (18% vs. 4%; p<O.Ol). This effect was mainly due to 
late restenosis. As observed in Figure 1, the curves of survival free of MACE begin to separate at 
about 2-3 months, coincident with the well-known time frame ofrestenosis occurrence 35• 
Although the need of repeat revascularization was still higher after stenting than after CABG, the 
utilization of coronary stents had clearly improved the late outcomes of patients with multi vessel 
disease treated percutaneously. In a metanalysis performed with the data from randomized trials on 
balloon versus CABG, the incidence of repeat revascularization at 1 year was 34% and 3% 
respectively 34. This figures contrast with the numbers observed in the pooled analysis of the 
ERACI 2, ARTS, SoS, and MASS 2 trials, where the need for additional revascularization was 18% 
after multivessel stenting (versus 4% after CABG). The absolute difference of repeat 
revascularization between surgery and PCI has decreased from 31% to 14% after stents were 
utilized, while no major modification was seen in the incidence of re-intervention after CABG 
(Figure 2). 
The AWESOME (Angina With Extremely Serious Operative Mortality 
Evaluation) trial 36 
The impact of percutaneous and surgical revascularization for patients at a higher risk for short- or 
long-term complications has been largely unexplored in randomized trials. The A WE SOME trial 
was designed with the main purpose of evaluating the advantages and disadvantages associated with 
PCI or CABG for cases with a higher risk of procedural and post-procedural mortality (Table 9) 36. 
Patients were selected over a period of 5 years (from 1995 and 2000) and randomly allocated to 
either invasive treatment. Patients with medically refractory myocardial ischemia and coronary 
anatomy judged to be amenable to both invasive modalities were considered for randomization if 
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presenting one or more of the 5 high-risk factors for CABG (age>70 years; LVEF<0.35%; 
myocardial infarction <7 days; prior CABG; IABP required to stabilize). 
In total, 22662 patients were screened and 2431 (11 %) met the first 3 clinical criteria for high-risk 
refractory angina. From these, 781 were deemed to be acceptable for both treatment modalities and 
454 (58%) were actually randomized to be treated with either CABG or PCI. The included study 
population had a relatively high age, a high prevalence of diabetes, recent MI, and prior CABG. 
Multivessel disease was present in more than 80% of patients. Overall, 57% of patients received a 
LIMA graft. However, the utilization of arterial grafts varied along the study (LIMA grafts were 
used in 57% of cases in 1995 and 78% in 1999/2000). Similarly, coronary stent implantation varied 
along the study, from 26% in 1995 to 88% in 1999/2000 (overall 54% of cases received at least one 
stent). 
Both surgical and percutaneous treatments were associated with similar mortality rates during the 
index hospitalization, at 30 days, 6 months, and 1 year (Table 9). Indeed, the incidence of death or 
an episode of unstable angina was similar between both treatment groups at 3 years (CABG: 35% 
vs. PCI: 41 %; p=NS). Patients treated with PCI had a higher incidence of repeat intervention during 
the follow-up (3-year death, UA or re-intervention for CABG or PCI: 39% vs. 52% respectively; 
p<0.001 by log-rank test). 
The AWESOME investigators conducted a parallel registry to evaluate the outcomes of patients not 
included in the main randomized study 37• During the screening phase, a total of 1650 patients were 
identified with high-risk refractory angina (the first 3 criteria above) but were not randomized based 
on the coronary angiogram fmdings according to the physicians' consensus. These patients were 
treated with CABG (n=692), PCI (n=651) or medical therapy only (n=307) and constituted the 
"physician-directed registry". Furthermore, among the 781 patients evaluated as candidates for both 
treatments, 327 patients declined randomization and were further followed-up as a "patient-choice 
registry". The mortality rates at 3 years between CABG and PCI in the randomized population and 
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in the "physician-directed" and the "patient-choice" registries were: 21% vs. 20%, 24% vs. 24%, 
and 20% vs. 11% respectively (p=NS for all). Therefore, percutaneous treatment of high-risk 
patients with multivessel disease (~80%) utilizing coronary stents in most of the cases was observed 
to be an alternative to surgical treatment. 
Patients with previous cardiac surgery were analyzed separately in an AWESOME substudy 38. In 
the randomized cohort, the physician-directed registry, and the patient-choice registry there were 
142, 719, and 327 patients with previous CABG respectively. The vast majority of patients in all 
groups presented with 3-vessel disease. At 3-year follow-up, the re-CABG and PCI survival rates 
were 73% and 76% for the randomized patients (p=NS), 71% and 77% for the physician-directed 
registry (p= NS) and 65% and 86% in the patient-choice respectively (p<O.Ol). The authors 
concluded that, instead of re-CABG, PCI could constitute a preferable choice for many patients 
with previous CABG. 
"Low-Risk" and "High-Risk" Patients with Multivessel Disease 
Patients with multivessel disease comprise a heterogeneous population with a wide range of risk 
profiles. Several factors have been identified as important predictors of perioperative mortality in 
patients treated with CABG, such as prior heart surgery, older age, poor left ventricular function, 
hemodynamic compromise, recent myocardial infarction, peripheral vascular disease, renal 
dysfunction, or chronic obstructive pulmonary disease 3639. Notably, patients with these 
characteristics have been systematically excluded from the randomized MASS-2, ARTS, and SoS 
trials [Hueb, 2001 #671;, 2002 #649;Serruys, 2001 #27]. The comparison between PCI with stent 
and CABG in low-risk patients with multivessel disease derived from these trials can be 
summarized as follows: 
• Short and long-term mortality and myocardial infarction rates are comparable, 
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• The need for repeat revascularization favors CABG but stents have narrowed the gap, and 
drug-eluting stents may narrow it further, 
• Hospital length of stay and length of recovery both favor PCI, 
• The relief of symptoms are comparable, but some studies favor CABG. 
According to these concepts, the choice between CABG and PCI for an individual patient with 
multivessel disease but at a lower risk of complications usually involves a 'balancing act' of 
multiple benefits and risks. In this context, although stents have reduced early and late repeat 
procedures, the need for repeat procedures is the single most important factor tipping the balance 
towards CABG. Clearly, measures to reduce late restenosis will shift the balance in favor ofPCL 
Patients at high risk for operative mortality have been mainly characterized by clinical factors (e.g. 
urgency of surgery, age, and prior CABG), while variables related to coronary anatomy had less 
predictive power 3941 . The AWESOME trial has specifically addressed the impact of percutaneous 
or surgical treatments in patients with high-risk clinical characteristics 36. Furthermore, high-risk 
patients composed most of the study population included in the ERACI-2 trial, which randomized 
to PCI or CABG patients with medically refractory angina, including post-myocardial infarction 
unstable angina and patients with peripheral vascular disease 32 . In AWESOME, short- and long-
term mortality rates were similar between both treatments 36. In ERACI-2, patients treated with PCI 
had a significantly lower incidence of death than those treated with surgery 32 . These fmdings are in 
line with the documented benefit of primary angioplasty in patients with acute myocardial 
infarction, a clinically high-risk group 42. Importantly, although randomized studies comparing 
CABG with PCI have focused on the occurrence of major cardiac and cerebrovascular events, 
greater concerns have been raised about post-CABG morbidity related to diffuse encephalopathy, 
prolonged post-operative obtundation, mediastinitis, acute and even permanent respiratory disability 
and acute and long-term renal failure 40 . As a rule, these complications are significantly increased in 
patients with a higher baseline risk profile 40. Together these findings suggest that "clinical high-
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risk" usually favors PCI, with the need to consider both the technical feasibility and risk provided 
by the coronary anatomy, but much less influenced by the threat ofrestenosis. 
Special Considerations 
Diabetic Patients 
Diabetes has been recognized as one of the most important risk factors for adverse outcomes after 
percutaneous interventions 4346 . In the randomized EAST and RlTA-1 trials, although not reaching 
statistical significance, diabetics tended to present a higher late mortality rate 10•12. In the EARl trial, 
which had the largest multivessel diabetic population, balloon angioplasty was observed to be 
associated with an increased risk of death at 5 years (20.6% vs. 5.8%; p=0.0003), a difference that 
was more evident among those using insulin and that was largely restricted to surgical patients 
receiving internal mammary artery grafts 47• The worse outcomes after angioplasty had been 
justified by the increased tendency to atheroscletotic disease progression in patients with diabetes, 
who would then be "more protected" after the more generalized surgical treatment than after the 
more localized percutaneous treatment48 . Interestingly, the analysis of the EARl-registry patients 
showed different results 49 . Clinically eligible patients in the EARl trial who did not consent to 
randomization were followed-up as a parallel registry, with patients being treated in a non-
randomized fashion with PCI, CABG, or non-invasively. Differently from the randomized patients, 
the presence of diabetes was not observed to significantly increase the risk of 5-year mortality 
among those treated with angioplasty in the registry. Patients treated with CABG or PCI in the 
registry differed in their baseline profile, which ultimately reflect the individual characteristics 
influencing the physicians' and/or patients' fmal therapeutic choice. Diabetics treated with PCI in 
the EARl registry had less severe coronary disease than those treated with surgery, which most 
likely had favorably influenced the outcomes of patients treated percutaneously. 
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In the ARTS trial, a subanalysis with diabetics treated with multivessel stenting showed no 
difference in the incidence of death or MI at 1 year, as compared to CABG so_ Patients with diabetes 
showed a trend towards more cerebrovascular events when treated with surgery than with PCI 
(6.3% vs. 1.8% respectively; p=0.096). In the ARTS trial, patients with diabetes treated with 
multi vessel stenting showed a significantly higher incidence of re-intervention at 1 year than after 
CABG (22.3% vs. 3.1% respectively; p<0.01). Furthermore, the rate of repeat revascularization 
after stenting was higher in diabetics than in non-diabetics (22.3% vs. 15.6%; p=0.04), reflecting 
the increase risk for restenosis in patients with diabetes 4s,46. Although both treatments did not differ 
in terms of mortality at 1 year in the ARTS, a more prolonged observation time is required to 
further evaluate the impact of multiple stent implantation on diabetics. In the EAST and BARI 
trials, a more evident separation in the survival curves of diabetics treated with either CABG or PCI 
occurred mainly after the first year of follow-up 10'49• However, in the AWESOME study, no 
differences in survival were observed among "high-risk" diabetics treated with CABG or PCI over a 
3-year follow-up period. Patients with diabetes included in the randomized trial or in the parallel 
registry (physician-directed treatment or patient-choice treatment) had similar 3-year survival rates 
for CABG and PCI (72% vs. 81 %; 73% vs. 71 %; 85% vs. 89%, respectively; p=NS for all) 51 . 
It is worth noting that the worse outcomes of diabetics treated with PCI in the randomized BARI 
trial 47 is supported by a similar tendency observed in the EAST and RITA-1 trials 10'12, but is not 
supported by their own (BARI) registry 49 , ARTS so, A WE SOME (randomized or registry) 36•37,s1, or 
ERACI 2 trials 32. Furthermore, the increased occurrence of adverse events after PCI in patients 
with diabetes was reported as post hoc subset analyses (which should be hypothesis generating, not 
policy formulating) of studies conducted in the pre-stent and pre-glycoprotein IIb/IIIa era. 
Currently, several reports have documented that glycoprotein Ilb!IIIa inhibitors may be particularly 
helpful in diabetics s2,s3• 
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Completeness of Revascularization 
The completeness of revascularization has been defined as anatomical, where all significant lesions 
are successfully treated, or functional, where the treatment is ultimately directed to stenotic vessels 
supplying a viable myocardial territory. Overall, incomplete revascularization is believed to 
negatively influence the outcomes of patients treated with surgical revascularization 5455, however 
its impact on PCI-treated patients is far less clear 56•58• The randomized studies on stenting versus 
CABG for multivessel disease have differed in their requirements for complete revascularization. 
As summarized in Table 4, in the ARTS and MASS 2 trials, PCI and CABG should provide an 
"equivalent" degree of revascularization, while a more liberal strategy was applied in the SoS trial. 
Conversely, complete functional revascularization was considered for all cases in the ERACI 2 trial. 
In the ERACI 2 trial, anatomical complete revascularization was more frequently achieved in the 
surgical group (85% vs. 50% in the PCI group; p=0.002). However, both groups had a similar 
degree of functional complete revascularization, with an equivalent frequency of normal or 
nonreversible perfusion areas at 30 days (85% in CABG vs. 84% in PCI; p=NS) 32. In the ARTS 
trial, complete anatomical revascularization was achieved in 84% of surgical patients and in 71% of 
stented patients (p<O.Ol) 30• Among patients treated with PCI, incomplete revascularization was 
associated with a significantly worse 1-year event rate than those with complete revascularization 
(incidence of death, myocardial infarction, cerebrovascular accident andre-intervention: 30.6% vs. 
23.4 respectively; p<0.05), a difference that was mainly explained by a higher incidence of 
additional bypass procedures in the first group (10.0% vs. 2.0%; p<0.05). Conversely, the degree of 
completeness showed virtually no impact on the outcomes of CABG patients after 1 year (event-
free survival87.8% vs. 89.9% for complete vs. incomplete revascularization; p=NS). 
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Procedural Aspects 
Although a high likelihood of acute success is expected with the currently available techniques 
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\ multivessel stenting tends to be a more complex procedure than single-vessel 
dilatation. Increased contrast utilization and prolonged intra-arterial manipulation may lead to peri-
procedural complications in these patients. The volume of contrast utilized during the angioplasty 
significantly increases the risk of post-procedure renal failure, which is a strong predictor of both 
early and late death after percutaneous interventions 62 . The utilization of iso-osmolar, nonionic 
contrast agents and of acetylcysteine have been shown to significantly reduce the incidence post-
procedure renal impairment in patients with mild to moderate decrease in baseline kidney function 
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. Such protective measures may be valuable for selected patients with planned multivessel 
dilatation. Furthermore, direct stenting without balloon predilatation has been demonstrated to 
decrease iodine contrast utilization as well as fluoroscopy time, material utilization, and procedural 
costs 65-68• Although not yet tested in procedures with multiple stent implantation, it seems 
reasonable to priorize a strategy of direct stent deployment for suitable lesions in patients with 
multivessel disease. 
Percutaneous dilatation of multiple lesions may be performed in one or more sessions. A strategy of 
elective staging with an interval of 4 to 8 weeks between procedures has been shown to be safe at 
30 days and associated with a trend towards less complications at 1 year (event rate 26% vs. 36% 
for staged vs. non-staged; p=0.08) 69• Although not evaluated in a randomized trial, the choice for 
elective staging seems to be attractive for selected patients treated with multi vessel stenting. 
Costs 
The costs associated with health care have been increasingly reported as a matter of concern 70•71 • In 
this regard, although coronary stenting may be less effective than surgery in reducing the need for 
re-intervention, its utilization had been demonstrated to significantly reduce by US$ 3,000.00 the 
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total direct medical costs at 1 year in the ARTS trial (Table 10) 29. Moreover, stenting was 
associated with reduced costs, as compared to CABG, both in diabetics and in non-diabetics (Table 
10) 50. Surgery was initially more expensive than stenting in diabetics and non-diabetics. This 
difference in costs was partially lost during the follow-up in the non-diabetics, due to the need of 
additional re-interventions in the PCI group. However, in the diabetic group the costs during follow-
up were similar between the CABG and the stent group. Although diabetics treated with PCI had a 
higher repeat revascularization rate than the surgical group, these extra costs were almost 
completely offset by an increased re-hospitalization rate in surgically treated patients. In total, 42% 
of diabetics treated with CABG were readmitted during the first year primarily due to comorbid 
factors (e.g. sternal infection, cerebrovascular events, and renal insufficiency). In ERACI 2, no 
differences in costs were observed between both strategies at 1 year. On average, after a mean 
follow-up of 18 months, the overall cost per patient was US$ 12,320 for stenting and US$ 11,160 
for CABG (p=NS). 
Future Directions 
Recently, coronary stents coated with paclitaxel or sirolimus have been demonstrated in large 
randomized trials to almost abolish the need for further revascularization 72"76. Persistent inhibition 
of neo-intimal proliferation has been demonstrated by intravascular ultrasound after 2 years of 
sirolimus-eluting stent implantation 77. However, these studies included relatively simple cases 
treated with single-lesion dilatation and therefore the impact of the new drug-eluting stents on the 
treatment of patients with multivessel disease is currently unknown. The ongoing Arterial 
Revascularization Therapies Study 2 (ARTS-2) will evaluate the outcomes of patients with 2- or 3-
vessel disease treated with sirolimus-eluting stent implantation 78 . This study was designed to 
compare patients treated with the sirolimus stent with a historical group composed by the CABG 
arm of the ARTS-I trial. Final results (1-year follow-up) are expected by 2004. Additionally, a 
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major randomized trial is planned to evaluate the outcomes of diabetics with multivessel disease 
treated with sirolimus-eluting stent in comparison with CABG (FREEDOM trial). The sirolimus-
eluting stent has been used as the device of choice for every percutaneous intervention in our 
institution (PLN, NM, and PWS) since April2002, as part of the RESEARCH (Rapamycin-Eluting 
Stent Evaluated At Rotterdam Cardiology Hospital) registry 79. Patients were treated without 
clinical or anatomical restrictions and the incidence of major adverse cardiac events (MACE; death, 
non-fatal myocardial infarction or repeat revascularization) has been evaluated and compared to a 
control group composed by patients treated with conventional techniques in the period immediately 
prior. After 6 months of enrollment, a total of307 consecutive patients with MVD had been treated 
with sirolimus-eluting stents and compared to 427 controls treated with bare metal stents (Figure 3). 
In a preliminary analysis, baseline characteristics were similar between both groups, with 38 % of 
patients presenting 3-vessel disease. In an interim analysis (to date, only 70% had completed 6-
month follow-up after the sirolimus stent implantation), sirolimus-eluting stent implantation was 
associated with a significantly better survival free of major events than those treated with 
conventional techniques (MACE-free survival at 6 months: 91.2% vs. 81.4%, respectively; p<O.Ol) 
(Figure 4). Albeit promising, further analyses are still needed to better evaluate the effect of this 
device on multi vessel disease patients. 
In this new "low-restenosis" context, the implementation of disease-modifying measures targeting 
the reduction of 'coronary atherosclerotic events' (i.e. non restenosis-related complications) has 
emerged as the major therapeutic goal, especially for the multivessel population, known to be at an 
increased risk for future complications. In a subanalysis of the Lescol Intervention Prevention Study 
(LIPS), long-term statin treatment after coronary intervention in multivessel patients was shown to 
effectively reduce the incidence of cardiac death, myocardial infarction, or repeat revascularization 
not due to restenosis 80 . In fact, statin had equalized the outcomes ofmultivessel patients with those 
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of single-vessel disease, virtually eliminating the negative impact of the disease extension on the 
late prognosis (Figure 4). 
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~ Table 1 -Randomized trials comparing PCI versus CABG in patients with multi vessel disease in the "Pre-Stent Era" 
Number 
% randomized 
2-vessel 
3-vessel 
LVEF (%) 
stent utilization (%) 
IMA(%) 
PCI success t 
In-
hospital 
Death(%) 
Q- MI (%) 
re-inter(%) 
Death(%) 
Cumm. 
Late Q- MI (%) 
events 
re-interv (%) 
Follow-up_period 
ERACI 7-- - GABI 8 
127 359 
9 4 
55 82 
45 18 
61 56 
0 0 
77 37 
92 92 
CAB PCI CAB PCI 
G G 
4.7 1.5 2.5 1.1 
6.0 6.0 8.1 2.3 t 
1.5 1.5 1.9 11.4 § 
4.7 9.5 6.5 2.6 
7.8 7.8 9.4 4.5 ** 
6.3 37 § 6 44 § 
EAST 9•10 
CA 
BG 
1 
3 
17.3 
26.5 
392 
8 
60 
40 
62 
0 
90 
88 
PCI 
10.3 § 
10.1 
20.7 
65.3 § 
RITA 1T,t2 
1011 
6 
43 
12 * 
0 
74 
87 
CAB PCI 
G 
1.2 
2.4 
8.6 
7.2 
14.3 
0.7 
3.5 
4.5 
7.9 
8.7 
49.8§ 
CABRl 13 
1054 
5 
58 
40 
63 
81 
91 
CAB PCI 
G 
1.3 1.3 
3.5 
2.7 3.9 
3.5 4.9 
2.1 35.6 § 
3 years _ l Yt:ar_ _ __ 8 _years _____ 6.5 _years 1 year 
BARI 14,15 
1829 
7 
59 
41 
57 
82 
88 
CAB 
G 
PCI 
1.3 
4.6 
0.1 
1.1 
2.111 
12.8 § 
15.6 19.1~ 
9.1 7.4 
13.1 59.7 § 
7.8 years 
CABG=coronary artery bypass graft surgery, IMA=internal mamma1y artery; L VEF=left ventricular ejection fraction; PCI=percutaneous coronary 
intervention; Q-MI=Q-wave myocardial infarction 
* Single-vessel disease in 45% 
t Successful dilatation of at least one lesion 
t p=0.02 CABG vs PCI 
§ p<O.OOl CABG vs PCI 
II p<O.Ol 
~p<0.05 
** Death/MI = 13.6 vs 6.0; p=0.02 (CABG vs PCI) 
g 
.g 
<D 
""' w 
Table 2- Observational Studies in PCI for multi vessel disease in the "Stent Era"- Baseline and in-hosEital outcomes 
Study Design size DM Ejection 3-vessel success IMA De at MI re-
(%) fraction disease (%) h (%) intervention 
(%) (%) (%) (%) (%) 
Komowski 1999 17 SV stenting * 1941 23 48 97 0.6 0.7 1.6 
MV stenting 398 24 48 96 0.5 0.9 0.5 
-- ------- ---------
Hermindez-Antolin 1999 18 MV stenting 136 21 66 95 0.7 4.4 0 
----------
Srinivas 2002 19 MY disease treated with PCI 904 19 t :j: 39 t 86.2 t 1.1 2.1 10.2 t in "pre-stent era" (BARI trial; 
stent 1 %) 
MY disease treated with PCI 
in "stent era" (NHLBI 857 23 t :j: 29 t 93.4 t 0.9 0.8 1.9 t registty; stent 76%) 
Mathew 1999 20 MV stenting 175 18 63 31 100 1.7 0 1.1 
··----
Kim2000 21 MV stenting 100 30 59 51 1.0 3.0 2.0 
MVCABG 100 22 57 61 76 2.0 3.0 0 $: 
Moussa 1997 22 MY stenting 100 10 57 26 100 1.0 2.0 4.0 s. ::::!: 
Laham 1997 23 MY stenting 103 44 99 1.0 1.9 0 ~ ---·- -----------
Villareal 2002 16 MVstenting 2793 23 § 13 II NA NA 0.8 -,r NA NA ~ 
MVCABG 2826 34 § 6411 3.6 -,r NA NA "' (i) 
::J 
SV =single vessel; MV =multi vessel; pts =patients; MI =myocardial infarction; TLR =target lesion revascularization; IMA=internal mamaty g: 
artery graft; DM=diabetes mellitus; NHLBI=National Heart, Lung and Blood Institute; BARI=Bypass Angioplasty Revascularization Investigation (Q 
trial ~ 
* 20% of the patients had multi vessel disease <:;; ~ t p< 0.05 o-t EF<50% in 19% BARI vs. 24% registty (p=O.Ol) 1§ § EF<50% in 27% stent vs. 38% surgety (p<O.OOl) @ II Single-vessel disease was present in 7.1% of surgical cases and 46.7% of stent cases (p<O.O 1) 
"' 
'1f Adjusted odds ratio 8.43 (95% confidence interval: 4.2- 16.9) "' c: ca 
0? I~ ()1 
CX> Table 3 -Observational Studies in PCI for multivessel disease in the "Stent Era"- Long-term outcomes g o-
Study Design size Follow-up Death(%) MI(%) TVR(%) EFS (%) .g 
Kornowski 1999 17 - SV stenting 1941 1 year 1.4 1.2 16.0 77.0 (i) ..... 
w 
MV stenting 398 0.7 0* 15.0 78.0 
Hern{mdez-Antolin 1999 18 MV stenting 136 18±13 5.1 0.7 9.5 75.0 
mo. 
--···----------···------- ·----
Srinivas 2002 19 - MV disease treated with 1 year 
PCI in "pre-stent era" 904 4.1 t 40.7 * 
(BARl trial; stent 1 %) 
MV disease treated with 
PCI in "stent era" 
(NHLBI registry; stent 857 4.9 t 19.4 * 
76%) 
----------
Mathew 1999 20 MV stenting 175 1 year 18.3 79.8 
·--
Kim 2000 21 
- MV stenting 100 21±10 0 1.0 19.0 * 70.0 ~ 
MVCABG 100 
mo. 
1.0 2.0 2.0 86.0 
Moussa 1997 22 MV stenting 100 21±10 2.0 2.0 30.0 87.0 § 
mo. 
Laham 1997 23 MV stenting 103 13±8 mo. 3.9 3.9 16.5 80.0 
Villareal 2002 16 - MV stenting 2793 20 II 
2826 
2.5 years 
1511 MVCABG 
EFS=event-free survival; MI =myocardial infarction; MV = multivessel; pts =patients; SV =single vessel; TLR =target vessel revascularization; 
* p<0.05 
t Death!MI in 11.0% BARI vs 7.9% registry (p=0.036) 
t p<O.Ol 
§Survival free ofMI or CABG 
II Mortality rates for patients with 3-vessel disease and proximal left anterior descending stenosis. Adjusted odds ratio for suvival (CABG:stent): 
0.93 (95% confidence interval: 0.53- 1.6); p=0.8 
OJ 
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Table 4- Randomized Trials ERACI-2, ARTS, SoS, MASS-2: coronaty stenting versus surgical revascularization for patients with multi vessel disease-
Study Design 
Study 
ERACI2 32 
ARTS 29 
SoS [, 2002 
#649] 
~MASS :2 31 -
Inclusion criteria 
-Large ischemic myocardial area, high grade 
stable angina (CCS III-IV) or unstable angina 
-Stenosis 2 70% in one major vessel and at least 
one other vessel with stenosis 2 50% 
-At least one treated vessel with diameter 2 
3.0mm 
Exclusion criteria 
- I-vessel disease 
-previous CABG 
- PCI in the last year 
-previous stenting 
- AMI < 24 hours 
-EF S 35% 
-All treated lesions should be amenable to PCI -valvular disease 
orCABG 
- silent ischetnia, stable angina pectoris, or 
unstable angina 
- 2 2 lesions potentially amenable to stent 
implantation and located in different vessels 
and territories. 
- Symptomatic multi vessel coronaty artety 
disease 
-consensus view of the surgeon and 
interventionist was that revascularisation was 
appropriate by either strategy. 
-At least one lesion as suitable for stent 
implantation. ___ _ 
- Symptomatic multivessel coronaty artety 
disease 
-consensus view of the surgeon and 
interventionist was that revascularisation was 
appropriate by either sh·ategy. 
-At least one lesion suitable for stent 
implantation. 
- LM stenosis 
-Previous CABG or PCI 
-AMI< I week 
-EF<30% 
-valvular disease 
- Previous CV A 
-Previous thoracotomy 
or coronary 
revascularization. 
-valvular disease 
-Previous thoracotomy 
or coronmy 
revascularization. 
- valvular disease 
-unstable angina 
Revascularization 
strategy 
-Complete 
functional 
revascularization 
- PCI and CABG 
should provide 
an equivalent 
degree 
revascularization 
-Equivalent 
revascularization 
not tnandatmy 
- PCI and CABG 
should provide 
an equivalent 
degree 
revascularization 
Total LM 
occlusio stenosis 
n 
Yes* Yes 
Yes t No 
Screene Eligible Rand 
d (%) (%) omiz 
ed 
2759 1076 450 
1205 
- t 988 
NA No 18692 2076 40811 
AMI=acute myocardial infarction; CABG=coronary artery bypass graft surgery; CCS=Canadian Canadian Cardiovascular Society class; TO=total 
occlusion; CV A=cerebro-vascular accident; IABP=intra=aortic balloon pump; LCx=left circumflex arte1y; LM=left main coronary; PCI=percutaneous 
coronary intervention. 
*No more than 2lesions with TO 
t Duration< 1 month 
t estimation based on patients undergoing multivessel revascularisation in each institution. 
§ Patients were also randomized to a third group without invasive treatment (n=203) 
II An additional group of203 patients was randomized for medical treatment (in total611 patients were enrolled in the MASS-2 trial) 
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Table 5- Randomized Trials ERACI-2, ARTS, SoS, MASS-2: coronary stenting versus surgical revascularization for patients with multivessel disease-
Baseline clinical and angiographic characteristics 
Study Male Age DM(%) Previous Previous PVD (%) EF (%) 2-vessel 3-vessel LM(%) LAD(%) 
(%) (years) MI(%) CABG(%) (%) (%) 
ERACI 2 32 PCI 77 63 17 29 0 19 53 40 55 5 91 
CABG 81 61 17 28 0 27 68 38 58 4 93 
-- --·----·-
ARTS 29 PCI 77 61 19 44 0 6 61 68 30 0 90 
CABG 76 61 16 42 0 5 60 67 33 0 90 
--·------· 
SoS [, 2002 PCI 80 61 14 44 0 31 57 62 38 1 92 
#649] 
CABG 78 62 15 47 0 35 57 52 47 1 92 
-------·- ----
MASS 2 31 PCI 67 60 23 51 0 0 68 42 58 0 93 
CABG 72 60 29 41 0 0 68 41 59 0 93 
-
CABG=coronary artery bypass graft surgery; DM=diabetes mellitus; EF=ejection fraction; MI=myocardial infarction; 
PCI=percutaneous coronaty intervention; peripheral vascular disease; SD= standard deviation; LM=left main stenosis> 50%; LAD 
stenosis>50% 
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Table 6- Randomized Trials ERACI-2, ARTS, SoS, MASS-2: coronmy stenting versus surgical revascularization for patients with multivessel 
disease - Procedural findings 
Study Number of lesions Lesions IIbiiia IMA Grafts per off-pump Complete anatomical time from hospitalization 
successfully with stent inhibitor (%) pt CABG revascularization (%) randomization to time (days) 
treated(%) (%) (%) (%) treatment (days) 
ERACI 2 32 PCI 1.9* NAt 28 50§ 4.2 5 § 
CABG 89 2.2 0.9 85 § 13.2 9§ 
------
ARTS 29,30 PCI 2.6 89 0 - 71 § 11 2, 
CABG - 9311 2.5 NA 84 § 27 6, 
SoS [, 2002 PCI 2.7 78 8 NA 14 3 
#649] 
CABG 93 2.8 3 NA 23 10 
MASS 2 31 PCI 2.1 72 0 41 34 3 
CABG - 93 3.3 0 74 49 14 
CABG=coronary artety bypass surgety; IMA=internal mammmy artety graft; PCI=percutaneous coronary intervention; pt=patient 
* 2 lesions treated successfully in 81% of patients 
t 1.4 stents I patient 
t Success rate for all planned lesions 
§ p<0.01 
II patients with at least one arterial graft 
, Non-coronary care unit,non-intensive care unit hospitalization days (p<O.O 1 for PCI vs CABG) 
#Use of stents increased during the study from 26% in 1995 to 88% in 1999/2000 
** Use of glycoprotein Ilbiiia inhibitors increased during the study from 1% in 1995 to 52% in 1999/2000 
tt IMA increased during the study from 57% in 1995 to 78% in 1999/2000 
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Table 7- Randomized Trials ERACI-2, ARTS, SoS, MASS-2: coronary stenting versus surgical revascularization for patients with multivessel 
disease- Long-term outcomes 
Study FUP time Death(%) Ml(%) any re-PCI or MACE(%) Free of angina 
(years) CABG(%) (%) 
ERACI 2 32 PCI 3.1 * 2.3 * 16.8 * 20 85 * 
1.5 
CABG 7.5 * 6.3 * 4.8 * 18.6 92 * 
-· ----- --- . ----------
ARTS 29 PCI 2.5 6.2 21.0 * 26.2 t 79 * 
1.0 
CABG 2.8 4.8 3.8 * 12.2 t 90 * 
---·------··-- ------·---
SoS [, 2002 PCI 5 * 5 t 21 * 22.5 * 66 * 
#649] 2.0 
CABG 2* 8 t 6* 12.4 * 79 * 
MASS 2 31 PCI 4.3 7.8 12.1 * 24.8 * 78 * 
1.0 
CABG 4.5 1.9 0.5 * 6.4 * 86 * 
-CABG=coronaty artety bypass surgety; EFS=event-free survival; FUP=follow-up; MACE=major adverse cardiac events (death, myocardial 
infarction, or repeat-revasculatization); MI=myocardial infarction; PC I =percutaneous coronaty intervention 
* p<0.05 
t Includes cerebro-vascular accident (p<0.05 PCI vs CABG) 
t The incidence ofMI or death was similar between both groups (p=0.8) 
§ Death, unstable angina, or repeat revascularization 
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Mu/tivessel stenting versus bypass surgery 
Table 8 -Coronary stenting versus surgical revascularization: pooled population from the ERACI 
2, ARTS, SoS, and MASS 2 randomized trials 
Clinical and angiographic characteristics 
Male(%) 
Age (yr) 
Diabetes mellitus (%) 
Previous myocardial infarction (%) 
Peripheral vascular disease(%) 
Ejection fraction(%) 
Unstable angina(%) 
2-vessel disease(%) 
3-vessel disease(%) 
Left anterior descending artery(%) 
Left main coronary artery (%) 
Procedural characteristics 
lib I Ilia inhibitor (%) 
Number of Stents implanted per patient (%) 
Number of conduits (%) 
Complete revascularization (%) 
Length of hospital stay (days [interquartile 
range]) 
30-day outcome 
Death(%) 
Non-fatal myocardial infarction(%) 
Repeat revascularization (PCI or CABG) (%) 
MACE(%) 
1-year outcome 
Death(%) 
Non-fatal myocardial infarction(%) 
Repeat revascularization (PCI or CABG) (%) * 
MACE(%)* 
EFS (%)* 
Free of angina(%)* 
Stent (n=l518) CABG (n=l533) 
77 77 
61 61 
18 18 
43 41 
7 8.2 
59±11 59±11 
29 27 
59 54 
41 46 
91 91 
6.7 
2.3±1.14 
2 (1, 4) 8 (6, 10) 
1.2 1.0 
2.2 3.3 
3.3 0.5 
5.5 5.3 
3.0 2.8 
5.8 5.5 
17.9 4.4 
23.9 13.1 
76 87 
77 82 
CABG=coronary artery bypass surgery; EFS=event-free survival; MACE=major adverse cardiac 
events (death, myocardial infarction, or repeat-revascularization); PC! =percutaneous coronary 
intervention 
* p<0.05 
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Table 9 - The AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) triaL 
Study design and main findings 36. 
Rationale and objective 
Inclusion criteria 
Population size 
Follow-up time 
Baseline characteristics 
Age> 70 years(%) 
Diabetes (%) 
Previous MI (%) 
Prior CABG (%) 
LVEF<0.35 (%) 
- High-risk patients have been excluded from randomized trials 
comparing PCI vs CABG 
-Objective: to evaluate the survival of patients with a high risk profile 
for CABG and refractory myocardial randomly allocated to treatment 
with CABG or PCI 
1) Medically refractory myocardial ischemia AND 
2) At least one risk factor for 1-month surgical mortality * 
3) Coronary anatomy judged to be acceptable for both surgical or 
percutaneous 
484 patients (58% of all illegible) 
3 years 
intraaortic balloon pump(%) 
MI < 7 days(%) 
53 
34 
71 
32 
23 
2 
32 
33 
40 
88 
50 
29 
70 
30 
18 
2 
35 
40 
40 
87 
2-vessel disease(%) 
3-vessel disease(%) 
LAD disease (%) 
Procedural characteristics 
number of anastomosis(%) 
LIMA graft (%) t 
Stent (%)t 
lib lila inhibitor (%) § 
Clinical outcome 
In-hospital death(%) 
30-day death(%) 
6-month death (%) 
3-year death(%) 
3-year death or UA (%) 
3-year death, UA or re-intervention (%) II 
2.9 
70 
4 
5 
10 
21 
35 
39 
54 
11 
1 
3 
6 
20 
41 
52 
CABG=coronary artery bypass graft surgery; LAD= left anterior descending artery; LIMA=left 
internal mammary artery; L VEF=left ventricular ejection fraction; MI=myocardial infarction; 
PCI=percutaneous coronary intervention; UA=unstable angina 
* Risk factors for post-CABG mortality: prior heart surgery, age >70 years, L VEF<0.35, intraaortic 
balloon pump before surgery, and MI < 7 days before CABG 
t LIMA utilization varied along the enrollement period, from 57% in 1995 to 78% in 1999/2000 
t Stent utilization varied along the enrollment period, from 26% in 1995 to 88% in 1999/2000 
§Use ofiibiiia inhibitors varied along the enrollment period, from 1% in 1995 to 52% in 1999/2000 
II p<0.001 (by log-rank test) 
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Table 10- Total direct medical costs at 1 year for percutaneous and surgical revascularization of multi vessel disease in the ARTS trial 29•50 . 
Total Population Diabetics Non-diabetics 
---~ 
Stenting CABG p-value Stenting CABG p-value Stenting CABG 
(n=600) (n=605) (n=l12) (n=196) (n=488) (n=509) 
Total direct medical costs at 1 year (US$) 10,665 13,638 <0.001 12,855 16,585 <0.001 10,164 16,585 
Event free-survival at one-year, %* 73.8 87.8 <0.001 63.4 84.4 <0.001 76.2 84.4 
*includes death, cerebrovascualr accident, myocardial infarction, and repeted revascularization 
p-value 
<0.001 
<0.001 
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Evidence Based Medicine: The Arterial Revascularization Therapies Study 29 
Acronym: ARTS 
Principal Investigator: Patrick W. Serruys 
Number of patients and sites: 1205 patients at 67 sites 
Trial design: Patients with multivessel disease randomly treated with coronary stenting or bypass 
surgery 
Primary endpoint: freedom from major adverse cardiac and cerebrovascular events at one year. 
Major findings: 
1. No significant difference between stenting and surgery in terms of death, stroke, or 
myocardial infarction at one year 
2. Stenting was associated with a significantly higher rate of repeat revascularization than 
surgery (21.0% vs. 3.8% respectively; relative risk: 5.52 [95 percent confidence interval: 
3.59 to 8.49]). 
3. The event-free survival at one year was 73.8% among the stent patients and 87.8% among 
surgical patients (P<0.001 by the log-rank test). 
4. Initial costs were $4,212 less for stenting but the difference was reduced during follow-up 
due to the need for re-interventions in this group. At one year, the net difference was 
estimated to be $2,973 per patient in favor of stenting 
Evidence Based Medicine: The Stent or Surgery trial [, 2002 #649] 
Acronym: SoS 
Principal Investigator: Ulrich Sigwart 
Number of patients and sites: 988 patients at 53 sites 
Trial design: Patients with multivessel disease randomly treated with coronary stenting or bypass 
surgery 
Primary endpoint: Incidence of repeat revascularization 
Major findings: 
94 
1. Additional revascularization procedures were needed in 21% of patients in the stenting 
group and in 6% of patients in the surgical group (hazard ratio 3.85; 95% CI: 2.56-5.79, 
p<0.0001) 
2. Death or Q-wave myocardial infarction rates were were similar in both groups (stent: 9% 
vs. surgery: 1 0%; hazard ratio 0.95 [95% CI: 0.63-1.42, p=0.80]). 
3. Death rate was lower in the surgical group than in the stent group (surgery: 2% vs. stent: 
5%; hazard ratio 2.91 [95% CI: 1.29-6.53, p=O.Ol]). 
Multivessel stenting versus bypass surgery 
Evidence Based Medicine: The Medicine, Angioplasty or Surgery Study for Multi vessel Coronary 
Artery Disease-2 31 
Acronym: MASS-2 
Principal Investigator: Whady A. Hueb 
Number of patients and sites: 611 patients at 1 site 
Trial design: Patients with multivessel disease randomly treated with medical therapy, coronary 
stenting or bypass surgery. 
Primary endpoint: Combined frequency of cardiac death, myocardial infarction or unstable angina 
at one year 
Major findings: 
1. Similar mortality rate in all three arms at 1 year: 4.5% with surgery, 4.0% with stent and 
2.0% with medical therapy . 
2. Higher frequency of myocardial infarction in the stent arm at 1 year: 2% with surgery, 8% 
with stent and 2.0% with medical therapy (p = 0.015). 
3. Higher frequency of repeat revascularization or crossover in the stent arm at 1 year: 0% 
with surgery, 14% with stent and 8% with medical therapy (p < 0.01). 
Evidence Based Medicine: The Argentine Coronary Angioplasty With Stenting Versus Coronary 
Bypass Surgery in Patients With Multiple-Vessel Disease-2 trial 32 
Acronym: ERACI 2 trial 
Principal Investigator: Alfredo Rodriguez 
Number of patients and sites: 450 patients at 7 sites 
Trial design: Patients with multivessel disease randomly treated with coronary stenting or bypass 
surgery. 
Primary endpoint: Major adverse events (death, Q-wave myocardial infarction, stroke, or repeat 
revascularization) at 30 days. 
Major findings: 
1. Lower incidence of major adverse events in the stent arm at 30 days (3.6% vs. 12.3%, 
p=0.002) 
2. Lower incidence of death in the stent arm at 30 days (0.9% vs. 5.7%, p<0.013) and at 18.5 
± 6.4 months (3.1% vs. 7.5%, p<0.017) 
3. Lower incidence of myocardial infarction in the stent arm at 30 days (0.9% vs. 5.7%, 
p<O.Ol3) and at 18.5 ± 6.4 months (2.3% vs. 6.4%, p<0.017) 
4. Higher incidence of repeat revascularization in the stent arm during follow-up (16.8% vs. 
4.8%, p<0.002). 
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Evidence Based Medicine: Angina With Extremely Serious Operative Mortality Evaluation trial 36 
Acronym: A WE SOME 
Principal Investigator: Douglass A. Morrison 
Number of patients and sites: 454 patients at 16 sites 
Trial design: High-risk patients with refractory myocardial ischemia randomly treated with 
coronary stenting or bypass surgery. Included patients had at least one of the following 
characteristics: including prior cardiac surgery, age > 70 years, left ventricular ejection fraction< 
0.35%, recent myocardial infarction (<7 days), or intraaortic balloon pump required. 
Major findings: 
96 
1. 30-day survival rate for surgery and angioplasty: 95% and 97%, respectively (p=NS) 
2. 6-month survival rate for surgery and angioplasty: 90% and 94%, respectively (p=NS) 
3. 36-month survival rate for surgery and angioplasty: 79% and 80%, respectively (p=NS) 
4. 36-month rates of death, unstable angina or re-intervention for surgery or angioplasty: 39% 
vs. 52%, respectively (p<O.OOl) 
Multivessel stenting versus bypass surgery 
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Randomized trials of Stenting vs. CABG in multivessel disease 
Overview 
• Five randomized trials are currently available comparing 
percutaneous coronary intervention and coronary artery bypass 
surgery for patients with multi vessel disease in the "stent 
era":ARTS, SoS, MASS-2, ERACI-2, and AWESOME 
(multivessel disease in ,..,80%) 
•Relatively non-complex patients were included in ARTS, SoS, 
andMASS-2. 
•Patients with a higher risk profile were enrolled in the ERACI-
2, and AWESOME trials 
Randomized trials of Stenting vs. CABG in multivessel disease 
Short-term outcomes 
•Stenting was consistently associated with a significantly shorter in-hospital 
stay 
•Overall, both stenting and surgery were associated with similar in-hospital 
outcomes 
•Periprocedural repeat revascularization occurred in approximately 3% after 
stenting (pooled analysis with patients from ARTS, SoS, MASS-2, ERACI-
2), which compares favorably with the fmdings of studies conducted in the 
balloon angioplasty era (13% periprocedural reintervention in the BARI trial) 
•In the ARTS trial, 40% of all events occurring in the first month after 
stenting was due to stent thrombosis 
•In AWESOME, high-risk patients presented a 30-day mortality after CAGB 
or PCI of 5% vs. 3% respectively (p=NS) 
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Randomized trials of Stenting vs. CABG in multivessel disease 
Long-term outcomes 
• At 1 year, multi vessel stenting and CABG were associated with 
similar rates of death as well as of death, myocardial infarction 
or cerebrovascular accident. 
•The incidence of major events after 1 year was significantly 
higher for patients treated with multivessel stenting (23.9% vs. 
13.1 %; p<0.01), which was almost entirely explained by the 
increased rate of re-intervention in this group (18% vs. 4%; 
p<0.01) (pooled analysis of ARTS, SoS, MASS-2, ERACI-2) 
• Although stenting still presented a higher rate of repeat 
revascularization than CABG, coronary stents clearly improved 
the late outcomes seen after balloon angioplasty (the incidence 
of repeat revascularization at 1 year was usually over 30%). 
Randomized trials of Stenting vs. CABG in multivessel disease 
Diabetes 
• In the pre-stent era, diabetes was associated with identified with higher mortality rates in the 
randomized EAST and RITA-1 trials (although not reaching statistical significance) and in 
the BARI trial (death rate at 5 years for angioplasty vs,. surgery: 20.6% vs. 5.8%, repectively; 
p=0.0003) 
• This difference in the BARI was more evident among those using insulin and was largely 
restricted to surgical patients receiving internal mammary artery grafts. 
• However, in the BAR!-registry (eligible patients in the BARI trial who did not consent to 
randomization), diabetes have not increased the risk of 5-year mortality among those treated 
with angioplasty. 
• In the ARTS trial, diabetics had similar rates of death or MI at 1 year in thestent and CABG 
arms. Patients with diabetes showed a trend towards more cerebrovascular events when 
treated with surgery than with PCI (6.3% vs. 1.8% respectively; p=0.096). 
• In the ARTS trial, patients with diabetes treated with multivessel stentingshowed a 
significantly higher incidence of re-intervention at 1 year than after CABG (22.3% vs. 3.1% 
respectively; p<O.O 1 ). The rate of repeat revascularization after stenting was higher in 
diabetics than in non-diabetics (22.3% vs. 15.6%; p=0.04) 
• In the AWESOME study, no differences in 3-year survival rates were observed in "high-risk" 
diabetics treated with CABG or PCI in the randomized trial or in the parallel registry 
(physician-directed or patient-choice treatments) (72% vs. 81 %; 73% vs. 71 %; 85% vs. 89%, 
respectively; p=NS for all) . 
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Randomized trials of Stenting vs. CABG in multivessel disease 
Completeness of Revascularization 
• In the ERACI 2 trial, anatomical complete revascularization was more 
frequent in the surgical group (85% vs. 50% in the PCI group; p=0.002). 
Both groups had a similar degree of functional complete revascularization, 
with an equivalent frequency of normal or nonreversible perfusion areas at 
30 days (85% in CABG vs. 84% in PCI; p=NS). 
• In the ARTS trial, complete anatomical revascularization was achieved in 
84% of surgical patients and in 71% of stented patients (p<O.Ol). In the 
PCI group, incomplete revascularization was associated with worse 1-year 
(incidence of MACE: 30.6% vs. 23.4%; p<0.05), mainly due to a higher 
incidence of additional bypass procedures (1 0.0% vs. 2.0%; p<0.05). 
Conversely, the degree of completeness showed virtually no impact on the 
outcomes ofCABG patients after 1 year (event-free survival87.8% vs. 
89.9% for complete vs. incomplete revascularization; p=NS). 
Randomized trials of Stenting vs. CABG in multivessel disease 
Costs 
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• As compared to surgery, stenting significantly 
reduce by US$ 3,000.00 the total direct medical costs 
at 1 year in the ARTS trial. 
• In ERACI 2, no differences in costs were observed 
between both strategies at 1 year (overall cost per 
patient: US$ 12,320 for stenting and US$ 11,160 for 
CABG [p NS] after a mean follow-up of 18 months). 
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74 year-old male, smoker, with 
previous myocardial infarction, 
admitted with stable angina (CCS 
3). The pre-procedure coronary 
angiogram showed a severe stenosis 
in the mid left anterior descending 
artery (upper panel), which was 
treated with implantation of a 3 x 
18-mm sirolimus-eluting stent (*). 
The first obtuse marginal branch 
(middle panel) presented a severe 
stenosis treated with the 
implantation of two overlapping 3 x 
18-mm sirolimus-eluting stents (*). 
A chronic total occlusion in the mid 
portion of the right coronary artery 
(lower pannel) was treated with 
implantation of a 3 x 18-mm 
sirolimus-eluting stent (*). The 
procedure was uneventful. After 7 
months, the patient remained 
asymptomatic and no evidence of 
restenosis was observed at elective 
7 -month control angiogram. 
Figure 4- MACE-free survival curves for patients with 
multivessel disease treated with s:irolimus-eluting stent 
implantation or conventional percutaneous techniques in te 
RESEARCH registry 
SES 
· -· •. control 
- -. 
--··-·-· 
.. ""L .... .., 82 4°1 
-. . 10 
lp<O.oii 
• L ' 
.. L L L .. I 
.. L .. •• 
80~--------------------------------------------------
106 
0 
Pts at risk 
307 
427 
2 3 
290 
374 
4 5 6 Months 
160 
354 
Multivesse/ stenting versus bypass surgery 
Figure 5 -Impact oflong-term fluvastatin treatment on the occurrence of 
cardiac atherosclerotic events in the LIPS trial 
~ 
> (!) 
I 
0 
40% 
30% 
·.p 20% 
~ 
,.......... 
0 
r:rJ 
0 
~ 10% 
~ 
1 
I p<O.Ol for all I 
Multivessel -placebo 
Single vessel - placebo } 
Multivessel - fluvastatin p=O .19 
Single-vessel - fluvastatin 
2 3 4 
years 
107 

Part 7: Clinical trials and observational studies on coronary revascularization 
Chapter4 
Characteristics, treatment and outcome of patients with non ST-
elevation acute coronary syndromes and multivessel coronary 
artery disease: Observations from PURSUIT 
BreemanA, Mercado N, Lenzen M, van den Brand M, Harrington 
RA, Califf RM, Topol EJ, Simoons ML, Boersma E 
Cardiology 2002; 98: 195-201 

Acute coronary syndromes and multivessel disease in the PURSUIT trial 
Characteristics, Treatment and Outcome of 
Patients with Non-ST-Eievation Acute Coronary 
Syndromes and Multivessel Coronary Artery 
Disease: Observations from PURSUIT (Platelet 
Glycoprotein lib/lila in Unstable Angina: 
Receptor Suppression Using lntegrelin Therapy) 
Arno Breemana Nestor Mercado a Mattie Lenzen a 
Marcel M.J. van den Brand a Robert A. Harrington b Robert M. Califfb 
EricJ. Topolc Maarten L. Simoonsa Eric Boersmaa 
for the PURSUIT Investigators 
•Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands; bDuke Clinical Research Institute, 
Durham, N.C., and 'Cleveland Clinic Foundation, Cleveland, Ohio, USA 
KeyWords rated from those who underwent a CABG (prior to a pos-
Multivessel disease· Medical treatment· Percutaneous sible PCI). The PCI group was further subdivided: pa-
coronary interventions· Coronary artery bypass grafting tients receiving ~ 1 coronary stents were separated from 
those in whom no stents were used. Results: The mortal-
ity rate at 30 days was 6.7, 3.9, 2.4 and 4.8% for the medi-
Abstract cal treatment, PCI (balloon), PCI (stent) and CABG 
Background: The 6-month clinical outcome of patients groups, respectively (p value = 0.002). Differences as 
with multivessel disease enrolled in PURSUIT (Platelet observed at 30 days were still present at 6-month follow-
Glycoprotein lib/lila in Unstable Angina: Receptor Sup- up with 11.1, 5.8, 5.5 and 6.5% mortality event rates for 
pression Using lntegrilin Therapy) is described. Patients the aforementioned groups (p value= 0.002). The 30-day 
with complete angiography data were included; multi- myocardial infarction (MI) rate according to the opinion 
vessel disease was stratified according to the treatment of the Clinical Events Committee was lower among med-
strategy applied early during hospitalization, i.e. medical icallythan non-medically treated patients, with the high-
treatment, percutaneous coronary intervention (PCI) est event rate observed in the CABG group (27.7%). 
(balloon), PCI (stent), or coronary artery bypass grafting Approximately half of the Mls in the PCI and CABG sub-
(CABG). Methods: Patients were divided into three groups occurred within 48 h after the procedure. Conc/u-
groups according to the treatment strategy applied dur- sions: The observed differences in clinical outcomes are 
ing the first 30 days of enrolment. Patients who did not explained by an imbalance in baseline characteristics 
undergo a percutaneous or surgical coronary interven- and comorbid conditions between the analyzed groups 
tion were classified as medically treated. Patients who of patients. 
underwent a PCI (prior to a possible CABG) were sepa-
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Introduction 
Several clinical trials have been performed to evaluate 
whether patients with coronary artery disease benefit 
most from medical treatment only, percutaneous coro-
nary intervention (PCI), or coronary bypass surgery 
(CABG) [1, 2]. Other studies have specifically compared 
percutaneous transluminal coronary balloon angioplasty 
(PICA) against CABG [3-9] and finally contemporary 
trials of coronary stenting and optimal adjunctive phar-
macological therapy versus CABG have recently been 
reported [10-12]. However, most of these studies have 
predominantly included patients with chronic stable angi-
na and few data are available on the characteristics and 
clinical outcome of patients with multivessel disease pre-
senting with an acute coronary syndrome. 
The Platelet Glycoprotein lib/Ilia in Unstable Angina: 
Receptor Suppression Using Integrilin Therapy (PUR-
SUIT) trial was a large-scale randomized clinical trial on 
the effects of eptifibatide versus placebo in patients with 
acute coronary syndromes without persistent ST eleva-
tion [13]. As the enrolment criteria were broad, PUR-
SUIT encompasses a wide variety of patients, hospital set-
tings and treatment policies, and therefore accurately 
reflects standard clinical practice. 
The aim of this study was to describe the characteris-
tics and short-term clinical outcome of patients with mul-
Fig. 1. PURSUIT patient population flow 
chart stratified according to the number of 
diseased vessels and treatment strategy ap-
plied to patients with multivessel coronary 
disease. VD =vessel disease. 
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tivessel coronary artery disease in the PURSUIT popula-
tion according to the treatment strategy applied early dur-
ing hospitalization. 
Materials and Methods 
Patient Population 
The design and methods of the PURSUIT trial have been pre-
viously published [13]. In summary, patients were eligible if they pre-
sented within 24 h of an episode of ischemic chest pain (> 10 min), 
and had either transient ST elevation (>0.5 mm), transient or persis-
tent ST depression (>0.5 mm), T wave inversion (>0.1 mm), or ele-
vation of the creatine kinase MB fraction (CK-MB) above the upper 
limit of normal (ULN). Patients with persistent(> 30 min) ST eleva-
tion were excluded. Eligible patients were randomly assigned to treat-
ment with eptifibatide or placebo. All other treatment decisions, 
including the use and timing ofPCI or CABG were left at the discre-
tion of the treating physician. 
Coronary angiography was performed within 30 days of enrol-
ment in 5,937 (63%) ofthe 9,461 patients who participated in PUR-
SUIT (fig. I). Among patients with complete angiographic data, 
3,067 (58%) had a significant stenosis (>50% diameter stenosis by 
visual inspection) in "'2 major native coronary arteries or in the left 
main stem. These patients were classified as having multi vessel coro-
nary artery disease and are the subjects of interest for the current 
analysis. 
Classification According to Applied Treatment Strategy 
Patients were divided into three groups according to the applied 
treatment strategy during the first 30 days of enrolment. Patients 
Acute coronary syndromes and multivessel disease in the PURSUIT trial 
who did not undergo a percutaneous or surgical coronary interven-
tion were classified as medically treated. Patients who underwent a 
PC! (prior to a possible CABG) were separated from those who 
underwent a CABG (prior to a possible PC!). The PC! group was 
further subdivided: patients receiving ~ 1 coronary stents were sepa-
rated from those in whom no stents were used (fig. 1 ). 
Data Analysis 
The statistical analysis was performed using the SAS 8.0 software 
package (SAS Institute, Cary, N.C., USA). Continuous variables are 
presented as mean values ± standard deviation and dichotomous 
variables as percentages. One-way analyses of variance (AN OVA) 
and x2 tests were applied to evaluate differences in baseline charac-
teristics, death, MI rates and rates of repeated coronary interventions 
(both at the 30-day and 6-month follow-up) between the different 
subgroups classified according to the applied treatment strategy. In 
case of a statistically significant difference in clinical events or 
repeated coronary interventions, which was specified at the conven-
tional p < 0.05level, repeated tests were performed to further evalu-
ate the inter-subgroup differences. The Bonferroni method [ 14] was 
used to avoid spurious significant results after multiple testing, and 
the level of significance was lowered top< 0.0167 and p < 0.0083 in 
case of 3 (balloon- stent- surgery) and 6 possible comparisons (med-
ical treatment- balloon- stent- surgery), respectively. 
Definition of Myocardial Infarction 
The primary endpoint of PURSUIT was a composite of death or 
nonfatal myocardial infarction (MI) at 30 days. A computerized algo-
rithm was used to review the clinical events. If a possible event was 
identified, further documentation was collected and the case re-
viewed in detail and adjudicated by a central Clinical Events Com-
mittee (CEC). MI was diagnosed on the basis of new ST segment 
elevations, new Q waves, or new or repeated CK-MB elevations 
above the ULN. Following percutaneous or surgical intervention, the 
elevation of CK-MB level was required to be at least 3-5 times the 
ULN. 
Table 1. Clinical baseline characteristics 
Demographics 
Mean age ± SD, years 
Male gender, % 
Caucasian, % 
Medical history and risk factors 
Hypertension, % 
Diabetes mellitus, % 
Current smoker, % 
Hypercholesterolemia, % 
Prior PC!,% 
Prior CABG, % 
PriorMI,% 
Heart failure, % 
PriorCVA,% 
Peripheral vessel disease, % 
Cardiac medication prior to admission 
Medical 
(n = 901) 
65±10 
70 
86 
62 
30 
28 
50 
17 
36 
47 
14 
7 
13 
Aspirin, % 73 
Beta-blocker, % 48 
Calcium antagonist, % 39 
Nitrates, % 7 3 
ACE inhibitors, % 30 
Clinical presentation 
CK-MB > 1 ULN,% 
ST depression >0.5 mm,% 
ST elevation >0.5 mm, % 
T wave inversion >0.5 mm, % 
52 
52 
12 
48 
PC! (n = 1,075) 
balloon 
. (n = 533) 
63±!! 
74 
89 
60 
26 
29 
46 
23 
24 
40 
8 
4 
8 
74 
50 
34 
75 
23 
52 
47 
17 
51 
stent 
(n= 542) 
62±11 
73 
91 
61 
23 
29 
53 
23 
29 
36 
10 
5 
9 
76 
49 
36 
77 
24 
44 
52 
15 
50 
CABG 
(n = 1,091) 
64± 10*** 
73 
90* 
57 
27 
26 
47 
14*** 
9*** 
34*** 
6*** 
3** 
9** 
74 
49 
36 
74 
21*** 
48* 
58*** 
13* 
45 
ACE= Angiotensin converting enzyme; CVA =cerebrovascular accident; other abbrevi-
ations, as defined in the text. Statistical tests (integral comparison of 4 groups): * p < 0.05; 
** p< 0.01; *** p< 0.001. 
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Results 
Patient Characteristics 
During the first 30 days of randomization, a PCI was 
performed in 1,075 of 3,067 (35%) patients, with stent 
placement in 542 cases (50% of the PCI procedures), 
whereas 1,091 of3,067 (36%) patients underwent CABG. 
The remaining 90 1 (2 9%) patients were medically treated 
(fig. 1 ). A significant difference was evident between the 
treatment subgroups with respect to age; medically 
treated and CABG patients were older than those un-
dergoing PCI (table 1 ). There were also differences re-
garding history of prior cardiovascular events and inter-
ventions. Almost one quarter of the PCI patients had a 
previous PCI versus 17 and 14% in the medical and surgi-
cal subgroups, respectively. A prior CABG was performed 
in 36% of medically treated patients, and this figure was 
only 9% in the CABG subgroup. A history of Ml, heart 
failure, cerebrovascular accident, as well as peripheral 
vessel disease was more frequently observed in the medi-
cally versus non-medically treated patients. No important 
differences were observed in the use of cardiac medica-
tions except for the use of ACE inhibitors, which was 
more frequent in medically treated patients. 
Angiographic Findings 
Patients who underwent CABG had more severe coro-
nary artery disease (52% had 3-vessel and 21% left main 
disease), immediately followed by medically treated pa-
tients with a similar percentage of 3-vessel disease (51%) 
but less often, left main disease (11 %) (table 2). A total 
occlusion in any of the major native coronary arteries was 
more often present in medically than in non-medically 
treated patients. Medically and surgically treated patients 
not only had more severe, but also more diffuse coronary 
artery disease than PCI patients, as in 34% (CABG) to 
40% (medically treated) of the patients, the culprit artery 
could not be identified; this percentage was only 8-10% in 
PCI patients. Left ventricular ejection fraction was lowest 
among medically treated patients. There were no appar-
ent differences in coronary angiography results between 
PCI patients receiving stents and those that did not 
receive stents. 
Clinical Outcome 
The 30-day mortality rate was significantly higher 
among medically treated patients (6.7%) than among 
those undergoing PCI either with (2.4%) or without stent 
placement (3.9%) (fig. 2). The observed difference in mor-
tality rate (p value= 0.067) between medically treated and 
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Table 2. Coronary angiography results 
Medical PC! CABG 
balloon stent 
Vessel disease, % 
2 38** 62** 61** 28*** 
3 51 32 30 52 
LM 11 6 9 21 
Significant stenosis (DS >50%) in 
RCA,Ofo 84 79 81 85** 
LAD,Ofo 88 77 82 91*** 
LCX,Ofo 84 77 72 79*** 
LM,Ofo 12 6 10 22*** 
Total occlusion (DS = lOOOfo) in 
RCA,Ofo 48 33 33 33*** 
LAD,Ofo 35 24 26 20*** 
LCX,Ofo 32 21 21 17*** 
Culprit artery, % 
RCA 14 27 25 16*** 
LAD 21 25 29 29*** 
LCX 14 31 21 9 
LM 2 1 1 9*** 
Graft 9 8 14 3*** 
None/unknown 40 8 10 34*** 
MeanLVEF ± SD 50±16 55±14 54±14 53± 14*** 
DS =Diameter of stenosis; LAD =left artery, descending; LCX = 
left circumflex; LM =left main; L VEF =left ventricular ejection frac-
tion; RCA= right coronary artery; other abbreviations, as defined in 
the text. Statistical tests (integral comparison of 4 groups): ** p < 
0.01; ***p<O.OOl. 
CABG patients (4.8% mortality) did not reach the re-
quired level of significance, which was prespecified as p < 
0.0083. 
The 30-day MI rate according to the opinion of the 
CEC was lower among medically than non-medically 
treated patients, with the highest event rate observed in 
the CABG group (2 7. 7% ); approximately half of the Mls 
in the PCI and CABG subgroups occurred within 48 h 
after the procedure. Differences in event rates as observed 
at 30 days were still present at the 6-month follow-up. 
Mortality was highest in the medically treated subgroup 
(11.1% ). Mortality rates were similar in the non-medical 
treatment subgroups (ranging from 5.5 to 6.5%). MI rates 
as judged by the CEC were lowest in the medically treated 
patients (20.8%) and highest in patients undergoing 
CABG (29.6%). 
Acute coronary syndromes and multivessel disease in the PURSUIT trial 
% % 
30 a 30 b 29.6 
20.8 20.8 
20 20 
10 10 
Medical Balloon Stent Surgery Medical Balloon Stant Surgery 
Fig. 2. 30-day (a) and 6-month (b) clinical outcome according to the treatment strategy applied. Black bars indicate 
mortality and white bars indicate MI adjudicated by the CEC. p Values for the overall comparison between any of the 
treatment strategies applied (medical treatment, balloon, stentor surgery) and each clinical endpoint are as follows: 
a death: p = 0.002, MI: p = 0.001 both at 30 days and 6 months. 
% % 
15.0 a 24 b 
20.7 
12.1 
7.5 12 
Medical Balloon Stent Surgery Medical Balloon Stent Surgery 
Fig. 3. 30-day (a) and 6-month (b) repeat revascularization procedures according to the treatment strategy applied. 
Black bars indicate PCI and white bars indicate CABG. p Values for the overall comparison between any of the 
re-interventions and each group based on the treatment strategy applied initially (medical treatment, balloon, stentor 
surgery) are as follows: PCI, CABG: p < 0.001 both at 30 days and 6 months. 
Repeat Revascularization Procedures 
The rate of repeat revascularization at the 30-day and 
6-month follow-up were significantly lower after CABG 
than after PCI (fig. 3). Patients undergoing stent implan-
tation during the initial PCI had lower CABG rates at 
each of these 2 points in time when compared to non-
stented patients. No apparent differences were observed 
in the rates of repeat interventions between stented and 
nonstented patients. A substantial number of medically 
treated patients still underwent a PCI (4.6%) or CABG 
(15.4%) procedure between 1 and 6 months after admis-
sion. 
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Discussion 
Patients who present with acute chest pain without 
persistent ST segment elevation represent a heteroge-
neous population, which spans from noncardiac chest 
pain (retrospectively diagnosed), to unstable angina and 
acute MI. The uncertainty in early clinical diagnosis 
forces clinicians to embark upon an empirical course of 
treatment, and this is the main reason why the clinical 
community still debates intensively regarding the optimal 
treatment strategy for patients with non-ST elevation 
acute coronary syndromes. Coronary angiography identi-
fies patients with nonsignificant coronary stenoses and 
those with multivessel or left main disease. The former 
group has an excellent prognosis with a low risk of pro-
gression to MI or death, whereas the latter group, which is 
at an increased risk of progression to any ofthe aforemen-
tioned events, may derive a survival benefit from revascu-
larization (either PCI or CABG) [ 15, 16]. Patients who are 
not suitable candidates for standard revascularization or 
those who are at high risk of major perioperative compli-
cations due to comorbid conditions represent a distinct 
category in which medical treatment is preferred. 
A major goal in PURSUIT was to understand the het-
erogeneity of the patient population and treatment strate-
gies applied. The investigators therefore chose to embed 
the study of the effects of epifibatide in a real-life clinical 
setting including a broad spectrum of clinical practices, 
from rural hospitals to major tertiary referral centers 
around the world. To reflect actual clinical practice, no 
recommendations were made regarding the use and tim-
ing of coronary angiography, percutaneous coronary in-
terventions or coronary bypass surgery, but all treatment 
decisions were left at the discretion ofthe team oftreating 
physicians. Therefore, the results of the present descrip-
tive analysis should be interpreted with this background 
in mind and viewed with the inherent limitations to sub-
group analysis of randomized clinical trials [ 17]. 
Although not prospectively randomized to each of the 
treatment strategies compared, it is important to note that 
the medical therapy, early PCI and CABG ratio in these 
subgroups of 3,067 patients with an acute coronary syn-
drome and multivessel coronary artery disease was almost 
1:1:1. 
Indeed, important differences were observed in clini-
cal characteristics and coronary anatomy between the dis-
tinct subgroups. Patients who did not undergo a coronary 
intervention within 30 days after enrolment, generally 
were in a less favorable clinical condition than patients 
undergoing early invasive treatment. The relatively high 
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30-day and 6-month mortality rate among medically 
treated patients is therefore not surprising and argues for 
the search of better treatment strategies in unstable pa-
tients with multivessel coronary artery disease that are 
not good candidates for revascularization procedures. Im-
portant determinants in the decision to refrain from inva-
sive treatment in this patient population seem to be 
comorbid conditions, left ventricular dysfunction (medi-
cally treated patients more often had a history of CABG, 
heart failure, and a worse left ventricular function as com-
pared to CABG patients) and the extent of coronary 
artery disease (medically treated patients more often had 
3-vessel and left main disease as compared to PCI pa-
tients). 
limitations 
This was a retrospective assessment of clinical, angio-
graphic characteristics and clinical events in patients 
enrolled in a multicenter clinical trial and stratified ac-
cording to the treatment strategy applied with a follow-up 
limited to 6 months, which can be considered as the main 
caveat of this study. We lack data on anginal status at 
baseline and 6 months; and on other predictors of adverse 
outcome such as completeness of revascularization; in 
both PCI and CABG patients. There were insufficient 
data on postprocedural cardiac enzymes as well. How-
ever, the present analysis reflected standard practice in a 
wide range of clinical settings, and contemporary treat-
ment strategies for the management of patients with acute 
coronary syndromes and multivesel disease were used in 
this trial. 
Conclusions 
The observed major differences in clinical outcome are 
explained by an imbalance in baseline and angiographic 
characteristics between the groups of patients analyzed 
according to the treatment strategy applied. 
Acute coronary syndromes and multivessel disease in the PURSUIT trial 
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Clinical and Qyantitative Coronary 
Angiographic Predictors of Coronary Restenosis 
A Comparative Analysis From the Balloon-to-Stent Era 
Nestor Mercado, MD, DSc,* Eric Boersma, PHD,* William Wijns, MD, PHD,t 
Bernard J. Gersh, MB, CHB, DPmL, FACC,:j: Carlos A. Morillo, MD,§ Vincent de Valk, PHD,II 
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Rotterdam and Utrecht, The Netherlands; Aalst, Belgium; Rochester, Minnesota; and Bucaramanga, Colombia 
OBJECTIVES We sought to assess whether coronary stents have modified the predictive value of 
demographic, clinical and quantitative coronary angiographic (QCA) predictors of coronary 
restenosis. 
BACKGROUND A systematic analysis in a large cohort of registries and randomized trials of the percutaneous 
transluminal coronary angioplasty (PTCA) and stent era has never been performed. 
METHODS A total of 9,120 treated lesions in 8,156 patients included in nine randomized trials and 10 
registries, with baseline, post-procedural and six-month follow-up QCA analyses, were 
included in this study. Predictors of restenosis were identified with univariate and multivariate 
logistic regression analyses. Interaction terms were introduced in the regression equation to 
evaluate whether the predictors of restenosis were common to both eras or specific for either 
one of the revascularization techniques. 
RESULTS The restenosis rate was 35% after PTCA and 19% after angioplasty with additional stenting. 
In the univariate analysis, favorable predictors were previous coronary artery bypass graft 
surgery (CABG), stent use, stent length and a large pre-procedural minimal lumen diameter 
(pre-MLD ); unfavorable predictors were weight, body mass index, diabetes mellitus, 
multi-vessel disease, lesion length and a high residual post-procedural diameter stenosis 
(post-DS). Predictors specific for the PTCA population were a large post-procedural MLD 
(post-MLD) as favorable and a severe pre-procedural DS (pre-DS) as unfavorable. Favorable 
predictors specific for the stent population were a large post-MLD and a large pre-procedural 
reference diameter (pre-RD). In the multivariate analysis, the best model included the 
following favorable predictors: stent use, a large post-MLD, previous CABG and the 
interaction term between stent use and a large post-MLD; unfavorable predictors were lesion 
length and diabetes mellitus. 
CONCLUSIONS There are no major differences in demographic and clinical predictors of coronary restenosis 
between PTCA and stent populations. In the modem (stent) era, a severe pre-DS is no longer 
an unfavorable predictor of restenosis. Still important, but more so in the stent population, is 
a large post-MLD (optimal result). Finally, a larger pre-RD became a favorable predictor 
with the advent of stenting. (J Am Coil Cardiol2001;38:645-52) © 2001 by the American 
College of Cardiology 
Coronary restenosis after a percutaneous intervention is a 
complex multifactorial phenomenon. With the advent of 
coronary stenting, constrictive vascular remodeling (a major 
component of the process of restenosis) has been prevented, 
and restenosis has decreased to a great extent. Nonetheless, 
restenosis remains an important clinical problem that con-
tinues to exert a major negative impact on patients' long-
term outcome after percutaneous coronary interventions. 
Several demographic, clinical, quantitative coronary angio-
graphic (QCA) and intravascular ultrasound (IVUS) 
variables have been described previously as predictors of 
restenosis in either percutaneous transluminal coronary 
angioplasty (PTCA) or stent populations (1-8). 
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lands; tCardiovascular Center, Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium; 
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From the mechanistic point of view, there is a clear 
difference between restenosis after PTCA alone and PTCA 
plus stenting. As assessed by IVUS studies, the prevailing 
mechanism in restenosis after PTCA alone is arterial 
remodeling, with late vessel contraction responsible for 
>60% of late lumen loss (9), whereas accelerated intimal 
hyperplasia predominantly causes in-stent restenosis (10). 
Previous reports, which are hampered by their small 
sample sizes, have analyzed a limited number of potential 
predictors of restenosis in either the stent or PTCA popu-
lation analyzed separately. The aim of this study was to 
assess to what extent the introduction of coronary stents has 
modified the predictive value of previously identified demo-
graphic, clinical and QCA predictors of coronary restenosis 
in the balloon era. We combined two patient populations: 
patients treated with PTCA only (PTCA population) and 
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Abbreviations and Acronyms 
CABG = coronary artery bypass graft surgery 
CI = confidence interval 
DS = diameter stenosis 
IVUS = intravascular ultrasound 
LAD = left anterior descending coronary artery 
MLD = minimal lumen diameter 
PTCA = percutaneous transluminal coronary angioplasty 
0 R = odds ratio 
QCA = quantitative coronary angiography 
RD = reference diameter 
patients who also had coronary stents implanted (stent 
population). 
METHODS 
Patients were selected from 19 different studies: six random-
ized trials comparing the use of active medications aimed at 
coronary restenosis prevention after PTCA alone or PTCA 
plus stenting with placebo (Coronary Artery Restenosis 
Prevention On Repeated Thromboxane A2-antagonism 
[CARPORT] study [11], Multicenter European Research 
trial with Cilazapril after Angioplasty to prevent Translu-
minal coronary Obstruction with Restenosis [MERCA-
TOR] [12], Prevention of Angioplasty Reocclusion with 
Ketanserin [PARK] [13], Multicenter American Research 
trial with Cilazapril after Angioplasty to prevent Translu-
minal coronary Obstruction with Restenosis [MARCA-
TOR] [14], FLuvastatin Angiographic REstenosis 
[FLARE] [15] and TRAPidil In Stent [TRAPIST] [16]); 
10 stent registries (BElgian NEtherlands STENT 
[BENESTENT-2] pilot study [17], stent Primary Angio-
plasty in Myocardial Infarction [PAMI] pilot study [18], 
West European Stent Trial [WEST-1] [19], WEST-2 
[20], Wallstent native study [21], Registry for Optimal 
beStent Evaluation [ROSE] [22], DUET [23], European 
Antiplatelet Stent Investigation [EASI] [24], Study Of 
PHosphorycholine coating On Stents [SOPHOS] [25] and 
MAGIC 5-L [26]); and finally, three randomized trials 
comparing PTCA plus coronary stenting with PTCA alone 
(BENESTENT-1 [27], BENESTENT-2 [28] and stent 
PAMI [29]). 
These 19 studies were chosen because they are highly 
representative of the randomized trials and registries of 
PTCA and coronary stenting that have been performed in 
the past decade, antedating the use of intracoronary brachy-
therapy. In eight studies, treatment of more than one lesion 
per patient was allowed (CARPORT, MERCATOR, 
PARK, MARCATOR, BENESTENT-2, FLARE, stent 
PAMI, MAGIC 5-L); the remaining studies included only 
patients with a single lesion. For patients with multilesion 
PTCA or multilesion coronary stenting, all lesions were 
analyzed, and each was considered independently. 
Patients were included in this analysis if they had three 
adequate angiograms-one immediately before the inter-
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vention, one immediately after and one at six-month follow-
up. Patients with an unsuccessful procedure or with a lesion 
in a saphenous vein graft were excluded. 
Off-line analysis of angiographic outcomes was done 
using identical and standardized methods of data acquisi-
tion and analysis and definitions of the variables in the same 
core laboratory (Cardialysis, Rotterdam, The Netherlands) 
using the Cardiovascular Angiography Analysis System II 
(CMS II) (Pie Medical, Maastricht, The Netherlands) 
(30). 
Definitions. Procedural success was defined as a post-
procedural diameter stenosis (post-DS) <50% on visual 
inspection in the early trials (CARPORT, MERCATOR, 
PARK, MARCATOR and FLARE). Subsequently 
(BENESTENT -1, BENESTENT-2 pilot, EASI, 
BENESTENT-2, stent PAMI pilot, WEST-1, WEST-2, 
Wallstent native, stent PAMI, ROSE, DUET, TRAPIST 
and SOPHOS), procedural success was defined as <50% 
post-DS by on-line QCA and no occurrence of an in-
hospital major adverse cardiac event (death, acute myocar-
dial infarction, coronary artery bypass graft surgery [ CABG] 
or repeat PTCA), and finally, in the latest trial (MAGIC 
5-L), procedural success was reset to <20% post-DS by 
on-line QCA in the absence of an in-hospital major adverse 
cardiac event. Coronary restenosis was defined uniformly in 
all but one randomized trial according to the binary criteria 
with a cut-off point 2:50% DS at follow-up (31). In this 
randomized trial (CARPORT), a noncategorical approach 
was used, and restenosis was defined as a loss of2:0.72 mm 
in the MLD from post-PTCA to six-month follow-up. For 
standardization purposes, we computed the binary resteno-
sis rate of this trial based on the DS on the follow-up 
angiogram. The standard definitions for proximal and distal 
segments of the right coronary artery, left anterior descend-
ing coronary artery (LAD) and left circumflex coronary 
coronary artery have been described elsewhere (32). The 
pre-procedural reference diameter (pre-RD) was obtained 
by the interpolation method, and the lesion length was 
defined by curvature analysis (33). 
Statistical analysis. Statistical analysis was performed us-
ing the SAS version 8.0 software package (SAS Institute, 
Cary, North Carolina). To test for differences in baseline 
variables across the studies, the Kruskal-Wallis test (contin-
uous data) and the chi-square test (categorical data) were 
applied. Univariate and multivariate logistic regression anal-
yses were used to evaluate the relationships between demo-
graphic data, clinical characteristics, stent use, QCA vari-
ables and the six-month outcome of angiographic 
occurrence of restenosis, which was coded as a binary 
variable according to the partial method. The stent length 
was :S15 mm (with a minimal length of 8 mm) in 68% of 
patients with stents. In the remaining patients, the stent 
length varied from 18 mm (DUET study) to 48 mm 
(MAGIC 5-L study). For restenosis assessment, these two 
different subsets of the stent population (:S15 and >15 mm) 
were compared with the PTCA population. 
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Table 1. Baseline Characteristics 
PTCA Stent Pooled 
Population Population Group p Value' 
No. of patients 5,230 2,926 8,156 
No. of treated lesions 6,110 3,010 9,120 
Age (years) 59 (51, 65) 60 (52, 67) 59 (51, 66) <0.0001 
Men(%) 80.5 78 79 0.003 
Height (em) 172 (165, 178) 171 (165, 177) 172 (165, 178) 0.025 
Weight (kg) 78 (70, 86) 78 (70, 87) 78 (70, 87) 0.732 
History 
Hypertension 33% 38% 35% <0.0001 
Diabetes mellitus 10% 12% 11% <0.0001 
MI 35% 29% 32% <0.0001 
PVD 5.3% 5.6% 5.4% 0.562 
Angioplasty 6% 10% 8% <0.0001 
Bypass surgery 3.7% 2.7% 3.2% 0.010 
Smoking status 
Current 25% 29% 27% <0.0001 
Previous 60% 40% 50% <0.0001 
MVD 29% 28% 28.5% 0.089 
Clinical diagnosis 
CSA 84% 49% 66% <0.0001 
UA 8% 35% 21% <0.0001 
AMI 8% 16% 12% <0.0001 
V esse! treated 
Proximal RCA 27% 34% 30.5% <0.0001 
Distal RCA 6.4% 6% 6.2% 0.493 
Proximal LAD 20% 24% 22% 0.0003 
Distal LAD 25% 20% 22.5% <0.0001 
Proximal LCx 6.2% 6.4% 6.3% 0.776 
Distal LCx 15.4% 9.3% 12.3% <0.0001 
*Diiferences between the PTCA and stent populations. Data are presented as the median value (25th, 75th percentiles) or as 
percentages. 
Aiv1I = acute myocardial infarction; CSA = chronic stable angina; LAD = left anterior descending coronary artery; LCx = 
left circumflex coronary artery; 1vii = myocardial infarction; MVD = multiple-vessel disease; PTCA = percutaneous 
transluminal coronary angioplasty; PVD = peripheral vascular disease; RCA = right coronary artery; UA = unstable angina. 
Interaction terms between demographic data, clinical 
characteristics, QCA variables and stent use were intro-
duced to evaluate the influence of coronary stents on the 
predictors of coronary restenosis. To prevent associations by 
chance, p < 0.001 was considered significant for these 
interaction terms. All variables were entered into the mul-
tivariate model, irrespective of the results of the univariate 
analysis (excluding the interaction terms in which the 
specified level of significance was not reached). The final 
multivariate model was constructed by backward deletion of 
the least significant variables, while the Akaike criterion was 
applied-that is, the applied threshold of significance de-
pended on the degrees of freedom ( df) associated with the 
variable at hand; if 4f = 1, then p = 0.157 (34). The 
predictive accuracy of the final multivariate model was 
evaluated using the C-index (35) and the goodness of fit of 
the model was tested with the Hosmer-Lemeshow 
goodness-of-fit test (36). 
RESULTS 
A total of 9,120 treated lesions in 8,156 patients were 
considered for this study. Sixty-four percent of the patients 
were treated with PTCA only (PTCA population: n = 
5,230; 6,110 lesions), and coronary stents were implanted in 
36% of patients (stent population: n = 2,926; 3,010 lesions). 
The restenosis rate at six-month QCA follow-up was 
35% after PTCA, compared with 19% after stenting. The 
baseline characteristics of the PTCA and stent populations 
are described in Table 1. 
As might be expected (in such a heterogeneous popula-
tion), the demographic data and clinical characteristics were 
significantly different across registries and trials. The pa-
tients' median age increased from 57 years in the oldest trial 
(CARPORT) to 62 years in the latest trial (MAGIC 5-L). 
The percentage of diabetic patients varied from 5.8% 
(MERCATOR) to 17% (Wallstent native); no temporal 
trend was observed for this condition. The prevalence of 
previous CABG varied from 1% (BENESTENT-1 and 
stent PAMI pilot) to 5.6% (MARCATOR). 
The pre- and post-procedural and six-month follow-up 
QCA variables are described in Table 2. It is important to 
note that the restenosis rate decreased from 38% in PARK 
(1993, PTCA) to 12.8% in WEST-2 (1998, PTCA plus 
stenting). This decrease in the restenosis rate was observed 
despite a parallel increase in the length of treated lesions, 
from a median of 5.8 mm in MERCATOR (1992, PTCA) 
up to 14.3 mm in MAGIC 5-L (1999, PTCA plus 
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Table 2. Pre-Procedural, Post-Procedural and Six-Month Follow-Up C2!,1antitative Coronary 
Angiographic Analysis of Treated Lesions 
PTCA Stent Pooled p 
Population Population Group Value 
No. of patients 5,230 2,926 8,156 
No. of treated lesions 6,110 3,010 9,120 
Pre-RD (mm) 2.65 (2.3, 3.02) 2.93 (2.64, 3.27) 2.75 (2.4, 3.12) <0.0001 
Lesion length (mm) 6.45 (5.03, 8.28) 8.94 (6.86, 12.38) 7.06 (5.4, 9.4) <0.0001 
Stent length (mm) 15 (15, 18) 15 (15, 18) 
Pre-MLD (mm) 1 (0.81, 1.21) 0.98 (0.77, 1.18) 0.99 (0.79, 1.2) 0.0003 
Post-MLD (mm) 1.77 (1.52, 2.05) 2.65 (2.38, 2.93) 2.02 (1.65, 2.5) <0.0001 
Pre-DS (%) 63 ± 15.8 69 ± 15 65 ± 15.7 <0.0001 
Post-DS (%) 34 ± 9.6 16.7 ± 7.6 28 ± 12 <0.0001 
Restenosis rate at 6-month 35 19 27 <0.0001 
follow-up (%) 
Data are presented as the median value (25th, 75th percentiwles) or as the mean value ± SD. 
Pre- and post-DS =pre- and post-procedural diameter stenosis; pre- and post-J\tlLD =pre- and post-procedural minimal 
lumen diameter; pre-RD = pre-procedural reference diameter; PTCA = percutaneous transluminal coronary angioplasty. 
stenting). The post-procedural minimal lumen diameter 
(post-MLD) increased as well, with median values ranked 
between 1.67 mm in PARK (1993, PTCA) to 2.89 mm in 
EASI (1997, PTCA plus stenting). 
By univariate analysis (Fig. 1), stent use clearly showed a 
highly protective effect against restenosis (odds ratio [OR] 
0.48, 95% confidence interval [CI] 0.43 to 0.53) when 
compared with PTCA alone. Interestingly, the interaction 
term for stent use was not significant when applied to 
demographic and clinical variables. For post-MLD, pre-
procedural DS (pre-DS) and pre-RD, the interaction term 
between stent use and the predictor was highly signiiicant 
(p = 0.0009, p = 0.0002 and p < 0.0001, respectively), 
meaning they have different predictive values in the PTCA 
and stent populations. 
Favorable predictors common to the PTCA and stent 
populations were previous CABG, stent use, stent length 
<15 mm, stent length 2:15 mm and a large pre-procedural 
MLD (pre-MLD); unfavorable predictors were weight, 
body mass index, diabetes mellitus, multi-vessel disease, 
lesion length and a high residual post-DS. Predictors 
specific for the PTCA population were a large post-MLD 
as favorable and a severe pre-DS as unfavorable. Favorable 
predictors specific for the stent population were a large 
post-MLD and a large pre-RD. 
In the multivariate analysis, the model with the best predic-
tive accuracy and that best fit the entire population (Table 3) 
was composed of the following favorable predictors: stent use 
(OR0.83, 95% CI 0.72 to 0.97), a large post-MLD (OR0.53, 
95% CI 0.46 to 0.61), previous CABG (OR 0.69, 95% CI 0.53 
to 0.9) and the interaction term between stent use and a large 
post-MLD (OR 0.34, 95% CI 0.31 to 0.39); unfavorable 
predictors were lesion length (OR 1.05, 95% CI 1.04 to 1.06) 
and diabetes mellitus (OR 1.33, 95% CI 1.16 to 1.54). The 
Hosmer-Lemeshow goodness-of-fit test indicated that the 
model fit well with the data (goodness-of-fit statistic 2.81, p = 
0.94). 
The C-index for predictive accuracy initially demon-
strated a poor ability for demographic and clinical charac-
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teristics to discriminate between patients who did and those 
who did not develop coronary restenosis (C-index = 0.51), 
which subsequently improved slightly when the post-
procedural variables (mainly QCA) were added to the final 
multivariate model (C-index = 0.63). 
DISCUSSION 
In this study, several clinical and QCA predictors of 
coronary restenosis were identified in a large number of 
patients in two distinct populations. Signiiicant demo-
graphic and clinical predictors of restenosis did not differ 
between patients treated with PTCA alone and those with 
stents. In contrast, three QCA variables were differentially 
associated with restenosis. A large post-MLD was a favor-
able predictor in both the PTCA and stent populations, but 
the protective effect was more marked in the stent popula-
tion. A severe pre-DS was an unfavorable predictor in the 
PTCA population only, and a large pre-RD was a favorable 
predictor in the stent population. 
Clinical predictors. DIABETES MELLITUS. Patients with 
diabetes mellitus have been repeatedly shown to have an 
increased risk of developing restenosis, as compared with 
nondiabetics (37,38). The mechanisms responsible for the 
increased proclivity for restenosis in the diabetic patient are 
not completely understood. In an IVUS analysis, it was 
concluded that the main reason for increased restenosis in 
diabetic patients was exaggerated intimal hyperplasia in 
both stented and nonstented lesions (38). However, data 
from Van Belle et al. (39) do not support this hypothesis, 
but rather favor vessel remodeling (i.e., vessel constriction) 
as the main mechanism. 
Alterations in the expression of components of the 
fibrinolytic system within the lesions of diabetic patients 
may also be an important determinant of restenosis. Sobel et 
al. (40) demonstrated, in a detailed immunohistochemical 
analysis of coronary atherectomy samples, a disproportion-
ate elevation of concentrations of the prothrombotic plas-
minogen activator inhibitor type 1, which may induce 
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Figure 1. Univariate analysis of demographic, clinical and quantitative coronary angiography (Q_CA) predictors of coronary restenosis. When a common 
odds ratio (OR) is presented, the interaction term between stent use and each of the variables was not significant (p 2: 0.001), and then this is the OR (and 
its corresponding 95% confidence interval [CI]) for the percutaneous transluminal coronary angioplasty (PTCA) and stent populations {solid circles). The 
interaction term between stent use and each of the variables was significant (p < 0.001) if the PTCA (solid triangles) and stent (solid squares) populations 
each had two ORs (with 95% Cis) presented. AMI =acute myocardial infarction; BMI =body mass index; CABG = coronary artery bypass graft surgery; 
CSA = chronic stable angina; DM = diabetes mellitus; DS = diameter stenosis; HTA = hypertension; LAD =left anterior descending coronary artery; 
LCx = left circumflex coronary artery; MI = myocardial infarction; MLD = minimal lumen diameter; MVD = multi-vessel disease; PVD = peripheral 
vascular disease; RCA = right coronary artery; RD = reference diameter; UA = unstable angina. 
restenosis by clot-associated mitogens. More recently, 
atherectomy specimens from restenotic lesions after PTCA 
showed a reduced intimal hypercellular tissue content in 
patients with diabetes (41). Collagen-rich sclerotic content 
Table 3. Multivariate Analysis: Clinical and Olrantita.tive 
Coronary Angiographic Predictors of Coronary Restenosis 
Variable OR 95% CI p Value 
Intercept coefficient = 0.12 
Stent use 0.83 0.72-D.97 0.0193 
Lesion length 1.05 1.04-1.06 <0.001 
Post-MLD 0.53 0.46-{).61 <0.001 
Previous CABG 0.69 0.53-{).9 0.006 
Diabetes mellitus 1.33 1.16-1.54 <0.001 
Stent use* post-MLD 0.34 0.31-{).39 0.002 
*Interaction term between stent use and post-MLD. Hosmer and Lemeshow 
goodness-of-fit statistic = 2.81; p = 0.94; C-index = 0.63. 
CABG = coronary artery bypass graft surgel}'i CI = confidence interval; 
post-MLD = post-procedural minimal lumen diameter; OR ::;;: odds ratio. 
is increased, suggesting an accelerated fibrotic rather than a 
proliferative response in diabetics with restenosis after 
PTCA, putting into context again the fundamental impor-
tance of vessel remodeling in diabetics. 
PREVIOUS CABG. In the present study, restenosis was less 
likely to occur in the subgroup of patients with previous 
CABG. Vein graft intervention was excluded from our 
analysis. We can only speculate about possible mechanisms 
leading to less restenosis in patients with previous CABG. 
Some baseline characteristics differed between patients with 
and those without previous CABG, such as a lower per-
centage of current smokers (14% vs. 26%) and a higher 
proportion of patients with chronic stable angina (85% vs. 
75%). However, these variables did not independently 
predict restenosis by univariate analysis. The association is 
weak, and residual confounding factors may have played a 
role. 
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WEIGHT. Overweightness was positively associated with 
restenosis by univariate, but not by multivariate analysis. It 
may be argued that a potential relationship between obesity 
and restenosis is mediated through increased lipid levels. 
However, we found no association between total choles-
terol, cholesterol subfractions and restenosis after successful 
PTCA by either a categorical or continuous approach (42). 
CLINICAL DIAGNOSIS. We did not find the clinical diagno-
sis at the time of enrollment to be a predictor of restenosis 
in either the PTCA or stent populations. However, in 
patients treated with directional coronary atherectomy, clin-
ical instability was associated with signs of plaque inflam-
mation, which may promote restenosis (43). 
Angiographic predictors. CORONARY STENTING. The 
protective effect of coronary stenting against restenosis was 
demonstrated unequivocally by two major randomized trials 
(27,44). Further improvements in the technique of stent 
deployment and new stent designs have also contributed to 
decreasing the restenosis rate ( 45). 
PRE-RD. The pre-RD is a predictor of restenosis in the stent 
population, but not in the PTCA population. Because the 
implantation of stainless-steel stents invariably results in 
neointimal regrowth, >50% stenosis is more likely to occur 
in vessels of small diameter. Supporting this concept, 
Banters et al. (3) showed that stenting in vessels with a small 
RD was not associated with a greater lumen loss. 
POST -MLD. The post-MLD clearly influences restenosis 
development. The "bigger is better" paradigm proposed by 
Kuntz et al. (46) means that for every millimeter of increase 
in the post-MLD, there is an OR of0.56 (95% CI 0.49 to 
0.64) for restenosis in the PTCA population and an OR of 
0.33 (95% CI 0.27 to 0.42) in the stent population. Our 
findings indicate that the additional gain in post-MLD for 
restenosis prevention is more relevant after stent deploy-
ment than after plain balloon angioplasty. 
LESION LENGTH. Previous reports (5,47) have shown that 
lesion length was positively related with restenosis in PTCA 
alone and stented lesions. In these studies, lesion length was 
dichotomized with cut-off values 2::6.8 mm for patients 
treated with balloons and > 15 mm for those treated with 
stents. In this study, we used a continuous approach for 
lesion length and for each millimeter of increase in length, 
we found an OR of 1.04 (95% CI 1.03 to 1.05) for lesions 
treated with both PTCA and stents. 
STENT LENGTH. Our dichotomous approach for stent 
lengths ~15 mm and stent lengths >15 mm, each com-
pared to PTCA, indicated that the protective effect of 
stenting against coronary restenosis is reduced by ~ 12% 
when longer stents are used. Kobayashi et al. ( 48) similarly 
demonstrated, in an analysis of 1,090 lesions in 725 patients, 
that a progressively longer stented segment is associated 
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with an increased risk of restenosis, with six-month resten-
osis rates of 24%, 35% and 4 7% for stented segment lengths 
~20, > 20 to ~35 and ::::35 mm, respectively. In a recent 
pooled analysis of four Multi-Link stent trials (49), stent 
length was found to be a significant predictor of restenosis 
both by univariate and multivariate analyses, and for each 
millimeter of increase in stent length, there was an or of 
1. 04 for restenosis development. 
LOCATION OF TREATED LESION. The impact of the loca-
tion of the treated lesion on restenosis has been described in 
previous PTCA (1) and stent (2) studies. Evidence is 
conflicting, but most often, it is claimed that LAD lesions 
are more prone to restenosis. In one study (1), an OR of1.7 
(95% CI 1.5 to 2.1) was found for proximal, as compared 
with nonproximal LAD lesions treated with PTCA alone in 
a sample of 2,500 patients. Another analysis of binary 
restenosis at follow-up in 1,399 lesions reported an OR of 
1.31 for stented lesions in the LAD (2). In these two 
previous studies, a positive association was found, whereas 
others noted that the location of the stented lesion had no 
impact on restenosis after coronary stenting (3). After a 
detailed analysis, our results indicate that there is no 
evidence to support the idea that a given treatment location 
plays a role in the restenotic process. 
Study limitations. Short- and long-term clinical and an-
giographic outcomes after PTCA and stenting certainly 
have improved over the past decade as a result of better stent 
deployment strategies and more effective antithrombotic 
regimens. Both balloon-expandable stents (Palmaz-Schatz 
[PS]-153: 8.7%; heparin-coated PS-153: 33%; MULTI-
LINK: 9%; beStent: 4%; MULTI-LINK DUET: 5.2%; 
Crossfiex: 9.2%; and BiodivYsio: 6.7%) and self-expanding 
stents (Magic Wallstent: 10.4%; Wallstent: 13.8%) were 
used, and we did not stratifY for the potential influence of 
different stent types on restenosis. 
New techniques, such as vascular brachytherapy (50) and 
drug-eluting stents (51), have become available recently. 
Patients treated with these modalities represent a distinctive 
population in which the results of our analyses should not be 
applied. 
Conclusions. There are no major differences in demo-
graphic and clinical predictors of coronary restenosis be-
tween PTCA and stent populations. In the modem (stent) 
era, a severe pre-DS is no longer an unfavorable predictor of 
restenosis. Still important, but more so in the stent popu-
lation, is a large post-MLD (optimal result). Finally, a larger 
pre-RD became a favorable predictor with the advent of 
stenting. 
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As noted repeatedly, the treatment of in-stent 
restenosis remains one of the most vexing short· 
comings in interventional cardiology. Coronary 
restenosis is often manifested by symptom recur-
rence, which is translated into an increased rate of 
repeat revascularization. 
In this issue, Radke and colleagues 1 report the 
results of a well-conducted meta-analysis with data 
gathered from published reports of 28 different 
studies. These studies included a total of 3012 
patients with in·stent restenosis treated with six 
different modalities (stent-in-stent, rotational 
atherectomy, balloon angioplasty, laser angi· 
oplasty, directional atherectomy and vascular 
brachytherapy) and their clinical outcome at a 
follow-up of 9±4 months. Any major adverse car-
diac event (MACE) as defined by death, myocardial 
infarction, and target lesion revascularization 
(TLR) occurred in 30% of the patients, irrespective 
of the type of device used. In 90% of these cases, 
this MACE rate was driven by the need for TLR as a 
result of restenosis. In the meta-regression analy· 
sis, post-procedural diameter stenosis (DS post) was 
significantly correlated with the MACE rate. The 
lower the DS post, the lower the MACE rate. 
After the adjustment of confounding factors 
(lesion length, pre-procedural diameter stenosis 
and diabetes), vascular brachytherapy was associ-
ated with a non-significant reduction of 16.9% in 
the probability of MACE, as compared to balloon 
* Corresponding author. Thoraxcenter, Clinical Epidemiology 
Unit, Department of Cardiology, Erasmus University Medical 
Center, Room H-554, 3015 Rotterdam, The Netherlands. Tel.: 
+31-10-4632893; fax: +31-10-4089484 
E-mail address: nestorfelipem@hotmail.com (N. Mercado). 
angioplasty. The authors concluded that balloon 
angioplasty should be the preferred modality for 
the treatment of in-stent restenosis, particularly in 
focal lesions and that vascular brachytherapy 
should be considered in patients with diffuse 
in-stent restenosis. 
Several other issues deserve further credit and 
are worth mentioning in the light of recently 
published data. First, the authors are to be com-
mended for addressing the difficult issue of how to 
treat in-stent restenosis, an area where little 
randomized controlled clinical data is available. 
However, if one looks specifically at intracoronary 
radiation for in-stent restenosis, the authors 
included only four studies in this analysis. 
These studies were two registries (Beta WRIST 
and Lausanne registry) and two randomized clinical 
trials (WRIST and GAMMA-1 ). In the mean time, 
several additional studies have emerged. 2-4 A 
pooled analysis from the p trials (Beta WRIST, 
START 30, START 40 and INHIBIT) showed a 
33% relative reduction (RR) in MACE favouring 
brachytherapy. Similarly, a pooled analysis from 
the y trials (SCRIPPS-2, WRIST, GAMMA-1, 
GAMMA-2, long WRIST, long WRIST high-dose and 
SVG WRIST) demonstrated a 36% RR and finally, 
when pooling the p and y trials, altogether, a 35% 
RR was exhibited. These data clearly support 
vascular brachytherapy as the preferred treatment 
of in-stent restenosis. 
Second, comparing individual treatment modali· 
ties (stent-in-stent, rotational atherectomy, laser 
angioplasty, directional atherectomy and vascular 
brachytherapy) to balloon angioplasty without 
taking into account the angiographic pattern of 
in-stent restenosis may be inappropriate. In this 
respect, the authors fall short in correlating the 
angiographic presentation (lesion length and 
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geographic location of neointimal proliferation 
relative to the initially implanted stent) of in-stent 
restenosis (focal, diffuse intrastent, diffuse prolif-
erative or total occlusion) with the subsequent 
need for TLR, which in turn, is the clinical event 
that mainly drives the MACE rate, as previously 
mentioned_ The pre-intervention angiographic pat-
tern of in-stent restenosis is a powerful predictor of 
future TLR; as the 1-year rate of TLR increases in 
parallel with increasing severity of angiographic 
in-stent restenosis, ranging from 19% for patients 
with focal in-stent restenosis to 83% for patients 
with total occlusions. 5 
Finally, registry data on sirolimus-eluting stents 
for the treatment of in-stent restenosis have also 
become recently available, and thus far 41 patients 
(16 in Rotterdam, The Netherlands and 25 in Sao 
Paulo, Brazil) were treated with a sirolimus-eluting 
stent for in-stent restenosis. The 1-year MACE rate 
in these patients was 9.8%. These results, although 
based on a small number of patients, are extremely 
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encouraging and should pave the way for rand-
omized clinical trials of drug-eluting stents for the 
treatment of in-stent restenosis, which perhaps will 
be its most important and ultimate challenge. 
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Abstract 
Background: Restenosis and consequent adverse cardiac events are increased in 
diabetics undergoing percutaneous coronary intervention. Use of intracoronary stents 
may ameliorate such risks; however, factors influencing the likelihood of restenosis 
following stent deployment in this high-risk patient subgroup are unknown. 
Methods and Results: We retrospectively analyzed all stented diabetic patients 
from the ADVANCE, BENESTENT I, BENESTENT II pilot, BENESTENT II, DUET, 
EASI, EXCITE, FINESS 2, MAGIC 5L, MUSIC, ROSE, SOPHOS, TRAPIST, WEST 
1, WEST 2 and WELLSTENT native studies. Univariate and multivariate analyses, 
with 37 clinical and angiographic variables, compared those with and without 
restenosis, and predicted restenosis rates calculated using reference charts derived 
from angiographic data. Within the studies, 418/3090 stented patients with 6 month 
angiographic follow-up (14%) had diabetes. Restenosis (2::50% diameter stenosis at 
follow-up) occurred in 550/2672 non-diabetic (20.6%) and 130/418 (31.1%) diabetic 
patients (p<0.001 ). Univariate predictors of restenosis in those with diabetes were 
vessel reference diameter (RD) (p<0.001 ), minimal luminal diameter (MLD) before 
stenting (p=0.01 ), MLD and % diameter stenosis after stenting (p<0.001, p=0.04 ), 
stented vessel length (p<0.001 ), and lower body mass index (BMI) (p=0.04 ). Using 
multivariate analysis, only RD (p=0.003), stented length (p=0.04) and lower BMI 
(p=0.04) were associated with restenosis. Reference charts demonstrated an 
incremental risk of restenosis dependent solely on vessel reference diameter 
Conclusions: Restenosis following stent deployment is significantly increased in 
diabetic patients; vessel calibre, stented vessel length and lower BMI are predictors 
of in-stent restenosis in patients with diabetes. 
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Condensed abstract 
We sought to identify clinical and angiographic factors associated with in-stent 
restenosis in patients with diabetes mellitus. Stented diabetic patients from the 
ADVANCE, BENESTENT I, BENESTENT II pilot, BENESTENT II, DUET, EASI, 
EXCITE, FINESS 2, MAGIC 5L, MUSIC, ROSE, SOPHOS, TRAPIST, WEST 1, 
WEST 2 and WELLSTENT native studies were analyzed. In the studies, 418/3090 
patients were diabetic; restenosis occurred in 20.6% of non-diabetics and 31.1% of 
diabetics. By multivariate analysis, vessel diameter, stented length and lower body 
mass index were associated with in-stent restenosis in diabetics. Moreover, there 
was an incremental increase in restenosis risk as vessel diameter decreased. 
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Introduction 
Patients suffering from diabetes mellitus have a substantially higher cardiovascular 
mortality than the general population, even after adjustment for confounding factors 
1
·
2
. Coronary angiographic studies have demonstrated higher incidences of 
multivessel and left mainstem disease in diabetics 3·4 , as well as more distal disease 
with a higher plaque burden, smaller vessel reference diameter and poorer collateral 
formation 5"9. Such propensity for coronary disease may be related to an underlying 
atherosclerosis-prone state involving such factors as endothelial dysfunction, 
dyslipidaemia, hyperglycaemia, insulin resistance and the presence of advanced 
glycosylation end-products 10-16. The increasing incidence of diabetes (reaching 
epidemic proportions) 17 has important implications for the management of coronary 
artery disease in this patient subset. 
Diabetes has been shown to be a predictor of poor outcomes in all modes of 
coronary revascularization, and therefore the optimal treatment strategy for these 
patients remains unclear. Randomized trials of PCI versus coronary artery bypass 
graft surgery (CABG) for multivessel disease in diabetics (BARI, EAST, ARTS) have 
consistently demonstrated a benefit for CABG in terms of symptomatic relief of 
angina, freedom from subsequent cardiac events and absolute survival 18"21 . Factors 
influencing this observed benefit include the increased rates of occlusive-type 
restenosis 22 and of new lesion formation in diabetic patients 23 following PCI. 
Procedural success rates for single-vessel PCI have been demonstrated to be similar 
for diabetic and non-diabetic individuals 24"26 and currently-available data suggests 
that stent deployment decreases restenosis and cardiac event rates in diabetic 
patients 24,26,27_ 
However, there is little data regarding the differences between those diabetics who 
develop restenosis following stent deployment and those who do not; whether 
diabetics are at higher risk owing to longer lesions, smaller vessel calibre and 
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therefore higher restenosis rates or whether simply being diabetic adds a constant 
increment to restenosis risk to all patients, is unclear. 
This study evaluates patients from 16 interventional trials, using multivariate analysis 
to determine clinical and angiographic factors that might be associated with diabetic 
in-stent restenosis. 
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Methods 
Patient population 
All patients from 16 percutaneous coronary interventional (PCI) studies including 
stent deployment were considered for analysis 28-43 . Of these studies, three were 
randomized trials of stent deployment versus balloon angioplasty (ADVANCE, 
BENESTENT I, BENESTENT II), ten were registries of newer stent designs 
(BENESTENT II pilot, DUET, EASI, FINESS 2, MAGIC 5L, ROSE, SOPHOS, WEST 
1, WELLSTENT), two assessed the efficacy of intravascular ultrasound guided stent 
implantation (MUSIC, WEST 2) and two assessed the efficacy of novel oral 
treatments to prevent restenosis following PCI (EXCITE, TRAPIST) (abbreviations 
and acronyms- table 1 ). 
Baseline characteristics of patients enrolled in these studies have been published. 
BMI was calculated by dividing an individual's weight in kilograms by the height in 
meters squared (kg/m2). According to the WHO classification, a BMI between 18.5 
and 24.9 was considered normal, between 25 and 30 overweight, and a BMI greater 
than 30 was considered obese 44'45 . All clinical information was monitored and 
forwarded to the core laboratory (Cardialysis, Rotterdam) and entered into the study 
databases. Studies were approved by institutional ethics committees and written 
informed consent was obtained from all patients. 
All patients who received intracoronary stents, underwent 6-month angiographic 
follow-up and had complete clinical and angiographic data were included in the final 
analysis. Angiographic restenosis, defined as :;o: 50% diameter stenosis at the treated 
site, was determined for diabetic and non-diabetic cohorts within each of the included 
studies. Univariate analyses were performed using 37 clinical and angiographic 
factors to establish whether any were predictive of restenosis in the overall diabetic 
cohort; significant findings were then entered into a multivariate analysis to remove 
confounding factors. 
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Reference charts to predict 6 month in-stent restenosis were constructed, using RD 
pre-procedure and stented length post-procedure as variables, as previously 
described 46 . Based on the data available, a statistical model was constructed to 
predict the probability of restenosis for given parameters. In general, probability of 
restenosis increases continuously for smaller RD and longer stented lengths. In order 
to visualize this, ranges designed to examine the data categorically rather than 
continuously were defined. As an estimate of the probability of restenosis in each 
category, the midpoint of the intervals was used, on the assumption that within each 
interval, the probability of restenosis is constant. A reference chart with a probability 
for restenosis in each interval/range was thereby generated, providing probabilities 
rather than actual/measured rates in the input dataset. 
Angiographic analysis 
All procedural and follow-up angiograms were sent to the core laboratory 
(Cardialysis, Rotterdam, The Netherlands) and analysed by the Cardiovascular 
Angiography Analysis System, which has previously been validated. For each 
patient, multiple matched angiographic views were obtained after intracoronary 
administration of nitrate. Patients with an unsuccessful procedure or without 
angiographic follow-up were excluded from the analysis. For patients who had 
undergone multi-lesion coronary angioplasty, the most severe restenotic lesion at 
follow-up was entered into the analysis. The MLD and RD obtained by an 
interpolated method were determined on an end-diastolic frame. 
Statistical analysis 
Statistical analysis was performed using the SAS software package (SAS Institute, 
Cary, North Carolina). Continuous variables were compared using Student's t test 
and the categoric variables by the Fisher's exact test. We performed a logistic 
regression on the dependent variable Y, where Y=1 for diabetic patients with 
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restenosis and Y=O for patients without restenosis. As explanatory variables we 
considered 37 clinical and angiographic variables. We executed a univariate logistic 
regression defined by the formula Log (P[Y=1 ] I ( P[ Y=O ] ) ) = A + B*X, with X as 
the explanatory variable, A the intercept, and B the regression parameter. 
Multivariate logistic regression defined by the formula Log (P[Y=1] I (P[Y=O])) =A + 
B(1)*X(1) + B(2)*X(2) + ... + B(n)*X(n) with X(1), ... ,X(n) as the explanatory variables, 
A the intercept and B(1), ... ,B(n) the regression parameters was then performed. With 
the stepwise procedure a group of explanatory variables was selected that as a 
group were multivariate significant. A p value of <0.05 was considered significant. 
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Results 
In the 16 studies analyzed, 3090 patients received intracoronary stents and 
completed planned 6 month follow-up angiography. The proportion of diabetics and 
individual restenosis rates for the included trials are summarized in table 2. Of the 
overall population, 418 were diabetic, in whom a total of 467 lesions were treated 
with PCI. Restenosis, defined as :2: 50% diameter stenosis at follow-up, was 
significantly increased in the diabetic population (550/2672 (20.6%) non-diabetic 
patients compared with 130/418 diabetics (31.1%); p<0.001) (table 2). 
By univariate analysis, favorable predictors of in-stent restenosis in diabetics were 
RD (OR=0.40 [95% Cl 0.25-0.63]; p=0.0001) and MLD (OR=0.46 [0.25-0.83]; 
p=0.01) before stenting, MLD (OR=0.37 [0.23-0.60]; p=0.0001) and RD (OR=0.45 
[0.28-0.71]; p=0.0008) after stenting, and higher BMI (OR=0.94 [0.89-1.00]; p=0.04]. 
Unfavorable predictors of restenosis were percentage diameter stenosis after 
stenting (OR=1.03 [1.00-1.06]; p=0.04) and stented vessel length (OR=1.04 [1.02-
1.06]; p=0.0008) (table 3). By stepwise multivariate logistic regression analysis, only 
RD before stenting (p=0.003; OR 0.38), stented length of vessel (p=0.04; OR 0.92) 
and lower BMI (p=0.04; OR=1.03) predicted restenosis in diabetics. 
Cumulative frequency curves for MLD and % diameter stenosis at 6-month follow-up 
angiography were similar for diabetic and non-diabetic patients (Figure 1 ). 
Reference charts to predict 6 month rates of in-stent restenosis were constructed 
using pre-procedure RD and stented length post-procedure as variables (Figure 2). 
Diabetic patients, as expected, had an increased frequency of restenosis for all 
vessel RD and stented lengths. When non-diabetic values were subtracted from 
diabetic predicted restenosis rates, a 'subtraction' graph was constructed, removing 
the baseline effect of non-diabetic restenosis in order to investigate the effect of 
diabetes alone. The striking finding was that vessel RD, rather than stented vessel 
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length appeared to govern the increased rate of restenosis, with rates being constant 
across the range of RD (Figure 3). There was a basic 6% increase in predicted 
restenosis rate for all diabetics, with further increments of an additional 3% for vessel 
RD between 2.65 and 3 mm and a further 4% for RD less than 2.65 mm. This gives 
overall additional restenosis rates over and above the risk for non-diabetic individuals 
of 6% for larger vessels, 9% for intermediate-sized vessels and 13% for small 
vessels. 
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Discussion 
Large studies of patients undergoing percutaneous coronary intervention with 
planned 6 month angiographic follow-up have identified the clinical and angiographic 
predictors of restenosis 7 . These studies have also demonstrated that angiographic 
restenosis is more frequent than clinically driven repeat target lesion 
revascularisation 47.48 . Our analysis demonstrates that diabetic patients develop in-
stent restenosis significantly more frequently than non-diabetics 6 months post-
intervention. Our finding that 31.1% of diabetic patients develop restenosis at 6 
months concurs broadly with the studies of Van Belle et al. 27 , where restenosis in 
stented diabetics was 27% at 6 months, and that of Elezi et al. 26 , where the 
restenosis rate was 37.5%. Furthermore, the occurrence of in-stent restenosis in 
diabetics signifies a worse prognosis in terms of both cardiac morbidity and overall 
mortality 22 . Clinical outcomes were not specifically investigated in this study; given 
increased restenosis in diabetics compared with non-diabetics and the known 
correlation of restenosis with coronary events, it would be expected that diabetics 
should fare less well than their non-diabetic counterparts following intracoronary 
stenting in terms of event-free suvival and mortality, as has been borne out in 
previous clinical studies 24·26 . 
In this series of patients enrolled in 16 PCI studies, univariate predictors of in-stent 
restenosis in diabetics were: indices of vessel calibre (RD pre- and post-PCI, MLD 
pre- and post-PCI), percentage diameter stenosis after stenting, stented vessel 
length and lower BMI. By multivariate analysis, only RD pre-procedure, stented 
vessel length and lower BMI were predictors of restenosis in diabetics. Both vessel 
calibre and stent length are determinants of restenosis in non-diabetic patients also, 
but hitherto, BMI has not been described as influencing restenosis. It is also 
interesting that lower BMI was associated with increased restenosis, although by 
WHO criteria, both groups were, on average, overweight but not obese, and the 
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absolute difference in BMI between the two groups was small (mean BMI without 
restenosis 28.9, mean with restenosis 27.9). It is interesting to speculate on the 
interpretation of such a result; whether the lower BMI in the restenosis group might 
reflect a smaller body habitus with consequent smaller coronary vessel calibre is 
unclear, as height was not recorded. Further studies might seek to elucidate the 
reason for this finding and explore the relationship between BMI, vessel calibre and 
restenosis risk. 
Vessel calibre was a predictor of restenosis in this study; previous authors have 
described increased risk of restenosis for percutaneous intervention to small vessels 
49
, a risk that may not be offset by coronary stent placement in diabetics 50 . Our data 
suggest that vessel calibre is the principal determinant of in-stent restenosis in 
diabetic patients, with an escalating risk not affected by stented vessel length. This 
finding concurs with the findings of Kastrati et al. 51 and of Ormiston et al. 52, who 
described no effect of stented vessel length on risk of restenosis, including after 
deployment of long (25-35 mm) stents. 
Not only does diabetes and its atherogenic vascular milieu influence the risk of 
restenosis following vascular injury such as stent deployment, but also this may be 
dictated by the antidiabetic drugs employed. Novel thiazolidinedione agents 
demonstrate greater inhibition of arterial smooth muscle cell proliferation than 
biguanides and sulphonylureas 53 and have been shown in preliminary trials to be 
effective in preventing restenosis 54• As we do not have data on the split within our 
study population between diet-controlled, insulin or non-insulin-dependent diabetics 
and in the latter case on the type of oral antidiabetic therapy employed, it is difficult to 
comment on how these variables may have affected our findings. 
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Study limitations 
Although there was some standardization of clinical and angiographic data collection, 
only data common to all 16 study databases were included in the analysis. 
Furthermore, in these studies, diabetes was recorded as a binary (yes/no) variable 
and therefore we cannot accurately define whether these results apply strictly to 
insulin-dependent or non-insulin-dependent diabetes mellitus, nor to the mode of 
treatment (diet/oral hypoglycaemic agents/insulin). In addition, exclusion criteria for 
PCI studies mean that this study population was carefully selected and probably at 
lower risk for restenosis than an unselected "everyday" PCI population. Finally, it 
should be noted that the different trials that make up this study population used 
different stent types, including both balloon-expandable and self-expanding designs. 
All stents used in these populations were bare metal stents, and it is possible that 
these results may not be applicable to current practice in view of the expanding 
implementation of the use of drug-eluting stents, a strategy that appears to be 
equally as effective in preventing major adverse cardiac events and restenosis in this 
high-risk patient subgroup 55. 
Conclusions 
Coronary in-stent restenosis following PCI occurs more frequently in diabetic 
individuals than non-diabetics. Predictors of in-stent restenosis at 6 months post-
procedure by multivariate analysis are vessel calibre, stented vessel length and low 
BMI. The rate of restenosis calculated by constructed reference charts demonstrated 
that vessel RD was the principal determinant of restenosis, with rates of 6%, 9% and 
13% over non-diabetic restenosis rates for large, medium and small-sized vessels 
respectively. 
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ADVANCE 
BENESTENT 
DUET 
EASI 
EXCITE 
FINESS 2 
MAGIC 5L 
MUSIC 
ROSE 
SOPHOS 
TRAPIST 
WEST 1,2 
WELLSTENT 
Additional stenting after balloon angioplasty for long lesions study 
Belgium & Netherlands stent study 
Evaluation of the ACS-Multilink DUET coronary stent system 
European Antiplatelet Stent Investigation 
Evaluation of oral Xemilofiban in Controlling Thrombotic Events 
First International NIR Endovascular Stent Study 
Influence of Magic Wallstent length on restenosis 
Multicenter Ultrasound Stenting in Coronaries study 
Registry for Optimal Stent Evaluation 
Study of Phosphorylcholine on Stents 
Trapidil for Prevention of ln-Stent Restenosis 
West European Stent Trial 
Self-expanding Wallstent for longer native coronary lesions study 
Table 1. Abbreviations and acronyms for trials included in this study. 
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n with QCA followup Restenosis rates(%) 
Non-diabetic Diabetic (%) Non-diabetic Diabetic p value 
ADVANCE 76 13 14,6 26,3 46,2 0,19 
BENESTENTI 221 16 6,8 21,3 25,0 0,75 
BENESTENT II pilot 178 14 7,3 11,2 21,4 0,23 
BENESTENTII 161 33 17,0 15,5 27,3 0,13 
DUET 161 24 13,0 16,1 20,8 0,56 
EASI 220 29 11,6 15,5 31,0 0,06 
EXCITE 435 91 17,3 26,4 34,1 0,16 
FINESS 2 109 29 21,0 18,3 24,1 0,60 
MAGIC 5L 217 32 12,9 39,6 34,4 0,70 
MUSIC 127 17 11,8 11,0 0,0 0,37 
ROSE 92 16 14,8 18,5 37,5 0,10 
SOPHOS 157 22 12,3 16,6 27,3 0,24 
TRAPIST 231 35 13,2 24,2 48,6 0,004 
WEST1 87 8 8,4 11,5 12,5 1,00 
WEST2 129 21 14,0 9,3 33,3 0,007 
WELLSTENT NATIVE 71 18 20,2 31,0 44,4 0,40 
Total 2672 418 13,5 
Overall 20,6 31,1 <0.001 
Table2 
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0. Univariate analysis () 
0 :::r 
No restenosis (%) Restenosis (%) p OR 95% Cl p 
-8 
n= 288 130 <D 
""' Demographics 'J 
Age, mean (range), y 61.6 (40.0-82.9) 63.2 (38.4-81.1) 0,11 0,11 
Male sex 221 76,7 93 71,5 0,27 0,26 
Body Mass Index, mean (range) 28.9 (17.7-41.7) 27.9 (20.3-37.3) 0,03 0,94 0.89-1.00 0,04 
Risk factors 
Hypertension 111 48,7 49 49,5 0.90 0,89 
Hypercholesterolemia 125 54,8 53 53,5 0.90 0,83 
Never smoked 81 28,1 35 26,9 0,91 0.80 
Ex-smoker 138 47,9 70 53,8 0,29 0,26 
Current smoker 69 24,0 25 19,2 0,31 0,28 
Family history 71 34,8 33 36,3 0.90 0,81 
Anginal status at screening 
Silent ischemia 8 3,5 3 3,1 1.00 0,84 
Stable angina 128 56.4 57 58,8 0,71 0,69 
Unstable angina 91 40,1 37 38,1 0.80 0.80 
Vascular disease at screening 
Previous Ml 80 35,1 39 39.4 0.46 0,46 
Q waves on EGG 26 17,9 10 21,3 0,67 0,61 
Previous CABG 8 3,5 5 5,1 0,54 0,51 
Previous PCI 33 14,5 14 14,1 1.00 0,94 
Peripheral vascular disease 16 7,6 12 12,1 0,21 0.20 
Medications at screening 
Beta blocker 79 59.4 26 60,5 1.00 0.90 
Nitrate 87 65.4 29 67.4 0,86 0,81 
Calcium channel blocker 62 46,6 14 32,6 0,11 0,11 
Aspirin 112 91,8 35 87,5 0,53 0.42 
ACE inhibitor 25 21,6 14 32,6 0,21 0,15 
Diuretic 14 12,1 4 9,3 0,78 0,63 
Heparin 13 12.4 3 7,5 0,56 0.41 
Warfarin/Coumadin 3 2,9 2 5,0 0,62 0,53 
Coronary angiography 
Multivessel disease 69 30,3 29 29,3 0.90 0,86 
Left mainstem lesion 0 0,0 2 1,6 1.00 0,99 
LAD lesion 130 48,1 56 43.4 0,39 0,38 
Circumflex lesion 79 29,3 32 24,8 0.40 0,35 
Right coronary lesion 102 37,8 52 40,3 0,66 0,63 
RD pre-PCI, mean (range), mm 2.9 (1.6-5.5) 2.7 (1.6-4.0) <0.001 0.40 0.25-0.63 0,0001 
% OS pre-PCI, mean (range) 64.7 (39.0-100.0) 65.6 (31.0-1 00.0) 0,48 0.44 
MLD pre-PCJ, mean (range}, mm 1.0 (0.0-2.1) 0.9 (0.0-2.4) 0,02 0.46 0.25-0.83 0.01 
Lesion/stented length, mean (range), mm 12.1 (2.2-47.6) 15.3 (2.8-53.6) 0,003 1.04 1.02-1.07 0.0008 
RD post-PCI, mean (range), mm 3.2 (1.8-4.4). 3.0 (2.0-4.7) <0.001 0.45 0.28-0.71 0.0008 
% OS post-PCI, mean (range) 15.7 (2.0-42.0) 17.4 (0.5-52.0) 0.05 1.03 1.00-1.06 0.04 
MLD post-PCI, mean (range), mm 2.7 (1.2-3.9) 2.5 (1.1-4.1) <0.001 0.37 0.23-0.60 0,0001 
Table 3 
Diabetic in-stent restenosis 
100 ' 
~ 0 80 ;., 
(J 
s:::: 
Cll 60 ::l 
0" 
Cll 
... 
-Cll 40: -~ 
-; 
:; 20-E 
::l 
u 
0 
0 
100-
~ 0 
;., 80 
(J 
s:::: 
Cll 60 ::l 
0" 
Cll 
... 
I 
-Cll 40 ~ 
> ~ 
:; 20 E 
::l 
u 
0 
20 40 60 80 
%Diameter stenosis at angiographic follow-up 
1.5 
--Non Diabetics --Diabetics 
2 
.t 
~/~ 
( 
I 
./ 
I 
/ 
2.5 3 3.5 4 
Vessel reference diameter (mm) 
--Non Diabetics --Diabetics 
4.5 
100 
5 
Figure 1. Cumulative frequency curves for % diameter stenosis (top 
panel) and vessel RD comparing diabetic and non-diabetic patients at 6-
month angiographic follow-up. 
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Figure 3. Subtraction graph derived from subtraction of non-diabetic predicted 
risk of restenosis from diabetic predicted risk, generating incremental risk for 
effect of diabetes alone on restenosis. 
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STRUCTURED ABSTRACT 
Objectives: The purpose of this study was to evaluate the impact of body mass index 
(BMI) on the long-term outcomes in patients with multivessel coronary artery disease 
randomized to either stenting or coronary artery bypass surgery (CABG). 
Background: Obesity is considered one of the major modifiable risk factors for coronary 
heart disease. However, the impact of BMI on the outcomes after coronary artery 
revascularization remains controversial. 
Methods: We studied 1,203 patients with multivessel coronary artery disease who 
underwent either stenting (n=599) or CABG (n=604) in the Arterial Revascularization 
Therapies Study (ARTS). Patients were divided into three groups according to BMI: 
normal BMI between 18.5 and 24.9, overweight with a BMI between 25 and 30 and obese 
with a BMI greater than 30. 
Results: At three-years follow-up, the incidence of death or cerebrovascular events or 
myocardial infarction was similar for each one of the three BMI categories, regardless the 
revascularization technique employed. Repeat revascularization procedures were 
significantly higher among patients randomized to stenting, but similar among the different 
BMI groups. For patients randomized to CABG, there was a trend towards lower repeat 
revascularization procedures in obese patients (p=0.07). Among patients who underwent 
stenting, BMI had no impact on the three-year combined endpoint of major adverse cardiac 
or cerebrovascular events (MACCE) rates. Among patients who underwent CABG, 
MACCE rates were significantly lower for obese (11 %) or overweight (15%) patients 
compared to normal BMI patients (23%)(p=0.012). 
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Conclusions: In a large cohort of patients with multivessel coronary artery disease who 
underwent either surgical or percutaneous revascularization, BMI had no impact on the 
three-year outcome of patients who underwent stenting. Conversely, among patients who 
underwent CABG, overweight and obese patients had a significantly better outcome than 
normal BMI patients regarding MACCE-free survival, mainly due to lower rates of repeat 
revascularization procedures. Therefore, obesity should not be a factor favoring stenting in 
multivessel disease. 
171 
ChapterS 
CONDENSED ABSTRACT 
We analyzed the impact of body mass index on the long-term outcomes of 1,203 patients 
who underwent either multivessel stenting or coronary artery bypass surgery in the Arterial 
Revascularization Therapies Study. Overall three-year survival or survival without 
cerebrovascular events or myocardial infarction was similar among the different body mass 
index groups, regardless of the type of revascularization procedure. There was no 
significant difference in terms of death, cerebrovascular events, myocardial infarction or 
repeat revascularization procedures in normal body mass index patients who underwent 
either stenting or surgical revascularization. However, for patients who underwent surgical 
revascularization, event-free survival was significantly better for obese or overweight 
patients compared to normal body mass index patients, mainly due to a lower rate of repeat 
revascularization procedures. Among patients who underwent stenting, body mass index 
had no impact on the three-year outcomes. 
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ABBREVIATIONS 
ARTS = Arterial revascularization Therapies Study 
BARI = Bypass Angioplasty Revascularization Investigation 
BMI = Body mass index 
CABG = Coronary artery bypass graft 
CK-MB =Creatinine kinase myocardial band fraction 
MACCE =Major adverse cardiac or cerebrovascular events 
MI =Myocardial infarction 
PCI = Percutaneous coronary intervention 
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INTRODUCTION 
Excess body fat, overweight and obesity have become major public, medical and social 
concerns of our times. In the last two decades the prevalence of this metabolic disorder has 
increased significantly, and according to recent data, it affects more than 61% of the adult 
population (1,2). Obesity is associated with a variety of diseases, including hypertension, 
non-insulin dependent diabetes mellitus, cardiovascular and cerebrovascular disease, 
dyslipidemia, cancer and sleep disorders (3). Diets high in fat and calories and a sedentary 
lifestyle with reduced physical activity are more likely to be blamed for this increase in the 
prevalence of obesity (4,5). In view of epidemiological studies that have linked obesity and 
cardiovascular disease, the American Heart Association has included obesity as one of the 
major modifiable risk factors for coronary heart disease on par with cigarette smoking, 
physical inactivity and elevated blood cholesterol levels (6,7). Although long-term 
longitudinal studies have also shown that obesity is associated with excess cardiovascular 
morbidity and mortality (7,8), there is limited data on coronary artery revascularization and 
obesity. Recent studies have shown that in patients with known coronary artery disease 
who undergo percutaneous coronary artery revascularization, patients with body mass 
index (BMI) within the normal range are at the highest risk for in-hospital complications 
and cardiac death (9,10) as compared to patients with elevated BMI. Furthermore, overall 
one-year mortality rates and cardiac related-deaths were significantly higher in these 
patients, compared to overweight or obese patients (9,10). However, data from the 
randomized and observational registry of the Bypass Angioplasty Revascularization 
Investigation (BARI) ( 11) has shown that among patients who underwent coronary artery 
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bypass graft surgery (CABG), an increased BMI is associated with a worse long-term 
outcome after CABG, but not after percutaneous coronary intervention (PCI). Currently, no 
defmite conclusion can be obtained regarding the impact of BMI on the outcome after PCI 
or following CABG. 
The Arterial Revascularization Therapies Study (ARTS) was a multicenter, 
randomized trial that was designed to compare PCI with stenting versus CABG in patients 
with multi vessel coronary artery disease. The purpose of the present analysis was to assess 
the impact of BMI on the three-year outcomes following multivessel stenting or CABG in 
patients who participated in the ARTS trial. 
METHODS 
Study Design 
A total of 1,205 patients with multi vessel coronary artery disease, who were 
considered to be equally treatable with both modalities, were randomized to either stenting 
(n=600) or CABG (n=605) between April1997 and June 1998 at 67 participating centers 
worldwide as parts of the ARTS trial. Details of this study have been described previously 
(12,13). In brief, patients who had not had a previous revascularization procedure were 
included in the study. Inclusion criteria included stable or unstable angina, silent ischemia, 
and at least two new lesions that were located in different vessels and territories that were 
potentially amenable to stent implantation. Exclusion criteria included left main disease, 
reduced left ventricular function (<30%), overt heart failure, prior cerebrovascular accident, 
recent myocardial infarction (less than a week), severe hepatic and renal dysfunction or the 
need for major concomitant surgery. Conventional balloon angioplasty was permitted in 
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vessels with a diameter 1.50 mm and 2.75 mm, as complementary to stenting, if at least 
two substantial lesions were targeted for stenting (each patient required to have more than 
one stent). Bypass surgery was performed according to standard techniques, preferably 
using the left internal mammary to graft the left anterior descending coronary artery. 
Clinical Definitions 
The National Heart, Lung, and Blood Institute and the World Health Organization 
have introduced a weight classification for BMI, which is calculated by dividing an 
individual's weight in kilograms by the height in meters squared (kg/m2). According to 
their classification, a BMI between 18.5 and 24.9 was considered normal, between 25 and 
30 overweight, and a BMI greater than 30 was considered obese (14,15). Clinical and 
angiographic data were analyzed and adjudicated by an independent core laboratory 
(Cardialysis, Rotterdam, the Netherlands). Myocardial infarction was defined in the 
presence of documented new Q-waves and either a ratio of serum creatinine kinase MB 
(CK-MB) isoenzyme to total cardiac enzyme that was greater than 0.1 or a CK-MB value 
greater that 5 times normal values. Non Q-wave myocardial infarction after PCI was 
defined as a creatinine kinase MB enzyme elevation at least 5 times the upper normal value 
without new Q waves. Major adverse cardiac or cerebrovascular events (MACCE), defined 
as death; stroke, transient ischemic attacks and reversible ischemic neurological deficits; 
documented nonfatal myocardial infarction; and repeated revascularization either 
percutaneous or surgical was the primary endpoint of this study. 
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Statistical Analysis 
Continuous variables are expressed as mean ± 1 standard deviation and categorical 
variables as percentages. Comparisons among the groups were performed by analysis of 
variance (ANOV A) for independent samples and the chi-square test for comparison of 
categorical values. Event-free survival was estimated by the Kaplan-Meier method, and 
differences were assessed by means of the log-rank test. Cox proportional hazards 
methodology was used to develop models for three-year mortality. Variables included in 
the multivariate model were: age, diabetes, hypertension, gender, hyperlipidemia and BMI. 
Statistical analysis was performed with SAS software, (SAS Institute, Cary, NC). A p value 
<0.05 was considered significant. 
RESULTS 
Clinical and Angiographic Characteristics of the Patients 
Data on 1,203 consecutive patients who underwent PCI was available for complete 
analysis (two patients did not have complete data for the calculation of the BMI). Half of 
the patients were overweight and 72% were either overweight or obese with only 28% 
having normal BMI in both arms of the study. The baseline clinical characteristics of all 
patients are shown in Table 1. There was a higher incidence of unstable angina and current 
smoker status in normal BMI patients who underwent PCI compared to overweight or 
obese counterparts, whereas normal BMI patients who underwent CABG were usually 
older and had less hypertension than overweight or obese patients who underwent CABG. 
When we compared patients by BMI status, a higher percentage of overweight female 
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patients underwent CABG (23% vs. 16%, p=0.04) whereas a higher percentage of obese 
patients with diabetes were randomized to the PCI arm of the study (30% vs. 18%, 
p=0.027). Angiographic and periprocedural characteristics are shown in Table 2. There was 
a higher incidence of three-vessel disease in obese patients assigned to either stenting or 
CABG. 
Clinical Outcomes 
Three-year clinical outcomes for all groups are shown in Table 3. First, it should be 
emphasized that there was no effect of obesity on mortality independent of the treatment 
modality, suggesting that obese patients can safely undergo percutaneous or surgical 
coronary artery revascularization as their normal BMI counterparts. Three-year Kaplan-
Meier survival curves are shown in Figure 1. There was no difference in mortality rates 
between the two revascularization procedures according to BMI. Likewise, the incidence of 
cerebrovascular accidents (CVA) and/or myocardial infarction was similar among the 
different BMI groups, regardless of the revascularization technique (Figure 2 and Table 3). 
Although repeat revascularization procedures were significantly higher for patients 
randomized to stenting compared to those randomized to CABG, there was a trend towards 
fewer revascularization procedures in obese patients randomized to CABG (p=0.07) (Table 
3). BMI did not seem to influence on the method chosen for repeat revascularization (PCI 
or CABG) among patients with different BMI who required repeat intervention during the 
follow-up period. While a trend in the benefit of CABG over PCI with stents was shown in 
MACCE-free survival (including repeat revascularization procedures) for normal BMI 
patients (77% vs. 70%, p=0.159) (Figure 3), overweight and obese patients who underwent 
CABG had a significantly better outcome compared to their counterpart who underwent 
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stenting (85% vs. 63%, p<O.OOOl and 89% vs. 67%, p<O.OOOl, respectively) (Figure 3). 
BMI had no influence on the long-term outcomes of patients who underwent stenting, but 
three-year MACCE rates were significantly lower for obese (11 %) or overweight (15%) 
patients who underwent CABG compared to normal BMI patients (23%)(p=0.012) (Figure 
4). In unadjusted analysis, overweight and obese patients treated with CABG had a 47% 
risk reduction in MACCE at three years as compared to patients with normal BMI (Hazard 
ratio=0.56; 95%CI: 0.37-083). After multivariate adjustment for age, diabetes mellitus, 
hypertension, gender and hypercholesterolemia, the association of BMI with MACCE was 
weakened, but remained statistically significant (HR=0.58; 95%CI: 0.38-0.88). 
DISCUSSION 
In this study, we analyzed the impact of BMI on the three-year outcomes of a large 
cohort of patients with multivessel disease who were randomized to either percutaneous 
revascularization with stents or CABG as part of the ARTS Trial. We observed that normal 
BMI patients (BMI <24.9) had similar MACCE-free survival (including death, 
cerebrovascular events, myocardial infarction or repeat revascularization) regardless the 
type of revascularization procedure, whereas overweight and obese patients who had been 
randomized to CABG had a better MACCE-free survival, compared to patients who 
underwent stenting. Furthermore, among patients who had been randomized to CABG, 
normal BMI patients had a worse outcome compared to overweight or obese patients, 
whereas for patients randomized to stenting, BMI did not influence on the overall outcome. 
In the present study, BMI was not a predictive factor for death, myocardial 
infarction or cerebrovascular events at three years after either PCI with stents or CABG. 
179 
ChapterS 
The better long-term MACCE-free survival in high BMI patients randomized to CABG 
was mainly related to a lower rate of repeat revascularization procedures in these patients, 
which was not seen in patients randomized to stenting. This difference can't be ascribed to 
lower physical activity in obese patients that would reduce the clinical expression of 
coronary artery lesions, as it would not explain for the lack of difference in patients 
randomized to stenting. Nevertheless, it is important to take into account that despite the 
fact that obese patients who underwent stenting had a significantly higher rate of adverse 
risk factors (i.e., female gender, hypertension, three vessel disease and diabetes), their 
outcome was still similar regarding irreversible clinical events (death, myocardial 
infarction or stroke) and repeat revascularization procedures. The potential influence of 
new developments in anti-restenosis therapy (e.g., drug-eluting stents) in the outcomes of 
patients with multivessel disease is unknown and will need to be addressed in the future. 
Previous Studies 
These results are in discrepancy with a recent report that analyzed the impact of 
BMI in patients who underwent coronary artery revascularization with either balloon 
angioplasty or CABG in the Bypass Angioplasty Revascularization Investigation (BARI) 
(11 ). In this study, a higher BMI was associated with a worse long-term prognosis after 
CABG. In point of fact, a higher BMI was associated only with a better in-hospital 
outcome (regarding death, MI, stroke or coma) and exclusively among patients who 
underwent percutaneous balloon angioplasty. It is important to take into account that the 
BARI trial was initiated in 1988 and coronary artery revascularization has undergone major 
changes since then. Previous results from a recently published large retrospective analysis 
of a series of patients who underwent PCI at the Washington Hospital Center (9), the 
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Cleveland Clinic (1 0, 16) and from the British Regional Heart Study (17) have shown that 
low or normal BMI patients who undergo PCI are at the highest risk for in-hospital and 
long-term worse outcome, including increased cardiac mortality. 
The increasing prevalence of obesity in the developing world has augmented our 
awareness on the impact of BMI on the prognosis of different cardiovascular diseases. 
Contrary to initial expectations, patients with essential hypertension or heart failure and 
increased BMI have a better survival compared to patients of recommended weight (18, 19). 
Furthermore, obesity was not only associated with increased survival, but also there was a 
lower risk of stroke compared to lean patients in the Systolic Hypertension in the Elderly 
Program (SHEP) study (19). The mechanism by which overweight and obese patients have 
a better outcome has not been complete understood. There are plenty of theories that try to 
explain the potentially protective effect of obesity, including altered cytokines, lower 
plasma renin and epinephrine levels and larger coronary arteries. Also, the lean population 
is often a combination of patients who have lost weight due to underlying debilitating 
diseases and smokers (who have a tendency to weight less and have higher mortality rates 
compared to non-smokers) (8,20,21). Conversely, other studies have shown that the 
apparent excess risk associated with leanness among middle aged-women was artifactual 
and disappeared after accounting for cigarette smoking and subclinical disease (22). 
Among women that never smoked, the leanest had the lowest mortality and among obese 
women, mortality was more than twice that amid lean women (22). 
It is important to take into account that the consequence of excess body weight on 
mortality is delayed and may not be seen in a relatively short period of time. The effects of 
obesity increase with the duration of follow-up and the age of the subjects, with increased 
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mortality in the very lean patients during the first years of follow-up, and increased 
mortality in the obese patients in subsequent years (23-26). 
Limitations 
The ARTS trial was designed as a multinational, multicenter, randomized study that 
was not intended to assess the impact of BMI on the short- and long-term outcomes after 
multivessel coronary revascularization. Therefore, the conclusions may be slanted. There 
were significant differences in baseline clinical characteristics among the groups, which 
may have had an influence in the outcomes. In the evaluation of our results, we also need to 
address the possibility of bias. Because both, interventional cardiologists and surgeons had 
to agree before randomization on the eligibility of all candidates to undergo 
revascularization by either technique, selection bias is improbable. The number of patients 
in the obese arm was small, limiting the statistical power of the analysis. 
Conclusions 
The results of this study suggest the following: 1) more than 70% of all patients 
who underwent stenting or CABG for the treatment of multi vessel coronary artery disease 
in the ARTS trial were either overweight or obese, with only 28% of all patients having a 
normal BMI. This is a clear reflection of the increasing prevalence of obesity in the western 
world and a cause of concern for the developing countries; 2) BMI had no impact on the 
long-term outcomes of patients who underwent PCI with stents. However, despite a 
significantly higher rate of adverse risk factors in obese patients, they had similar outcomes 
regarding all endpoints as their normal BMI counterparts; 3) overweight and obese patients 
who underwent CABG had a significantly better outcome than normal BMI patients who 
underwent CABG; 4) normal BMI patients had similar outcomes regardless of the type of 
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revascularization procedure, whereas overweight and obese patients did significantly better 
with surgical revascularization; 5) Three-year mortality rates were similar for each one of 
the three BMI categories, regardless of the revascularization technique employed, and; 6) 
the relatively short follow-up period (three years) does not allow for the assessment of 
long-term adverse effects of obesity in any one of the two arms. We are only beginning to 
understand the effects of obesity on the short- and long-term outcomes of patients with 
cardiovascular diseases. The discrepancy of results observed in recent studies, only 
underscore the need for further research in this field. 
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FIGURE LEGENDS 
Figure 1. Three-year Kaplan-Meier survival curves among patients assigned to coronary 
stenting (dashed line) vs. coronary bypass surgery (solid line) stratified according to body 
mass index (BMI): normal BMI (BMI <24.9), overweight (BMI=25-30) and obese (BMI 
>30). 
Figure 2. Three-year Kaplan-Meier estimates of survival without cerebrovascular events or 
myocardial infarction among patients assigned to coronary stenting (dashed line) vs. 
coronary bypass surgery (solid line) stratified according to body mass index (BMI) in three 
categories: normal BMI (BMI <24.9), overweight (BMI=25-30) and obese (BMI >30). 
Figure 3. Three-year Kaplan-Meier event-free survival curves for MACCE (including 
death, cerebrovascular events, myocardial infarction or repeat revascularization) of patients 
assigned to coronary stenting (dashed line) vs. coronary bypass surgery (solid line) 
stratified according to body mass index (BMI): normal BMI (BMI <24.9), overweight 
(BMI=25-30) and obese (BMI >30). 
Figure 4. Three-year Kaplan-Meier event-free survival curves for MACCE (including 
death, cerebrovascular events, myocardial infarction or repeat revascularization) among 
patients assigned to coronary stenting or coronary bypass surgery stratified according to 
body mass index (BMI) at three categories: normal BMI (BMI <24.9), overweight 
(BMI=25-30) and obese (BMI >30). 
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Table 1. Baseline Clinical Characteristics. 
Coronary Stenting Bypass Surgery 
(n=599) (n=604) 
Normal Overweight Obese p Normal Overweight 
n=J68 n=307 n=124 n=J69 n=299 
Age (years) 61±10 61±10 60±10 0.43 63±10 61±9 
Female(%) 29.2 16.3 30.7 0.0004 22.5 23.0 
Unstable angina(%) 42.2 37.8 30.0 0.09 38.4 34.7 
Stable Ischemia(%) 52.3 56.6 62.9 0.20 56.2 59.8 
Silent Ischemia(%) 5.5 5.6 7.1 0.75 5.4 5.5 
PriorMI (%) 47.0 45.6 38.0 0.25 42.6 40.0 
Hypertension (%) 37.5 45.0 53.2 0.03 37.3 44.4 
Diabetes mellitos (%) 8.9 19.5 30.0 <0.0001 14.2 15.7 
PVD(%) 6.5 4.9 5.6 0.75 7.1 5.3 
Family history(%) 39.3 36.0 45.0 0.07 42.6 42.4 
Hypercholesterolemia(%) 51.8 58.6 63.0 0.14 52.6 59.8 
Current smoker (%) 37.0 24.4 24.2 0.007 26.6 24.0 
Ejection fraction (%) 61±12 60±12 62±13 0.34 60±13 60±13 
BMI 23±1.6 27±1.3 32±2.3 <0.0001 23±1.5 27±1.4 
MI = myocardial iofarction; CABG = coronary artery bypass graft surgery; PVD =peripheral vascular 
disease. 
Obese 
n=l36 
59±9 
28.0 
33.2 
63.2 
3.6 
45.5 
55.1 
17.6 
2.2 
40.0 
59.0 
28.6 
62±14 
32±2.3 
p 
0.009 
0.47 
0.58 
0.46 
0.73 
0.56 
0.007 
0.71 
0.15 
0.82 
0.21 
0.65 
0.15 
<0.0001 
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Table 2. Periprocedural Characteristics. 
Coronary Stenting Bypass Surgery 
(n=599) (n=604) 
Normal Overweight Obese p Nonnal Overweight Obese p 
n=168 n=307 n=124 n=169 n=299 n=136 
One-vessel disease (%) 0.6 0.6 0 0.45 0 0.6 0 0.3 
Two-vessel disease(%) 68.4 70.0 62.0 0.75 69.3 64.0 60.0 0.48 
Three-vessel disease(%) 31.0 29.4 38.0 0.045 30.7 35.4 40.0 0.04 
Vessel territory with stenosis 
Left anterior descending(%) 91.6 88.2 91.1 0.44 88.7 90.3 89.7 0.87 
Left circumflex (%) 69.0 66.0 71.7 0.45 71.0 73.0 74.2 0.81 
Right coronary (%) 69.6 74.2 75.0 0.48 71.0 71.5 76.4 0.50 
Complete revascularization (%) 74.8 73.7 68.0 0.51 93.3 93.2 97.0 0.08 
Number of stents 2.6±1.0 2.7±1.2 2.6±1.2 0.85 - - - -
Number of grafts 
- - - - 2.4±0.6 2.5±0.7 2.5±0.6 0.48 
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Table 3. Clinical outcomes at three-year follow-up 
Coronary Stenting Bypass Surgery 
(n=599) (n=604) 
Normal Overweight Obese p Normal Overweight Obese 
n=168 n=307 n=124 n=169 n=299 n=136 
Death(%) 6 (3.6) 11 (3.6) 5 (4) 0.97 8 (4.7) 14(4.7) 5 (3.7) 
CVA(%) 6 (3.6) 13 (4.2) I (0.8) 0.19 7 (4) 9 (3) 4 (3) 
MI(%) 12 (7) 20 (6.5) 12 (9.7) 0.52 13 (7.7) 12 (4) 7 (5) 
Repeat revascularization (%) 36 (21.4) 91 (29.6) 33 (26.6) 0.15 16 (9.5) 19 (6.3) 4 (3) 
CABG(%) 13 (7.7) 30 (9.7) 12 (9.7) 0.74 4 (2.4) 3 (!) 0 (0) 
PCI (%) 26 (15.5) 70 (22.8) 24 (19.3) 0.16 14 (8.3) 18 (6.0) 4 (3) 
TotalMACCE 51 (30.4) 114 (37) 41 (33) 0.31 39 (23) 45 (15) 15 (11) 
MACCE =Major adverse cardiac and cerebrovascular events; MI =myocardial infarctwn; CABG =coronary 
artery bypass graft surgery; CVA= cerebrovascular accident; PCI =percutaneous coronary intervention 
p 
0.87 
0.77 
0.23 
0.07 
0.15 
0.15 
0.012 
191 
ChapterS 
Figure 1 
NonnalBMI Overweight Obese 
100$ ---------~.~~~~::~~9821.. l{l\!{. CABGS~; lffi% CABGS""" 97.lW. 97.4'/. L-------------------- -
CABGS~ 96.4% 97.3"/. Coxonru:yStel'rtinig 96.81. 
~ ~ ~ 
~ ~ ~ 
m ;w m 
L>gR•nk !.OJ, df: 1 L>gR<ml"0.001, df: 1 L>g~0275,df: 1 
p -value"" 0311 p -v>lw.. 0973 p-v>lue• 0.6IJO 
ill( ill( !!& 
ID 00 !ro Ub I~ !ro Ub ID liD !ro Ub 
Days since Randomization 
Figure 2 
NonnalBMI Overweight Obese 
100% 100~ 100% 
·l ••••• \. Coro!UU)'Stenting 
"'\:: CABGS~ L~ CABGS1llg1>ty 92.61 .. t. _____ ,_ _____ \..91.6% 
'--),. 92% -l.----1,. _______________ 
88.7% ~ Coro,.";j;si;;.tl;,i · ·'' · • 90·2'/. m Coronaxy Srenting 903l'. CABGSuzgm; 
~ ~ ~ 
ill> m m 
L>g~O.SS,df:1 L>gRonk:0.58. df: 1 LogRw' 056, df: 1 
p -v>!ue • 0.356 p -v>lu.. 0.443 p -v>l .. - 0.452 
Sf> ill( ill( 
lro !ro w liD lln w ID lm !1ll w 
Days since Randomization 
192 
BMI and outcomes in the ARTS trial 
Figure 3 
NonnalBMI Overweight Obese 
Log Rank 2.25, df: 1 
p -V>lue. 0.133 
~+--.----,-~---, 
& I~ 
Logfuulk22.9.df: 1 
p -value< 0.0001 
iffi$~ 
,~% 
I 
lW.\ 
\., 
--L-, 
1..\ 
ill> '· 
--
1 
.. ~--.. 142'7 .. 
CoroM!)rStell!mi ••• ' -· 
LogRwk: 16.6, df: 1 
p-V>lue<0.0001 
Days since Randomization 
Figure 4 
Coronary Stenting 
lUll% 
--.;;::'::..,--,__ j~~ Obese 
j'i)% 
LogRW.: 0.37. df; 2 
p -V>lue = 0.645 
66%-f-'--~--~--,---, 
• 90 
72.3'1. 
CABG Surgery 
LogRwk623.df:2 
p -V>lue • OD44 
66%}-~~---r--,---, 
Days since Randomization 
193 

Part 3: Special subgroups on coronary revascularization 
Chapter9 
The Impact of renal failure on clinical outcomes in patients with 
multivessel disease undergoing coronary revascularization: The 
Arterial Revascularization Therapies Study (ARTS) 
Ix JH, Mercado N, Shlipak M, Boersma E, Lemos PA, Lindenboom 
W, O'Neill WW, Wijns W, Serruys PW 
Submitted for publication 

Renal insufficiency and clinical outcomes in the ARTS trial 
The Prognostic Impact of Renal Insufficiency on Long-term Clinical 
Outcomes in Patients with Multivessel Coronary Artery Disease 
Undergoing Coronary Revascularization: The Arterial 
Revascularization Therapies Study (ARTS) 
Joachim H. Ix, MD, Nestor Mercado, MD, DSc, Michael G. Shlipak, MD, MPH, Pedro 
A. Lemos, MD, Eric Boersma, PhD, Wietze Lindeboom, MSc, William W. O'Neill, MD, 
William Wijns, MD, PhD and Patrick W. Serruys, MD, PhD 
From the General Internal Medicine Section (J.H.L, M.G.S.), Veterans Affairs Medical 
Center, Departments of Medicine (M.G.S.) and Epidemiology and Biostatistics (M.G.S.), 
University of California, San Francisco, California; Department of Interventional 
Cardiology and Clinical Epidemiology Unit, Thoraxcenter (N.M., P.A.L., E.B., P.W.S.), 
Erasmus Medical Center and Cardialysis (W.L.), Rotterdam, the Netherlands; Division of 
Cardiology (W.W.O.), William Beaumont Hospital, Royal Oak, Michigan; and 
Cardiovascular Center (W.W.), Onze Lieve Vrouw Hospital, Aalst, Belgium. 
Reprint requests and correspondence: Prof. Patrick W. Serruys, Thoraxcenter, Bd 408, 
Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. 
E-mail: serruys@card.azr.nl 
197 
Chapter9 
ABSTRACT 
Background 
Chronic renal insufficiency (CRI) is associated with adverse outcomes after coronary 
artery bypass surgery (CABG) and percutaneous coronary intervention (PCI). In the 
Arterial Revascularization Therapies Study (ARTS) we evaluated the effect of CRI on 
outcomes after coronary revascularization and we compared the outcomes of patients 
with CRI who were randomly assigned to CABG or PCL 
Methods and Results 
The ARTS study randomly assigned 1205 patients with multivessel coronary artery 
disease (CAD) to CABG or PCL Of 1205 patients enrolled, 1176 (97%) had baseline 
creatinine data, among whom 290 (25%) had CRI, defmed by creatinine clearance::::; 60 
rnl/min estimated by the Cockroft-Gault equation. The primary clinical endpoint was the 
composite of death, myocardial infarction (MI), or stroke; and, a secondary outcome was 
repeat revascularization. The primary outcome occurred in 18% of patients with CRI and 
10% of patients without CRI at 3-years of follow-up (adjusted HR=l.61; 95%CI: 1.10-
2.35; P < 0.01). Within the CRI subgroup, no difference was observed in the primary 
endpoint after CABG vs. PCI (adjusted HR=0.93; 95%CI: 0.54-1.60; P = 0.97). 
However, CABG was associated with a reduced risk for repeat revascularization. 
(HR=0.28; 95%CI: 0.14-0.54; P < 0.01). 
Conclusions 
In patients with multivessel CAD, CRI is a risk factor for death, MI, or stroke after 
coronary revascularization. These outcomes occurred at equal rates among CRI patients 
treated with CABG or PCI, but CABG was associated with decreased repeat 
revascularizations. 
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CONDENSED ABSTRACT 
The effect of chronic renal insufficiency (CRI) on clinical outcomes after coronary 
revascularization was evaluated among the 1176 subjects randomized to PCI or CABG in 
the ARTS triaL CRI was associated with increased risk of MT, stroke, or death within 3 
years after revascularization (adjusted HR=l.6; 95% CI 1.1-2.3; P < 0.01). Amongst the 
290 CRI subjects, no difference in the primary outcome was observed between those 
treated with CABG vs. PCI (adjusted HR=0.93; 95% CI 0.54-1.60; P = 0.97). However, 
CABG was associated with reduced risk for repeat revascularizations (HR 0.28; 95% CI 
0.14-0.54; p < 0.01). 
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INTRODUCTION 
Chronic renal insufficiency (CRI) is common in the general population, estimated to 
affect over one forth of persons aged 65 and older in the United States\ and is an 
independent predictor of incident stroke, myocardial infarction (MI) and all cause 
mortalit;?-7. In addition, CRI is associated with increased mortality after coronary artery 
bypass grafting (CABG)8-10, perhaps because such patients have longer post-operative 
mechanical ventilation time, higher post-operative bleeding rates and transfusion 
requirements, and increased length of hospital stal. However, percutaneous coronary 
intervention (PCI) in these patients is also high-risk due to their increased incidence of 
acute renal failure, restenosis, and mortality1H 5. Whether CABG or PCI offers a better 
clinical outcome and prognosis has not been prospectively studied. 
The Arterial Revascularization Therapies Study (ARTS) was a multinational trial that 
randomly assigned patients with multivessel coronary artery disease (CAD) to either 
CABG or PCI with multivessel coronary stenting. In the present study, we evaluated the 
effect of CRI on outcomes after coronary revascularization, and we compared the 
outcomes of patients with CRI who were randomly assigned to CABG or PCI to assess if 
the alternative strategies were associated with different clinical outcomes. 
METHODS 
Patient selection 
Study design and primary results of the ARTS have been described previously16•17• 
Briefly, the study was a randomized trial comparing CABG vs. PCI with multivessel 
coronary stenting in patients with ischemic symptoms. Patients who had not previously 
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undergone CABO or angioplasty were eligible for coronary revascularization if they had 
either stable angina pectoris, unstable angina pectoris or if they had silent ischemia with 
at least two lesions on angiography located in different vessels and territories and 
amenable to stenting. All patients were thought to be equal candidates for either CABO 
or PCI with stenting by the cardiac surgeon and interventional cardiologist at each 
participating center. Patients gave written consent and were randomly assigned to either 
procedure via a central telephone service with stratification by clinical site. Patients were 
excluded if they had a left ventricular ejection fraction < 30 percent, overt congestive 
heart failure, prior stroke, transmural MI in the previous week, intolerance of aspirin or 
ticlopidine, need for other concomitant major surgery, presence of severe hepatic disease, 
diseased saphenous veins, neutropenia, or thrombocytopenia. Patients were also excluded 
if they had a serum creatinine > 1.7mg/dL (150mmol/L). Creatinine clearance was 
estimated by the Cockcroft-Oault formula18 [(140-age) * body weight (kg)/serum 
creatinine (mg/dL) * 72] (* 0.85 in women), and CRI was defined as::; 60 mVmin. 
Clinical outcomes 
The primary outcome was the event free survival without stroke, transient ischemic 
attack, nonfatal MI, or death. The secondary outcome was the need for repeat 
revascularization by percutaneous intervention or surgery. Within the first seven days 
after revascularization, the diagnosis of MI required documentation of a new abnormal Q 
wave (according to the Minnesota code)19 plus a ratio of serum creatine kinase MB (CK-
MB) isoenzyme to total cardiac enzyme> 0.1 or a CK-MB value five times the upper 
limit of normal. After the first week, either abnormal Q waves or enzymatic changes were 
sufficient to diagnose MI20'21 . All Mis were confirmed by the electrocardiographic core 
laboratory and the clinical-events adjudications committee. Cerebrovascular events were 
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divided into three categories: stroke, transient ischemic attacks, and reversible ischemic 
neurologic deficits. Events were classified in ischemic or non-ischemic categories, and 
were confirmed by the clinical-events adjudications committee. 
Follow-up was initiated at the time of randomization and clinical information was 
obtained by telephone contact with the patient or patient's family or via the referring 
physician at 1, 6, 12, 24 and 36 months. Questionnaires, which included information on 
the occurrence and date of a primary clinical endpoint, angina status according to the 
Braunwald22 or Canadian Cardiovascular Socielf3 classifications, working status and 
cardiac medications were completed at each time point. 
Statistical analysis 
Baseline characteristics of patients with and without CRI were compared with the chi-
square test for discrete variables, and the Student's unpaired t-test for continuous 
variables. Fisher's exact test was used for categorical variables with nominal scales and 
the Wilcoxon rank-sum test for those with ordinal scales. Event-free survival distribution 
was estimated according to the Kaplan-Meier method, and the incidence of adverse 
events was tested with the log-rank test. To determine the association of CRI with clinical 
outcomes after revascularization, we used Cox proportional hazard models that were 
adjusted for baseline differences. variables that were associated with the primary clinical 
outcome with a P-value <0.1 in the univariate analysis were selected as potential 
covariates. The fmal multivariate model was constructed after backward deletion of the 
least significant variables24. The analyses comparing randomized subjects with CRI were 
conducted as intention-to-treat analysis; however, because smoking status was 
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unbalanced in the two groups, we used a Cox proportional hazards model that adjusted 
for smoking status. We also tested for interaction with age, hypertension, diabetes 
mellitus, and ACE inhibitor use. All statistical analyses were performed using the SAS 
8.0 software package (SAS Institute, Cary, North Carolina); a two-sided p-value ::; 0.05 
was considered statistically significant. 
RESULTS 
Baseline characteristics and treatment 
From April 1997 to June 1998, a total of 1205 patients at 67 centers were randomly 
assigned to undergo PCI with multivessel stenting (600 patients) or CABG (605 patients). 
A total of99% ofthe patients in the stenting group (593) and 96% ofthose in the surgery 
group (579) received the assigned treatment. The average interval between randomization 
and revascularization was 11±16 days for PCI, and 27±39 days for the CABG. Of the 
1176 (97%) patients with baseline creatinine values, 290 (25%) had renal insufficiency. 
Compared with patients who had normal renal function, those with CRI were more likely 
to be female, older, hypertensive, and to have stable angina (Table 1). Those with CRI 
also had lower body mass index and were less likely to be current smokers. Medication 
use, and number of diseased vessels were similar between renal function groups. 
Effect of renal insufficiency on clinical outcomes 
In unadjusted analysis, renal insufficiency was associated with a nearly two-fold 
increased risk of the primary outcome (HR=1.9; 95% CI: 1.4-2.7; P < 0.01). After 
multivariate adjustment, the association of CRI with the primary outcome was weakened, 
but remained statistically significant (HR=1.6; 95% CI: 1.1-2.4; P < 0.01) (Figure 1 and 
Table 2). In addition, CRI was the strongest independent predictor of the primary 
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outcome based on the wald chi square statistic. For comparison, diabetes was less 
strongly associated with the primary outcome (HR=1.4; 95%CI 0.95-2.1; P = 0.34). We 
examined the individual outcomes of death, stroke, non-fatal MI and repeat 
revascularization and found CRI to be particularly associated with stroke (Table 2). The 
point estimate for death was also strong, although the P value did not reach statistical 
significance. 
We tested for interactions with age, hypertension, diabetes mellitus, and ACE inhibitor 
use. Among these, only hypertension had a statistically significant interaction (HR=0.45; 
95%CI 0.22-0.90; P = 0.02). Compared with patients with neither hypertension nor CRI, 
those with either hypertension alone (HR=1.7; 95%CI 1.1-2.7; P = 0.01) or CRI alone 
(HR=2.8; 95%CI 1.7-4.6; P < 0.01) were at increased risk of the primary outcome, but 
the combination of both risk factors (HR=1.3; 95%CI 0.8-2.1; P = 0.52) was not 
associated with additive risk. 
Given the interaction with hypertension, subjects with CRI with and without hypertension 
were also analyzed separately. In multivariate analysis, CRI predicted a significant 
increased risk of the primary outcome in persons without hypertension (HR=2.2, 95% CI: 
1.3-3.8, P < 0.01), but the association did not reach statistical significance among 
subjects with hypertension (HR=l.2, 95% CI 0.7-2.1, P = 0.43). 
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Comparison of clinical outcomes after CABG and PCI in subjects with CRI 
Among the 290 subjects with CRl, 151 were assigned to PCI, and 139 to CABG. 
Baseline and angiographic characteristics of subjects within each treatment group were 
similar except that higher smoking rates were observed in the PCI group (Table 3). 
The incidence of the primary outcome was similar in patients assigned to CABG and to 
PCI (Figure 2) and there was no difference in the frequency of the individual outcomes of 
stroke, MI or death between treatment groups (Table 4). However, CABG was associated 
with one-third the rate of repeat revascularization as compared with PCI at 3 years of 
follow-up (HR= 0.28; 95%CI 0.14-0.54; P < 0.01) (Figure 3). 
DISCUSSION 
In this analysis from the ARTS trial, we found subjects with CRJ to have a 50% increased 
risk for the combined outcome of death, MI or stroke within three years after coronary 
revascularization. However, in analyses limited to subjects with CRJ, we found no 
difference in the incidence of these major outcomes among patients treated with CABG 
or PCL Subjects with CRJ undergoing CABG did have substantially lower rates of repeat 
revacularization compared with those undergoing PCI at three-year follow-up. 
This study represents the first randomized prospective study to evaluate differences in 
outcomes between CABG and PCI in subjects with CRl. Observational data have been 
conflicting about the implications of CRl on clinical outcomes following coronary 
revascularization. Szczech and colleagues found no difference in survival between 
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CABG and PCI in subjects with serum creatinine< 2.5mg/dL in a large community based 
observational studyl5. In another study evaluating 4500 subjects with CAD, Reddan and 
colleagues found a survival advantage with CABG compared with PCI, which appeared 
to increase as renal function declined26. These studies, however, may have been 
susceptible to confounding by indication. Other studies have found CRI to be associated 
with worse outcomes after either PCI or CABG, in isolation20·21•27• Our study differs 
from these prior studies because it was nested within a randomized trial, and as all 
subjects randomized to PCI were treated with stents, it represents cardiovascular practices 
that more closely resemble those now in standard clinical practice. 
The strong association of CRI with adverse outcomes in our study is particularly striking 
because subjects with severe renal disease were excluded from our study population. The 
average estimated creatinine clearance amongst those with CRI in our study was 50 
mVmin. The strength of the association of this degree of CRI with adverse events 
highlights the significance of even mild renal impairment as a prognostic indicator. CRI 
was in fact a stronger predictor of the primary outcome than any other risk factor, 
including diabetes mellitus. 
The results of our study indicate that coronary revascularization, regardless of procedure 
type, is a high-risk procedure in subjects with CRI. To our knowledge, there is no study 
comparing aggressive medical management to coronary revascularization in subjects with 
multivessel CAD and CRI. In subjects with normal renal function, the presence of 
symptomatic multivessel CAD is considered a high-risk condition for adverse cardiac 
events and is an indication for coronary revascularization. Because CRI is a strong risk 
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factor for cardiovascular events either with20'25-27 or without6•7 coronary revascularization, 
we believe that patients with high-risk coronary anatomy and concomitant CRl should 
benefit from revascularization despite their increased risk from these procedures. These 
patients should therefore not be denied these potentially useful procedures based on our 
findings. 
The equivalent rates of death, stroke, or non-fatal MI between treatment groups amongst 
subjects with CRJ should reassure clinicians that multivessel stenting is an acceptable and 
less invasive alternative to CABG, but at the expense of increased repeat 
revascularization procedures within three years. However, the recent introduction of 
drug-eluting stents have strikingly decreased the incidence of coronary restenosis and the 
need for repeat revascularization28'29. Whether future stent technology will decrease the 
rates of repeat revascularization in CRl patients to rates equivalent to those after CABG 
is an exciting possibility that will need to be assessed in future studies. 
It is not clear why subjects with CRJ are at increased risk for adverse cardiovascular 
outcomes. The excess risk with CRl is explained in part by a higher prevalence of well-
established cardiovascular risk factors such as hypertension and diabetes. However, CRl 
remains a powerful predictor for cardiovascular events even after controlling for these 
standard risk factors5-7J5.27• Multiple novel cardiac risk factors are now being evaluated 
as possible mediators of this effect. A pro-inflammatory state present in renal disease is a 
potential mechanism. Elevated levels of C-reactive protein, interleukin-6, and fibrinogen 
are associated with increased cardiovascular risk in healthy populations30-32 and are 
known to be markedly elevated in subjects with CRl of similar magnitude to that in our 
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study33 . Alternatively, alterations in lipid metabolism534•35 , or increased levels of 
homocysteine36 which in tum enhances oxidation of low-density lipoproteines37 may 
contribute to the increased cardiovascular risk. The relative contribution of these novel 
risk factors to the increased risk merits further investigation. 
The primary limitation of this study was its sample size. Although the relative risk for 
CABG compared with PCI for the primary outcome was unity, the confidence intervals 
cannot exclude a moderate advantage with either therapy. Secondly, we relied on 
estimated creatinine clearance, which is an imprecise measure of renal function. 
However, the gold standard for measurement of glomerular filtration is cumbersome and 
expensive38 . Subjects were excluded if their serum creatinine was > 1.7mg/dL 
(150mmoVL), and our results may therefore not be generalizable to patients with more 
severe decrements in renal function. Lastly, although this was a randomized sample, CRI 
was not a pre-specified subgroup for stratified randomization. Because CRI is clearly a 
risk factor for adverse cardiovascular outcomes, larger numbers of patients with CRI 
should be included in future cardiovascular clinical trials. Such studies could identify 
interventions to improve the health status and survival of persons with CRI. 
In conclusion, the present study demonstrates that subjects with mild to moderate renal 
insufficiency have similar rates of death, stroke and non-fatal MI at 3-years follow-up 
after revascularization with CABG or PCI, but that PCI is associated with a three-fold 
increased risk for repeat revascularization. We found that even mild renal insufficiency is 
an important risk factor for patients undergoing coronary revacularization. Clinicians 
should be aware of the excess risk associated with even mild CRI and should factor it into 
their decision to pursue coronary revascularization. 
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1'0 19 ~ Table 1. Characteristics of the 1176 patients assigned to CABG or PCI, by presence of renal insufficiency* .j:, {l 
Normal Renal Function Renal Insufficiency p- Value I~ 
(n = 886) (n = 290) 
Male gender (% of patients) 83 57 < O.Ql 
Age (yr) 58±9 68±6 < 0.01 
Creatinine (mg/dl) 1.0±0.3 1.3±0.3 < O.Ql 
Creatinine Clearance (ml/min) 134±180 50±8 < 0.01 
Body Mass Index 28±4 26±3 <0.01 
Previous MI (%) 44 39 0.19 
Diabetes Mellitus(%) 17 18 0.79 
Hypertension(%) 43 50 0.03 
Hypercholesterolemia(%) 58 55 0.34 
Peripheral vascular disease (%) 5 6 0.30 
Current smoker (%) 31 13 < O.Dl 
Cardiac medications 
ACE inhibitors(%) 24 29 0.08 
10 
~ 
(]1 
Aspirin(%) 89 86 0.17 
B-blockers (%) 69 71 0.71 
Enrollment diagnosis 
Stable angina(%) t 56 64 0.01 
Unstable angina(%) § 39 31 0.02 
Silent ischemia(%) 6 5 0.46 
Ejection fraction(%) 61±12 60±13 0.44 
Number of diseased vessels (%) 
2 66 65 0.70 
3 33 34 0.79 
*Data presented as percent or as the mean value± SD. tStable angina was defined according to the system of the Canadian 
Cardiovascular Society. §Unstable angina was defined according to the Braunwald classification 
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Table 2. Association of renal insufficiency with 3-year clinical outcomes following coronary revascularization 19 _, o-
-8 
<D 
Normal Renal Renal Unadjusted P- Values Adjusted Hazard P- Values I~ 
Function Insufficiency Hazard Ratio Ratio 
(95% CI); (95% Cl)* 
(n = 886) (n = 290) 
n (%) n(%) 
Composite of 86 (10) 52 (18) 1.9 (1.35-2.70) < 0.01 1.6 (1.10-2.35) < 0.01 
death, stroke or 
MI 
Death 26 (3) 19 (7) 2.2 (1.25-4.09) < 0.01 1.6 (0.84-3.29) 0.09 
Stroke 19 (2) 18 (6) 2.9 (1.56-5.67) < 0.01 2.3 (1.15-4.70) < 0.01 
MI 52 (6) 20 (7) 1.2 (0.71-2.0) 0.50 1.0 (0.58-1.83) 0.96 
Total repeated 
revascularization # 143 (16) 49 (17) 1.1 (0.78-1.50) 0.64 1.1 (0.75-1.50) 0.68 
CABG 42 (5) 18 (6) 1.3 (0.76-2.30) 0.32 1.3 (0.70-2.35) 0.57 
PCI 111 (13) 39 (13) 1.1 (0.77-1.60) 0.57 1.1 (0.74-1.62) 0.53 
*Adjusted for diabetes mellitus, hypertension, ejection fraction, ACE inhibitor use, aspirin use, peripheral vascular disease, 
hemoglobin, silent ischemia, COPD, and hyperlipidemia. 
Table 3. Characteristics of subjects with renal insufficiency randomly assigned to PCI or CABG* 
PCI CABG P- Value 
(n = 151) (n = 139) 
Male gender(% of patients) 57 56 0.91 
Age (yr) 68±6 69±7 0.51 
::u 
<D 
Creatinine (mg/dl) 1.3±0.3 1.3±0.3 0.90 I§_ 
:s· 
Creatinine Clearance (mVmin) 50±8 49±8 0.54 I~ 
::1; 
Body Mass Index 26±3 26±3 0.98 
0 I <D· 
::J 
0 
Previous MI (%) 39 40 0.90 I"' § 
Diabetes Mellitus(%) 20 16 0.44 lg-§' 
Hypertension(%) 47 54 0.24 18: 
0 
Hypercholesterolemia (%) 54 57 0.64 lc: 0 
0 
Peripheral vascular disease (%) 5.3 8 0.48 I~ (/) 
:s· 
Current smoker (%) 17 9 0.04 13= 
<D 
Cardiac medications I~ 
Cii 
t'0 ACE inhibitors (%) 30 29 0.80 l::t ~ Q. '..J 
f\.) 
~ 
OJ 
Aspirin(%) 88 85 0.49 
B-blockers (%) 67 75 0.16 
Enrollment diagnosis 
Stable angina(%) t 65 64 0.90 
Unstable angina(%)§ 31 31 0.97 
Silent ischemia(%) 4 5 0.78 
Ejection fraction(%) 60±13 59±13 0.94 
Number of diseased vessels (%) 
2 69 61 0.16 
3 30 38 0.17 
*Data presented as percent or as the mean value ± SD. tStable angina was defined according to the system of the Canadian 
Cardiovascular Society. §Unstable angina was defined according to the Braunwald classification 
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Table 4. Clinical outcomes amongst subjects with renal insufficiency randomly assigned to CABG or PCI at 3 year follow-up* 
PCI CABG Hazard Ratio* P- Value 
(95% CI) 
(n = 151) (n = 139) 
--
Composite of death, 28 (19) 24 (17) 0.93 (0.54-1.61) 0.80 :::0 <D 
stroke, or MI :::J Q_ 
:s· 
Death 10 (7) 9 (7) 0.98 (0.40-2.42) 0.97 ,~ 
~ 
Stroke 12 (8) 6 (4) 0.54 (0.20-1.45) 0.22 I~-
() 
MI 9 (6) 11 (8) 1.34 (0.55-3.23) 0.42 I"' § 
Q 
() 
Total repeated ,~ 
revascularization # 38 (25) 11 (8) 0.28 (0.14-0.54) < 0.01 Q. 
0 
CABG 15 (10) 3 (2) 0.21 (0.06-0.73) 0.01 c: 10 
0 
PCI 30 (20) 9 (7) 0.30 (0.14-0.63) < O.ol ,§ 
"' :s· 
*Hazard ratios adjusted for smoking status. l:st 
<D 
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:::0 
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FIGURE LEGENDS 
FIGURE 1 
Three-year Kaplan-Meier event-free survival curves for death, stroke or myocardial infarction stratified according to renal function 
*Adjusted for diabetes mellitus, hypertension, ejection fraction, ACE inhibitor use, aspirin use, peripheral vascular disease, 
hemoglobin, silent ischemia, COPD, and hyperlipidemia 
FIGURE2 
Three-year Kaplan-Meier event-free survival curves for death, stroke, or myocardial infarction of patients with renal insufficiency 
randomized to PCI (Solid line) or CABG surgery (Dotted line) 
FIGURE3 
Three-year Kaplan-Meier event-free survival curves for repeat revascularization in patients with renal insufficiency randomized to 
PCI (Solid line) or CABG surgery (Dotted line) 
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Renal insufficiency 
CABG 
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70% 
HR (95% CI) = 0.28 (0.14-0.54); p = 0.0002 
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0 275 550 825 1100 
Numbers at risk Days since Randomization 
PCI 151 122 117 114 113 
CABG 139 133 130 129 128 
FIGURE3 
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Abstract 
Background: Mild renal impairment is an important risk factor for late cardiovascular complications. 
The present study assessed the effect of fluvastatin on the outcome of patients with or without renal 
dysfunction in the Lescol Intervention Prevention Study. Additionally, the effect of fluvastatin on renal 
function and the relation between changes in renal function on the incidence of adverse events were 
evaluated. 
Methods: Complete data for creatinine clearance calculation were available for 1558 patients (93% of the 
total population), who were randomised to fluvastatin (normal renal function, n=631; impaired renal 
function, n= 150), or placebo (normal, n=617; impaired, n= 160) following successful completion of a first 
PCI. Follow-up time was 3-4 years. The primary endpoint was survival time free of coronary 
atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary reinterventions not 
related to restenosis). 
Findings: Renal impairment significantly increased the incidence of coronary atherosclerotic events in 
placebo-treated patients (RR 1.42 [95% CI: 1.00- 2.01]; p=0.048). Among those treated with fluvastatin, 
however, no differences were observed between patients wit and without renal impairment (RR 0.97 
[95% CI: 0.61 - 1.56]; p=0.912). No further deterioration in creatinine clearance was observed during 
follow-up, regardless of baseline renal function or allocated treatment. The occurrence of adverse events 
was not related to changes in renal function during follow-up. 
Interpretation: Fluvastatin treatment strikingly reduced the risk of coronary atherosclerotic events after 
percutaneous intervention in patients with mild renal impairment. The benefit of fluvastatin was unrelated 
to any effect on renal function. 
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Introduction 
Mild-to-moderate renal impairment has been identified as an important risk factor for future adverse 
events in patients with diagnosed cardiovascular disease, 1-8 an effect observed even after surgical or 
percutaneous treatment4-6 mainly due to an increased rate of death and myocardial infarction, without a 
major impact on restenotic complications, among those treated with angioplasty.45 Although renal 
impairment is commonly associated with a higher frequency of conventional risk factors 1·4-8 and increased 
levels of inflammatory, procoagulant, and atherogenic markers,9-16 the mechanisms involved with the 
augmented risk in this population remain unclear.10 
Blood pressure reduction and long-term treatment with ramipril have both been described to improve the 
outcomes of patients with mild renal impairment.7•17 However, patients with renal impairment treated 
with therapeutic schemes were still at a higher risk than patients with normal renal function, indicating 
that the hazardous effect of renal dysfunction was only partially reduced by these treatments. 7•17 Recently, 
treatment with HMG-CoA reductase inhibitors (statins) has been observed to be safe and to decrease the 
incidence of adverse events in patients with previous myocardial infarction regardless of the baseline 
renal function. 18 In addition to lowering lipid levels, statins may give beneficial effects through their so-
called pleiotropic effects, which may or may not be related to changes in lipid metabolism. 19 Previously, 
statin treatment has been shown to significantly decrease proteinuria20 and renal function deterioration in 
hypertensive patients.21 
In the Lescol Intervention Prevention Study (LIPS), treatment with long-term fluvastatin has been 
recently shown to decrease the incidence of cardiac events in patients treated with percutaneous coronary 
intervention (PCI).22 The aim of the present study was to analyse the results of LIPS in order to 
investigate: 1) the impact of mild renal impairment on the occurrence of long-term adverse events, 2) 
whether treatment with fluvastatin reduces the expected hazardous effect of mild renal impairment, 3) the 
effect offluvastatin on the renal function during the follow-up period, and 4) and the relation between the 
changes in renal function over time and the occurrence of adverse events. 
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Methods 
Study Design and Patient Population 
The study design and primary results of LIPS are described elsewhere.22 Briefly, following a first 
successful PCI (residual stenosis <50%, absence of post-procedure in-hospital myocardial necrosis, repeat 
revascularisation, or death) patients were randomised to receive treatment with either fluvastatin (Lescol, 
Novartis Pharma AG, Basel, Switzerland) 40 mg bid or placebo for 3 to 4 years. 
At enrolment, patients had to fulfil at least one of the following lipid profile criteria: 1) total cholesterol 
(TC) between 3.5-7.0 mmol/1 (135-270 mg/dl) with fasting triglycerides (TG) <4.5 mmol/1 (400 mg/dl); 
2) TC <5.5 mmol/1 (212 mg/dl) for patients whose lipids levels were measured between 24 hours and 4 
weeks after an episode of myocardial infarction; or 3) TC <6.0 mmol/1 (232 mg/dl) for patients with 
diabetes mellitus. Exclusion criteria included a baseline serum creatinine value> 160 f.Lmol/1 (1.8 mg/dl). 
The study protocol was approved by local ethics committees and all patients gave informed written 
consent 
Lipoproteins and Renal Function Evaluation 
Each patient was clinically evaluated at least eight times after randomisation. Blood lipid levels were 
measured at all visits and serum creatinine was measured at baseline, at 52, 104 and 156 weeks. All 
biochemical analyses were performed at a central laboratory (Analytico Medinet, Breda, The 
Netherlands). The creatinine clearance was calculated according to the formula proposed by Cockcroft 
and Gault: creatinine clearance (mllmin)=(l40 - age) x weight (kg) + 72 x serum creatinine (mg/dl) (x 
0.85 for women).23 
Clinical Endpoints 
Outcomes were evaluated as a composite of atherosclerosis-related adverse cardiac events detmed as the 
incidence of cardiac death (all deaths except those unequivocally related to a non-cardiac cause), non-
fatal myocardial infarction (new pathological Q-waves or a total plasma creatine kinase [CPK] level 
greater than twice the normal upper limit with presence of CPK isoenzyme MB), and all re-interventions 
(either surgical or percutaneous) not caused by coronary restenosis occurring after the index procedure. 
Atherosclerosis-related adverse cardiac events were a pre-detmed endpoint of LIPS22, based on the fact 
that the benefit of fluvastatin after PCI have been previously demonstrated to be unrelated to any effect of 
the drug on restenosis24• Additionally, the incidence of target lesion revascularisation was analysed in 
both renal function groups. 
Statistical Analysis 
All analyses were carried out on an intention-to-treat basis. Continuous variables were expressed as mean 
±standard deviation (SD) and were compared using Student's two sample t-test. Fisher's exact test was 
used for categorical variables, and Wilcoxon scores were used for categorical variables with an ordinal 
scale. Discrete variables were expressed as counts and percentages, and were compared in terms of 
relative risks with 95% CI. All statistical tests were 2-tailed. Event-free survival distribution was 
estimated according to the Kaplan-Meier method, and the overall incidence of adverse events was tested 
using the log-rank test. Patients lost to follow-up were considered at risk until the date of last contact, at 
which point they were censored. 
The Cox proportional hazards models were used to assess risk reduction of adverse events. Patients were 
divided into two groups according to the baseline creatinine clearance. An abnormal creatinine clearance 
was defined as a value in the lowest quintile (55.9 mllmin). Such restrictive detmition was applied in 
considering the LIPS study protocol, which excluded patients with frankly decreased renal function. The 
treatment/renal impairment interaction was calculated in a multivariate approach with allocated treatment, 
renal impairment and an interaction factor specifying the simultaneous absence or presence of both 
previous factors in the model. When considering the baseline creatinine clearance as a continuous 
variable, estimated risk ratios were calculated from the observed data with the mean clearance of the 
entire study population chosen as a reference point for the placebo group (risk ratio= 1). To ensure a 
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better fit to gaussian distributions, creatinine clearance measurements were converted by logarithmic 
transformation. 
All baseline clinical, angiographic and procedural characteristics available in the study's database were 
tested to evaluate their relation with the incidence of clinical adverse events. Variables presenting a 
univariate p<O.l were tested as candidates in a multivariate analysis and a fmal model was constructed by 
stepwise selection of the most significant variables (the following variables were selected from the 
univariate analyses: allocated treatment, creatinine clearance, stable/unstable angina, smoking, high 
density lipoprotein cholesterol levels [HDL-C], gender, hypertension, diabetes, previous stroke, previous 
myocardial infarction, cholesterol lowering diet, height, body-mass index, diastolic blood pressure, 
systolic blood pressure, multi-vessel disease, pathological Q-wave in lead aVL, number of stents 
implanted, and number of sites with TIMI grade 3 flow). 
Lipid profiles, and the clearance-time profile, were analysed by analysis of covariance models 
incorporating the baseline values as covariate, adding the factors treatment, visit number and renal 
function subgroup with all possible interaction terms. In order to evaluate the relation between the 
occurrence of clinical events and the behavior of renal function over time, separate analyses were 
performed evaluating the clearance-time profile for patients with or without adverse events during follow-
up. 
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Results 
Patient Population 
Between Aprill996 and October 1998, a total of 1677 patients were enrolled in LIPS. Complete data for 
creatinine clearance calculation were available for 1558 patients (92.9%) and were included in the present 
study. Table 1 shows the baseline characteristics of the 1248 patients with normal renal function 
(creatinine clearance above the first quintile [;::: 55.9 ml/min]) and of the 310 patients with impaired renal 
function (creatinine clearance in the lowest quintile [< 55.9 mllmin]). Overall, patients with renal 
impairment were more likely to be older, female, to have lower weights and heights and more severe 
coronary artery disease and co-morbidities. 
Four groups were considered for analysis: 1) Normal renal function treated with placebo (n=617); 2) 
Normal renal function treated with fluvastatin (n=631 ); 3) Impaired renal function treated with placebo 
(n=l60); 4) Impaired renal function treated with fluvastatin (n=150). Baseline characteristics did not 
differ between fluvastatin and placebo groups (pooled across renal function categories) except that 
fluvastatin-treated patients were of greater height (169.8±8.4 em vs. 168.9±8.4 em; p=0.02) and weight 
(77.2±11.4 kg vs. 75.6±11.4 kg; p<O.Ol), and showed a higher prevalence of diabetes (14.3% vs. 10.0%; 
p<O.Ol). 
Cardiovascular Events 
Over a mean follow-up period of 3.8±0.1 years, the presence of mild renal impairment significantly 
increased the incidence of coronary atherosclerotic events in patients allocated to the placebo group 
(29.4% vs. 20.3% in patients with normal renal function; RR 1.42 [95% CI: 1.00- 2.01]; p=0.048) (Table 
~ and 1). Fluvastatin treatment, however, virtually abolished the negative influence of renal impairment 
on the incidence of adverse events, with no difference being observed between the outcomes of patients 
with and without renal dysfunction (15.3% vs. 15.7% respectively; RR 0.97 [95% CI: 0.61 - 1.56]; 
p=0.912) (Table 2 and};~). 
Fluvastatin significantly reduced the incidence of coronary atherosclerotic events both in patients with 
normal renal function (15.7% vs. 20.3% in patients allocated to placebo; RR 0.73 [95% CI:0.56- 0.95]; 
p=0.020) and in patients with renal impairment (15.3% vs. 29.4% in patients allocated to placebo; RR 
0.50 [95% CI: 0.30- 0.84]; p=0.008) (Table 2 and}; Figure 2). No significant difference was observed 
between the benefit of fluvastatin for patients with renal dysfunction as compared to the benefit for those 
with normal renal function (Treatment/Disease interaction: p=0.203). No differences were observed in the 
incidence of repeat revascularisation caused by restenosis in patients with and without restenosis (4.4% 
vs. 5.2% respectively; p=0.65). 
Lipoprotein Levels and Renal Function Outcome 
Baseline lipoprotein levels were similar in both renal function groups, with the exception of HDL-C 
levels (Table 1). By 6 weeks, fluvastatin significantly reduced LDL-C levels compared with placebo in 
patients with renal impairment (median change with fluvastatin, -24% [95% CI: -28 - -20%] vs. + 13% 
[95% CI: +9- + 17%]; p<O.OOl), and with normal renal function (-28% [95% CI: -30- -25%] vs. + 11% 
[95% CI: +9- +13%]; p<O.OOl). The reduction was similar between patients with and without renal 
impairment and was maintained throughout the study. At the end of the study no significant differences in 
TG levels were observed between treatment groups. HDL-C levels increased by a median of 12% 
regardless of the allocated treatment or baseline renal function. 
Renal function remained stable throughout follow-up and the predicted clearance-time profile was not 
influenced by fluvastatin treatment regardless of baseline creatinine clearance (Eigure 3). No significant 
changes were observed in the renal function either in patients with or without adverse events during the 
observation period (Eigure 3). 
Predictors of Increased Cardiovascular Risk 
Figure 4 shows the estimated risk ratios according to baseline creatinine clearance calculated by the Cox 
Proportional Hazards Model from the observed data (the mean clearance of the entire study population 
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was chosen as a reference point for the placebo group [risk ratio = 1 ]). A progressive increase in the risk 
of long-term complications is predicted with lower values of creatinine clearance. However, fluvastatin 
treatment caused a downward shift and flattening of the entire risk ratio curve. Interestingly, a risk ratio of 
1 was associated with a baseline creatinine clearance of approximately 70 mllmin in the placebo group, 
but only 25 ml/min in fluvastatin-treated patients. 
Multivariate Cox proportional hazards analysis identified creatinine clearance as an independent predictor 
of atherosclerosis-related adverse cardiac (Table 4). Other variables significantly associated with the 
incidence of adverse events included fluvastatin treatment, diabetes mellitus, multivessel disease, and the 
number of stents implanted during the procedure (Table 4). 
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Discussion 
The major fmding of the present study is that the presence of mild renal impairment significantly 
increases the incidence of coronary adverse atherosclerotic events after a first successful PCI, and that 
this effect is virtually abolished by long-term treatment with fluvastatin. The benefit of fluvastatin in 
patients with renal impairment could not be explained by a differential action on lipid levels or on renal 
function during follow-up. Moreover, no association was observed between the incidence of adverse 
events and changes in renal function during the follow-up period. 
Together with measures to alleviate symptoms and myocardial ischemia, secondary prevention of further 
adverse events constitutes the core action in the chronic management of patients with diagnosed coronary 
disease. Although the need for repeat intervention has been recognized as the major limitation of 
angioplasty, the newly introduced drug-eluting stents has been shown to remarkably reduce restenosis 
rates.25 In this scenario, the adoption of measures aiming to modify the natural course of the 
atherosclerotic disease itself (i.e. non restenosis-related complications) becomes the main focus of 
attention after percutaneous treatment. In the present study, fluvastatin was shown to significantly reduce 
the incidence of adverse events after angioplasty both in patients with and without renal dysfunction. 
Secondary prevention strategies comprehend a conjoint of measures directed to reduce the impact of 
known risk factors on the outcomes of patients with already diagnosed coronary disease. The ideal 
treatment of a particular risk factor should decrease the risk of treated patients to the level of subjects not 
having the condition. Mild renal impairment has been identified as an important predictor of adverse 
events in patients with previous cardiovascular disease. 1•8 Although diuretic-based blood pressure control 
as well as long-term ramipril have previously been reported to improve the clinical outcomes, the 
hazardous effect of mild renal impairment was only partially decreased by these treatments.7' 17 Pravastatin 
has recently been demonstrated to reduce the incidence of events in patients with renal dysfunction. 
However, differently from the vast majority of reports, in that study the presence of renal impairment 
have not influenced the late clinical outcomes.18 Moreover, the extent to which the statin reduced the risk 
was not evaluated in relation to patients with normal renal function. 18 In the current study, mild renal 
impairment was detected to significant and independently impair the long-term clinical outcomes after 
coronary intervention. Notably, fluvastatin treatment was shown to equalize the outcomes of patients of 
mild renal impairment and patients with normal renal function, virtually abolishing the hazardous effect 
of the renal dysfunction. 
In contrast to previous studies/1 no effect of fluvastatin treatment on renal function was observed during 
the 4-year follow-up period. These results suggest that the benefit of fluvastatin was not mediated by a 
direct effect to stabilize or improve creatinine clearance. Moreover, the occurrence of adverse events was 
not related to changes in renal function. In addition, the effect of fluvastatin in patients with renal 
dysfunction could not be explained by a more pronounced lipid reduction in this group. These results 
suggest that the benefit of statins on patients with renal impairment may be associated to mechanisms not 
related to a direct effect on the kidney physiology and independent of their lipid-lowering effects. 
Although not assessed in this study, statins have been extensively reported to positively influence a 
variety of pathophysiological atherogenic mechanisms known to be altered in patients with renal 
impairment.9. 16' 19 
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Study Limitations 
It should be noted that the fmdings of the present study may not be extrapolated to all patients with 
coronary heart disease, as only patients who underwent successful elective percutaneous interventions 
were included. Therefore, medically- and surgically-treated patients, and those undergoing unsuccessful 
procedures, were not represented in the study population. Furthermore, the impact of fluvastatin on 
patients with severe renal impairment was also not assessed in the present study, while more detailed 
investigations of the nature of the renal impairment (e.g. diagnosis of underlying renal pathology or 
assessment of microalbuminuria or proteinuria) and measurements of biochemical pro-atherogenic 
markers were not available. These limitations do not alter the overall conclusion that fluvastatin treatment 
has a clinically relevant impact in patients with mild renal impairment. 
Conclusions 
Patients with mild renal impairment show an increased risk of long-term complications following 
coronary intervention. Long-term treatment with fluvastatin, however, provides a safe and effective 
means of obviating this risk acting through mechanisms not related to an improvement in kidney function. 
Effective diagnosis of mild renal dysfunction therefore represents an important step in the risk assessment 
evaluation of patients with coronary heart disease, and treatment with fluvastatin should be included as an 
important intervention to minimize the occurrence oflong-term adverse events in this population. 
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Table 1. Baseline patient characteristics according to renal function 
Normal Mild renal 
renal 
function impairment p-value 
(n=l248) (n=310) 
Age, y±SD 58±9 69±7 <0.01 
Female sex, n (%) 146 (11.7) 102 (32.9) <0.01 
Height, cm±SD 170±8 165±8 <0.01 
Weight, kg±SD 79±11 68±10 <0.01 
Risk factors and cardiovascular antecedents 
Previous MI, n (%) 540 (43.3) 144 (46.5) 0.34 
Diabetes, n (%) 152 (12.2) 38 (12.3) 1.00 
Hypertension, n (%) 435 (34.9) 159 (51.3) <0.01 
Previous stroke, n (%) 28 (2.2) 14(4.5) <0.03 
Peripheral vascular disease, n (%) 62 (5.0) 33 (10.6) <0.01 
Current smoker, n (%) 363 (29.1) 53(17.1) <0.01 
Cholestero1lowering diet, n (%) 217(17.4) 76 (24.5) 0.01 
Family history of CAD, n (%) 372 (30.0) 76 (24.7) 0.07 
Ejection fraction, %±SD 62.3±1 1.8 61.4±12.7 0.24 
Single-vessel disease, n (%) 818 (65.5) 175 (56.5) 0.01 
Multi vessel disease, n (%) 430 (34.5) 135 (43.6) 0.01 
Clinical presentation 
stable angina, n (%) * 618 (50.2) 164 (53.2) 0.37 
unstable angina, n (%) 618 (50.2) 164 (53.2) 0.37 
Treated vessel t 
RCA,n(%) 484 (29.8) 128 (29.5) 0.91 
LAD,n(%) 766 (47.2) 207 (47.7) 0.87 
LCx, n (%) 371 (22.9) 98 (22.63) 0.95 
Lesions treated per patient, 1.30±0.6 1.40±0.7 0.03 les/pt±SD 
Lesion type 
A, n (%) 325 (20.1) 70 (16.2) 0.07 
B1, n (%) 566 (35.0) 153 (35.5) 0.91 
B2, n (%) 540 (33.4) 150 (34.8) 0.65 
C, n(%) 185 (11.4) 58 (13.5) 0.28 
Lesions treated with stent, n (%) 910 (56.1) 245 (56.5) 0.91 
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Lipids, mmol/l±SD [mg/dl±SD] 
Total cholesterol 5.17±0.81 5.18±0.88 0.87 [200±31] [200±33] 
LDL-C 3.43±0.76 3.38±0.82 0.40 [133±29] [131±31] 
HDL-C 0.96±0.30 1.02±0.29 <0.01 [37±12] [39±12] 
Triglycerides 1.75±0.77 1.71±0.69 0.51 [154±68] [150±69] 
Serum creatinine, mmol/l±SD [mg/dl±SD] 99±16 121±27 <0.01 [1.11±1.7] [1.33±2.8] 
Creatinine clearance, mllmin±SD 80±18 47±7 <0.01 
CAD=coronary atherosclerotic disease; RCA=right coronary artery; LAD=left anterior 
descending; LCx=1eft circumflex artery; SD=standard deviation 
* Includes patients with silent ischemia 
t Categories are not mutually exclusive 
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Table 2. Incidence of adverse coronary atherosclerotic events at follow-up according to renal function at baseline and allocated treatment. 
Normal renal function Renal impairment 
~--------~-----------------~-- ------~---~-·--·------
Placebo Fluvastatin p-value* Placebo Fluvastatin p-value* (n=617) (n=631) (n=160) (n=150) 
Adverse Coronary Atherosclerotic Eventst, n(%) 125 (20.3) 99(15.7) 0.039 47 (29.4) 23 (15.3) 0.004 
Cardiac death, n(%) 14 (2.3) 7 (1.1) 0.13 3 (1,9) 3 (2.0) 1.0 
Non-cardiac death, n(%) 0 0 -- 0 0 
All-cause death, n(%) 14 (2.3) 7 (1.1) 0.13 3 (1,9) 3 (2.0) 1.0 
Cardiac death/myocardial infarction, n(%) 37 (6.0) 28 (4.4) 0.25 13 (8.1) 7 (4.7) 0.25 
All-cause death/myocardial infarction, n(%) 37 (6.0) 28 (4.4) 0.25 13 (8.1) 7 (4.7) 0.25 
*Placebo vs. fluvastatin by Fisher's exact test 
t cardiac death, non-fatal myocardial infarction, andre-interventions not related to restenosis 
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Table 3. Risk of adverse coronaty atherosclerotic events* at follow-up according to renal function at baseline and allocated 
treatment (derived from Cox proportional hazards analysis accounting for the treatment/disease interactiont). 
Effect Risk reduction 
Effect of renal impairment on patients with placebo RR 1.42 (95% CI: 1.00-2.01); p=0.048 
Effect of renal impairment on patients treated with fluvastatin RR 0.97 (95% CI: 0.61-1.56); p=0.912 
Fluvastatin effect on patients normal renal function RR 0.73 (95% CI:0.56-0.95); p=0.020 
Fluvastatin effect on patients with renal impainnent RR 0.50 (95% CI: 0.30-0.84); p=0.008 
Treatment/Disease interaction t RR 0.83 (95% CI: 0.62-1.11 ); p=0.203 
* cardiac death, non-fatal myocardial infarction, andre-interventions not related to restenosis 
t The treatment/disease interaction reflects the effect offluvastatin treatment in the renal impairment subgroup relative to the treatment effect in 
the non-renal impainnent subgroup 
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Table 4. Multivariate predictors of adverse coronary atherosclerotic events at follow-up. 
Fluvastatin treatment 
Diabetes Mellitus 
Multivessel disease 
Number of stents implanted 
Creatinine clearance* 
*logarithmic transformation 
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Hazard Ratio (95% Cl) 
0.66 (0.52-0.83) 
1.57 (1.14-2.16) 
1.33 (1.04-1.69) 
1.25 (1.04-1.51) 
0.63 (0.42-0.95) 
p-value 
0.0005 
0.0063 
0.0236 
0.0186 
0.0271 
Fluvastatin abolishes effect of renal impairment 
Patients treated with placebo 
~ 35 0 p=0.009 (log-rank) 
'-" 30 
.... 
= ~ 25 ... 
~ 
..= 20 ..... 
"!! 
= 
15 
0 
:0 10 .. 0 
~ 
0 5 .. p., 
o+'-------,---...,.----,----, 
Patients at risk 
Renal impaiment 
0 
160 
Normal renal function 617 
133 
546 
2 
117 
519 
3 
107 
498 
4 
42 
192 
Patients treated with fluvastatin 
,-.., 20 
~ 
'-" 
.... 
= 15 ~ 
... 
~ 
..= 
..... 
"!! 10 
= 0 
:0 
.. 5 0 
~ 
0 
.. p., 
0 
0 
Patients at risk 
Renal impairment 150 
Normal renal function 631 
p=0.92 (log-rank) 
2 
Time (Years) 
137 126 
568 537 
Renal impairment 
Normal renal function 
3 4 
122 40 
523 217 
Figure 1. Cumulative risk of atherosclerosis-related adverse cardiac (cardiac death, non-fatal myocardial infarction 
and all reinterventions not caused by coronary restenosis) in patients treated with placebo (upper) or with fluvastatin 
(lower) according to the baseline renal function. 
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Figure 2. Cumulative risk of atherosclerosis-related adverse cardiac (cardiac death, non-fatal myocardial infarction 
and all reinterventions not caused by coronary restenosis) in patients with renal impairment (upper) or normal renal 
function (lower) treated with placebo or with fluvastatin. 
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Figure 3. Predicted changes in creatinine clearance (ml/min) throughout follow-up in patients randomised to receive 
placebo or fluvastatin. Four baseline clearance levels are depicted in the figure: 4 7 mVmin (actual mean clearance of 
patients with renal impairment), 80 ml/min (actual mean clearance of patients with normal renal function), 33 mVmin 
(mean clearance of patients with renal impairment -2 S.D.) and 116 mVmin (mean clearance of patients with normal 
renal function +2 S.D.). Changes in renal function are shown for the total population (upper), for patients without 
events (med), and for patients with at least one adverse event during follow-up (lower). 
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Figure 4. Estimated risk ratios as a function of creatinine clearance (ml/rnin) in patients randomised to receive 
treatment with either fluvastatin or placebo. The hazard ratio curves were estimated according to the Cox 
Proportional Hazards Model (risk ratios calculated with the mean creatinine clearance of the entire study population 
chosen as a reference point for the placebo group [risk ratio = 1 ]). 
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Abstract 
Aims: To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin 
treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention 
Prevention Study. 
Methods and Results: 1063 patients with single-vessel disease and 614 patients with multivessel disease 
were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first 
successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac 
death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was 
evaluated. Patients with multivessel disease tended to be older and presented a higher prevalence of 
associated risk factors and cardiovascular antecedents. In patients allocated to placebo, the presence of 
multivessel coronary disease was associated with a significantly higher rate of cardiac atherosclerotic 
events compared with single-vessel disease (RR 1.67 [95% CI: 1.24- 2.25]; p<0.001). However, patients 
with mu1tivessel or single-vessel disease treated with fluvastatin presented similar long-term outcomes 
(RR 1.28 [95% CI: 0.90 -1.81]; p=0.168). 
Conclusions: Long-term fluvastatin after percutaneous intervention reduced the risk of patients with 
multivessel disease to the level of those with single-vessel disease. 
Key words: HMG-CoA reductase inhibitors, coronary disease, cholesterol, angioplasty 
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INTRODUCTION 
The extent of atherosclerotic disease has been identified as one of the most important predictors of long-
term cardiac events in patients with coronary heart disease 1-5. In previous studies, the presence of 
multifocal disease on coronary angiography, together with low ventricular function, has been shown to be 
a reliable predictor oflong-term mortality in patients who have not undergone early invasive treatment 1-5• 
Currently, patients with multivessel coronary disease account for a significant proportion of patients 
undergoing invasive procedures 6. Although a high likelihood of procedural success can be expected 7-13, 
neither percutaneous nor surgical approaches have been shown to decrease the long-term risk of 
multivessel disease to the level of risk associated with less severe disease stages (i.e. single-vessel disease) 
2
•
3
• Despite reducing ischemia-related symptoms, myocardial revascularization techniques do not delay the 
underlying pathophysiological processes involved in atherosclerotic disease progression. 
Long-term administration ofHMG-CoA reductase inhibitors (statins) is established as an effective means 
of reducing the incidence of cardiovascular complications, especially in patients with higher individual 
baseline risk 14-18• In the recent randomized Lescol Intervention Prevention Study (LIPS), long-term 
fluvastatin significantly reduced the incidence adverse events in patients with coronary atherosclerotic 
disease treated with percutaneous intervention 18 . The present study constitutes a prespecified, post-hoc 
analysis of the LIPS trial and aimed to evaluate the impact of the extent of coronary disease and of 
fluvastatin treatment on the incidence of late cardiac atherosclerotic complications. 
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METHODS 
Study Design and Patient Population 
The study design and primary results of LIPS have been described elsewhere 18'19 . Briefly, LIPS was a 
prospective, multinational, placebo-controlled, double-blind trial in which patients were randomized to 
receive either fluvastatin (Lescol, Novartis Pharma AG, Basel, Switzerland) 40 mg twice per day or 
placebo. Study medication was administered for at least 3 years, but no longer than 4 years, and dietary 
and lifestyle counseling was given to all patients. 
Patients who had undergone a first successful PCI (angiographic residual stenosis< 50% and absence of 
post-procedure in-hospital myocardial necrosis, repeat target lesion revascularization, or death) were 
considered eligible for the study. At eurollment, patients had not received lipid-lowering therapy in the 
preceding 6 weeks and fulfilled one of the following baseline lipid profile criteria: 1) total cholesterol 
between 135 mg/dl (3.5 mmol/1) and 270 mg/dl (7.0 mmol/1) with fasting triglycerides < 400 mg/dl (4.5 
mmol/1), 2) total cholesterol < 212 mg/dl (5.5 mmol/1) for patients whose lipids levels were measured 
between 24 hours and 4 weeks after an episode of myocardial infarction, or 3) total cholesterol < 232 
mg/dl (6.0 mmol/1) for patients with diabetes mellitus. Local investigators were blinded to the results of 
the biochemical analysis, unless total cholesterol levels were> 278 mg/dl (7.2 mmol/1). If total cholesterol 
values remained above this level for more than 3 months, open-label statin treatment or other interventions 
could be administered. All blood analyses were performed at a central laboratory (Analytico Medinet, 
Breda, The Netherlands). 
Patients were divided into two groups (single-vessel or multivessel) based on the extent of coronary 
disease, which was evaluated in the baseline pre-procedure angiogram 5• Single-vessel disease was 
diagnosed if significant luminal stenosis (> 50% diameter stenosis by visual analysis) was restricted to one 
vessel territory. Patients were included in the multivessel group if obstructive lesions were identified in 
two or three vessel territories. The actual number of treated lesions as well as the choice of the 
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interventional strategy was left to the discretion of the operator. The study protocol is in accordance with 
the Declaration of Helsinki and was approved by local ethics committees. All patients gave informed 
written consent. 
Follow-up and Clinical Endpoints 
In this substudy, outcomes were evaluated as the incidence of atherosclerosis-related adverse cardiac 
events, defmed as: 1) cardiac death, 2) non-fatal myocardial infarction (new pathological Q-waves or a 
total CPK level greater than twice the normal upper limit with presence of CPK-isoenzyme MB), or 3) all 
new revascularizations (either surgical or percutaneous) not caused by the occurrence of coronary 
restenosis. Atherosclerosis-related adverse cardiac events were a pre-defined endpoint of LIPS 18,~ 9 , and 
was specified due to the fact that the benefits of fluvastatin after PCI have been previously shown to be 
unrelated to any effect of the drug on restenosis 20• 
Statistical Analysis 
All analyses were carried out on an intention-to-treat basis. Continuous variables were expressed as mean 
± SD and were compared using Student's unpaired t-test. Fisher's exact test was used for categorical 
variables, and Wilcoxon scores were used for categorical variables with an ordinal scale. Discrete variables 
were expressed as counts and percentages and were compared in terms of relative risks (for multivessel 
disease compared with single-vessel disease) with 95% CI. All statistical tests were 2-tailed. Event-free 
survival distribution was estimated according to the Kaplan-Meier method, and the overall incidence of 
cardiac events was tested using the log-rank test. Patients lost to follow-up were considered at risk until the 
date of last contact, at which point they were censored. The Cox proportional hazards model and the 
Cochran-Mantel-Haenszel test were used to assess risk reduction and to compare the incidences of the 
primary and secondary clinical endpoints, respectively. 
The treatrnent/multivessel disease interaction was calculated in a multivariate approach with treatment, 
extent of multivessel disease, and an interaction factor specifying the simultaneous absence or presence of 
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both previous factors in the model. This enabled calculation of the effect of fluvastatin in patients without 
multivessel disease (i.e. single-vessel) separately from the effect in patients with multivessel disease. This 
approach also allowed calculation of the effect of disease extent in patients treated with placebo or 
fluvastatin. Lipid profiles were analyzed in an analysis of covariance model incorporating the baseline (at 
visit 1) as covariate, and adding as factors, treatment, visit number (visits > 1) and subgroup with all 
possible interaction terms. 
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RESULTS 
Patient Population and Baseline Characteristics 
Between April 1996 and October 1998, a total of 1677 patients were enrolled in LIPS. Of these, 1063 
patients (63.4%) had single-vessel disease (541 randomized to placebo and 522 to fluvastatin treatment) 
and 614 patients (36.6%) had multivessel disease (292 randomized to placebo and 322 to fluvastatin 
treatment). 
Patient characteristics, subdivided according to the coronary disease pattern and allocated treatment, are 
shown in Table 1. Several differences were observed between patients with single- and multivessel disease 
(pooled over treatment groups). Patients with multivessel disease were more likely to be older, and to have 
suffered previous myocardial infarction, peripheral vascular disease and stroke. Patients with multivessel 
disease were also less likely to be current smokers, and showed ejection fractions that were slightly, but 
significantly, reduced. Treated vessels differed between single- and multivessel patients. The right 
coronary artery and the left circumflex were treated more frequently in patients with multivessel disease, 
while the left anterior descending artery was more frequently treated in patients with single-vessel disease. 
The number of lesions treated in the index procedure was higher in the multivessel group; two or more 
lesions were dilated in 42.5% of multivessel patients and in 14.2% of single-vessel patients (p<O.OOl). 
Baseline characteristics did not differ between the fluvastatin and placebo groups (pooled over the single-
vessel and multivessel groups) with the exception of weight, which was higher in fluvastatin-treated 
patients. A higher prevalence of diabetes was observed in multivessel patients treated with fluvastatin than 
those treated with placebo. 
Long-term Atherosclerosis-Related Adverse Cardiac Events 
Fluvastatin treatment significantly reduced the risk of coronary atherosclerotic events by 43% compared 
with placebo in patients with multivessel disease (17. 7% vs 29.5%, respectively; RR 0.57 [95% CI: 0.41 -
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0.81]; p=0.002) (Table 2). The benefit offluvastatin treatment in single-vessel patients (14.9% vs 18.7% 
in single-vessel with placebo; RR 0.75 [95% CI: 0.56 - 0.01 ]; p=0.057) was not significantly different 
from the benefit observed in patients with multivessel disease (treatment/disease interaction: p=0.25) 
(Table 2). 
In patients receiving placebo, the presence of multivessel disease significantly increased the risk of cardiac 
events compared with patients with single-vessel disease (RR 1.67 [95% CI: 1.24- 2.25]; p<O.OOl) (Table 
2 and Figure 1). After treatment with fluvastatin, however, no significant difference in outcomes between 
patients with multivessel or single-vessel disease was observed (RR 1.28 [95% CI: 0.90- 1.81]; p=0.168) 
(Table 2). As shown in Figure 1, multivessel and single-vessel disease patients treated with fluvastatin 
showed similar curves for survival free of cardiac events after 4 years of follow-up (p=O.l9 by log-rank 
test). 
A multivariate Cox proportional hazards analysis was performed to determine whether the severity of 
coronary disease could independently predict the incidence of long-term coronary atherosclerotic events. 
Additionally, separate analyses were performed in order to identify the predictors in patients randomized 
to placebo or fluvastatin (Figure 2). The fmal multivariate model for the entire patient population included 
the following variables: fluvastatin treatment, diabetes, multivessel disease, number of stents implanted, 
and calculated creatinine clearance (logarithmic transformation) 21 . Similarly, when the analysis was 
restricted only to patients in the placebo group, the presence of multivessel disease independently 
predicted the occurrence of long-term coronary atherosclerotic events. In patients treated with fluvastatin, 
however, multivessel disease did not influence the risk of future cardiac events (Figure 2). 
Lipoprotein Levels 
There were no differences in baseline blood lipid levels between individual groups (Table 1 ). By 6 weeks, 
fluvastatin significantly reduced LDL cholesterol levels compared with placebo in patients with both 
single-vessel disease (median change with fluvastatin, -28.2% [95% CI: -30.3% - -25.8%] vs +10.2% 
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[95% CI: +8.1%- +13.5%]; p<O.OOl), and with multivessel disease (median change with fluvastatin,-
25% [95% CI: -28.3%--22.7%] vs +12.5% [95% CI: +9.1% -+16.7%]; p<O.OOl). The reduction inLDL 
cholesterol levels produced by fluvastatin was maintained throughout the study and was of similar 
magnitude in patients with single- and multivessel disease (Figure 3). 
HDL cholesterol levels increased by a median of 11.1 %, regardless of treatment or coronary disease 
pattern. By 6 weeks, fluvastatin produced a significant decrease in triglycerides compared with placebo in 
patients with single-vessel disease (median change with fluvastatin -14.3% [95% CI: -17.9%--11.1 %] vs 
0% [95% CI: -3.7%- +5.6%]; p<O.OOl). A similar reduction was observed in patients with multivessel 
disease (median change with fluvastatin -17.2% [95% CI: -23.5%- -10%] vs 0% [95% CI: -4.3%-
+4.8%]; p<O.OOl). By the end of the study, however, triglyceride levels were similar regardless of 
allocated treatment or coronary disease pattern. 
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DISCUSSION 
The results of the present study show that long-tenn fluvastatin effectively eliminated the negative effect 
of multivessel disease on the incidence of future coronary atherosclerotic events after percutaneous 
intervention. Although the presence of multivessel disease significantly and independently increased the 
rates of adverse events among patients treated with placebo, patients with multivessel disease receiving 
fluvastatin presented similar outcomes during the 4-year follow-up period as compared with patients with 
single-vessel disease. 
Fluvastatin Effect on Atherosclerotic Disease Progression 
The extent of atherosclerotic disease, both coronary and at extra-cardiac sites, has been recognized as a 
powerful predictor of cardiovascular events, especially during long-tenn follow-up 1·5•22·24. Indeed, the 
presence of multivessel disease and other well-known clinical risk factors, such as diabetes and 
hypercholesterolemia, were demonstrated to be the only predictors of 20-year survival in patients with 
coronary heart disease 2, with no influence of the type of initial revascularization strategy employed, 
whether surgical or percutaneous 2• These findings demonstrate the critical importance of the underlying 
chronic disease progression, which is not affected by current invasive treatments. In the present study, 
patients with multivessel disease treated with fluvastatin showed a flattened curve for survival free of 
events beyond 1 year, in clear contrast to the placebo group, which showed a persistent occurrence of 
events throughout the follow-up period. Indeed, fluvastatin virtually equalized the long-tenn outcomes of 
multivessel and single-vessel patients. These favorable clinical effects may be due to an effective, 
sustained action of fluvastatin on atherosclerotic disease stabilization. Importantly, these fmdings were 
observed in a study population with average baseline lipid levels. Nevertheless, fluvastatin treatment was 
associated with a significant reduction in blood cholesterol that was maintained during the entire study 
period, with no significant differences between patients with single- or multivessel disease. 
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Repeat Revascu/arization 
The need for subsequent repeat revascularization has been recognized as the main limitation of 
percutaneous procedures in the treatment of multivessel disease, and this complication has been only 
partially overcome by the use of coronary stent implantation ID-!3,25 • However, drug-eluting stents have 
been proven to strikingly decrease the incidence of restenosis 26·27. Although it has not yet been tested in 
patients with multivessel disease, this new therapy is expected to decrease the rate of target lesion 
revascularization after PCI to levels observed in surgical patients. Therefore, in this 'restenosis-free' 
context, the implementation of disease-modifying measures to reduce cardiac events related to the 
atherosclerotic disease process itself (i.e. non restenosis-related complications) becomes the major focus 
of medical attention after percutaneous interventions. In light of the marked clinical benefit observed in 
our study, long-term fluvastatin treatment can clearly be considered to be an important measure in the 
post-procedure management following PCI. Both patients with single- or multivessel disease were shown 
to benefit from fluvastatin treatment, which essentially equalized the long-term clinical outcome of the 
two patient groups. To the best of our knowledge, this is the first report to evaluate the relative impact of 
the angiographic extent of coronary disease on the long-term incidence of atherosclerotic complications in 
patients treated with statins. 
Study Limitations 
The findings of this study cannot be extrapolated to all patients undergoing PCI because only patients who 
had undergone a successful procedure were considered for enrollment. The present investigation also 
suffers from the inherent limitations of subgroup analysis, namely a lack of statistical power due to limited 
sample sizes. In addition, coronary angiograms were analyzed locally, rather than at a central angiographic 
laboratory. The fact that the extent of coronary artery disease was evaluated by angiography may lead to 
an underestimate of the actual atherosclerotic burden 28; nevertheless, angiography alone has been 
extensively demonstrated to be one of the most powerful predictors oflong-term outcomes in patients with 
coronary artery disease. Indeed, in the present study, angiographic characterization was able to distinguish 
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effectively between patients at two different risk levels (single- or multivessel disease) among those 
treated with placebo. 
Conclusions 
Fluvastatin represents an effective therapeutic measure to reduce the occurrence of late cardiac 
atherosclerotic adverse events after percutaneous coronary interventions. During a 4-year follow-up 
period, fluvastatin reduced the risk of patients with multivessel disease to the level of those with single-
vessel disease. 
258 
Fluvastatin reduces cardiac risk in multivessel patients 
References 
1. Keelan PC, Bielak LF, Ashai K, et al. Long-term prognostic value of coronary calcification detected 
by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 
2001; 104:412-7. 
2. van Domburg RT, Foley DP, Breeman A, et al. Coronary artery bypass graft surgery and 
percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur Heart J. 
2002;23 :543-9. 
3. Hannan EL, Racz MJ, McCallister BD, et al. A comparison of three-year survival after coronary 
artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 
1999;33:63-72. 
4. Marie PY, Danchin N, Durand JF, et al. Long-term prediction of major ischemic events by exercise 
thallium-201 single-photon emission computed tomography. Incremental prognostic value compared 
with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol. 
1995;26:879-86. 
5. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery 
disease from the Coronary Artery Surgery Study (CASS). J Clin Invest. 1983;71:1854-66. 
6. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era 
compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 
2000; 102:2945-51. 
7. Komowski R, Mehran R, Satler LF, et al. Procedural results and late clinical outcomes following 
multivessel coronary stenting. JAm Coll Cardiol. 1999;33:420-6. 
8. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice of percutaneous coronary 
intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute 
(NHLBI) Dynamic Registry. Am J Cardiol. 2001;87:964-9; A3-4. 
259 
Chapter 7 7 
9. Smith SC, Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary 
interventions (revision of the 1993 PTCA guidelines. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 
1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 
200 1 ;3 7:223 9i-lxvi. 
10. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in 
patients with multivessel coronary artery disease (the Stentor Surgery trial): a randomised controlled 
trial. Lancet. 2002;360:965-70. 
11. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for 
the treatment of multivessel disease. N Engl J Med. 2001;344:1117-24. 
12. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with 
Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-
day and one-year follow-up results. ERACI II Investigators. JAm Coll Cardiol. 2001;37:51-8. 
13. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery 
bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for 
adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of 
Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality 
Evaluation (AWESOME). JAm Coll Cardiol. 2001;38:143-9. 
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease 
and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57. 
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the 
Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. 
16. MRC/BHF Heart Protection Study of cholesterol lowering with sirnvastatin in 20,536 high-risk 
individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. 
260 
F/uvastatin reduces cardiac risk in multivesse/ patients 
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial 
infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial 
investigators. N Engl J Med. 1996;335:1001-9. 
18. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following 
successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 
2002;287:3215-22. 
19. Serruys PW, De Feyter PJ, Benghozi R, et al. The Lescol(R) Intervention Prevention Study (LIPS): a 
double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after 
successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent. 
2001;4:165-172. 
20. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for 
prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin 
angiographic restenosis (FLARE) trial. Eur Heart J. 1999;20:58-69. 
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 
1976;16:31-41. 
22. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in 
predicting clinical coronary events. Ann Intern Med. 1998;128:262-9. 
23. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor 
for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative 
Research Group. N Engl J Med. 1999;340: 14-22. 
24. Davila-Roman VG, Murphy SF, Nickerson NJ, et al. Atherosclerosis of the ascending aorta is an 
independent predictor of long-term neurologic events and mortality. J Am Coll Cardiol. 
1999;33:1308-16. 
25. King SB, 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus 
Surgery Trial (EAST). JAm Coll Cardiol. 2000;35:1116-21. 
261 
Chapter 7 7 
26. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with 
a standard stent for coronary revascularization. N Engl J Med. 2002;346: 1773-80. 
27. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after 
sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and 
intravascular ultrasound follow-up. Circulation. 2002; 106:1610-3. 
28. Mintz GS, Painter JA, Pichard AD, et al. Atherosclerosis in angiographically "normal" coronary 
artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coli 
Cardiol. 1995;25:1479-85. 
262 
Fluvastatin reduces cardiac risk in multivessel patients 
Table 1 ~Baseline patient characteristics according to coronary disease pattern and treatment 
Single-vessel disease Multivessel disease 
····- ·--------------·----·--
·· Placebo (n,;:i92) --------------Placebo (n~541) Fluvastatin (n~522) Fluvastatin (n~322) p 
value* 
Age. y± SD 58.9 ± 10.1 59.4± 10.4 61.9 ± 9.0 61.0±9.7 <0.01 
Male sex, n (%) 454 (83.9) 431 (82.6) 241 (82.5) 280 (87.0) 0.39 
Height, em± SD 169±8 170±9 168±9 170±8 0.13 
Weight. kg± SD j· 75.5 ± 11.5 77.1 ± 11.6 75.9 ± 11.2 77.3 ± 11.1 0.55 
Risk factors and cardiovascular 
antecedents 
Previous MI. n (%) 219 (40.5) 203 (38.9) 154 (52.7) 168 (52.2) <0.01 
Diabetes. n (%) t 52 (9.6) 64 (12.3) 30 (10.3) 56 (17.4) 0.06 
Hypertension. n (%) 192 (35.5) 202 (38.7) 125 (42.8) 128 (39.8) 0.09 
Previous stroke, n (%) 12(2.2) 8 (1.5) 15 (5.1) 9 (2.8) 0.01 
Peripheral vascular disease, n (%) 31 (5.7) 20 (3.8) 26 (8.9) 30 (9.3) <0.01 
Current smoker, n (%) 160 (29.6) 140 (26.8) 75 (25.7) 71 (22.0) 0.05 
Family history of CAD, n (%) 157 (29.2) 151 (29.2) 94 (32.3) 88 (27.5) 0.79 
Ejection fraction, % ± SD 62.1 ± 11.2 63.0 ± 11.6 61.2± 13.2 61.0 ± 12.4 0.03 
Clinical presentation 
stable angina, n (%) § 267 (49.8) 248 (47.9) 149 (51.9) 170 (53.5) 0.13 
unstable angina. n (%) 269 (50.2) 269 (52.0) 138 (48.1) 148 (46.5) 0.13 
Number of segments with 1.2±0.5 1.2 ± 0.5 2.8± 1.0 2.8± 1.0 <0.01 
significunt stenosis 
Treated vessel 
RCA,n(%) 165 (26.0) 169 (28.0) 145 (32.3) 177 (32.9) <0.01 
LAD,n(%) 346 (56.2) 310 (51.4) 179 (39.9) 214 (39.8) <0.01 
LCx.n(%) 113 (17.8) 123 (20.4) 124 (27.6) 147 (27.3) <0.01 
2 or more lesions treated. n (%) 79 (14.6) 72 (13.8) 115 (39.4) 146 (45.3) <0.01 
Lesions treated per patient(± SD) 1.2 ± 0.4 1.2 ± 0.4 1.5±0.8 1.7±0.9 <0.01 
Lesions treated with stent, n (%) 359 (56.6) 350 (58.0) 239 (53.2) 289 (53.7) 0.07 
263 
Chapter 7 7 
Lipids, mg/dl ± SD [mmolll ± SD] 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
Triglycerides 
199.5±32.9 [5.16±0.85] 199.9±32.9 [5.17±0.85] 
131.5±30.5 [3.40±0.79] 133.8±30.5 [3.46±0.79] 
37.5±12.0 [0.97±0.31] 36.7±10.8 [0.95±0.28] 
154.0±67.3 [1.74±0.76] 151.3±56.6 [1.71±0.64] 
200.7±31.3 [5.19±0.81] 199.5±30.5 [5.16±0.79] 0.90 
131.9±28.6 [3.41±0.74] 132.3±29.4 [3.42±0.76] 0.43 
37.9±11.2 [0.98±0.29] 37.9±13.1 [0.98±0.34] 0.57 
157.5±70.0 [1.78±0.79] 151.3±6.4 [1.71±0.75] 0.20 
SD - standard deviation; CAD- coronary atherosclerotic disease; RCA- right coronary artery; LAD- left anterior descending; LCx -left 
circumflex artery 
*Related to the comparison between the single-vessel and multivessel groups, regardless of treatment allocation. 
t p ~ 0.006 for difference between placebo vs fluvastatin treatments pooled over single- and multivessel groups. 
t p ~ 0.01 for the difference between placebo vs fluvastatin in the multi vessel group 
§ Includes patients with silent ischemia 
Table 2. Incidence and relative risks of adverse atherosclerotic events at follow-up according to coronary disease extent at baseline and allocated 
treatment. 
Relative Risks of atherosclerosis-related adverse cardiac events* 
Fluvastatin effect on patients with multi vessel disease 
Fluvastatin effect on patients with single-vessel disease 
Effect of CAD extension (single- vs multivessel disease) on patients with fluvastatin 
Effect of CAD extension (single- vs multivessel disease) on patients with placebo 
Treatment/Disease interaction t 
CAD-coronary artery disease 
RR 0.57 (95% CI: 0.41- 0.81); p-0.002 
RR 0.75 (95% Cl: 0.56- 1.01); p~0.057 
RR 1.28 (95% CI: 0.90- 1.81); p~O.l68 
RR 1.67 (95% CI: 1.24- 2.25); p<O.OOl 
RR 0.88 (95% CI: 0.70- 1.10); p~0.252 
* cardiac death, non-fatal myocardial infarction, andre-interventions not related to restenosis. Relative risks derived from the Cox proportional 
hazards analysis. 
t The treatment/disease interaction reflects the effect offluvastatin treatment in the multivessel group relative to the treatment effect in the single-
vessel group 
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Figure 1. Cumulative curves for survival free atherosclerosis-related adverse cardiac events in patients 
with either single- or multivessel disease randomized to receive treatment with placebo (upper graph) or 
fluvastatin (lower graph). Event-free survival distribution was estimated as described in the text, and p 
values were obtained from the log-rank test. 
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All patients 
Fluvastatin treatment 
(HR 0.66 [95% Cl 0.52-D.83]) 
Diabetes (HR 1.57 [95% Cl1.14-2.16]) 
Number of stents implanted 
(HR 1.25 [95% Cl1.04-1.51]) 
Multivessel disease 
(HR 1.3395% Cl1.04-1.69]) 
Calculated creatinine clearance 
(HR 0.63 [95% Cl 0.42-D.95]) 
Patients allocated to placebo 
Mu~ivessel disease 
(HR 1.41 [95% Cl1.02-1.96]) 
Patients treated with fluvastatin 
Multivessel disease 
(HR 1.1295% Cl 0.76-1.66]) 
0 
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---, 
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Relative risk 
Figure 2. Relative risks and 95% confidence intervals of independent predictors for atherosclerosis-related 
adverse cardiac events in all patients (upper). Also the relative risks and 95% confidence intervals for the 
presence of multivessel disease is shown for patients randomized to placebo (mid) or fluvastatin (lower). 
Relative risks were calculated according to a multivariate Cox proportional hazards analysis, as described 
in the text NS, not significant. A logarithmic transformation was used for the calculated creatinine 
clearances. I 
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Figure 3. Mean change in LDL cholesterol levels (mg/dl) throughout follow-up in patients with either 
single- or multivessel disease randomized to receive treatment with either fluvastatin, 40 mg twice daily or 
placebo. 
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Summary and Conclusions 
Coronary revascularization with percutaneous coronary intervention or coronary artery bypass 
graft surgery is used for the treatment of obstructive coronary atherosclerosis in symptomatic 
patients. In this thesis, we evaluated the results obtained after coronary revascularization in 
different subsets of patients. 
Part 1: Clinical trials and observational studies on coronary revascularization 
The concept of plaque sealing by balloon angioplasty for mild lesions at strategically 
important sites (proximal locations in large vessels) has been proposed to prevent acute 
coronary events in patients with angiographically non-significant coronary lesions1. The 
hypothetical clinical benefit of reducing the risk of subsequent thrombotic occlusions thanks 
to the neoendothelium overgrowing the inflicted wound has not yet been prospectively 
validated. In chapter 1, we investigated the clinical and angiographic outcome of patients 
with chronic stable angina and a single de novo lesion, categorized in 3 groups based on the 
angiographic degree of stenosis severity prior to percutaneous coronary intervention (<50%, 
50%-99% and >99% pre-procedural diameter stenosis). The one-year mortality and rate of 
non-fatal myocardial infarction did not differ between balloon and stented angioplasty for any 
of the stenosis severity categories. These results argue against the performance of PCI on 
angiographically non-significant stenoses because the relatively high one-year event rates 
outweigh any hypothetical long-term benefit that might be derived from this type of 
intervention. 
In Chapter 2, we examined the clinical outcome of patients with multivessel disease 
undergoing coronary revascularization with either percutaneous coronary intervention with 
multiple stenting or bypass surgery. After one year of follow-up, 8.7% of 1518 patients 
randomized to coronary stenting versus 9.1% of 1533 patients randomized to bypass surgery 
reached the primary clinical endpoint of death, nonfatal myocardial infarction or stroke 
(Hazard Ratio=0.95; 95%CI 0.74-1.23). Mortality was also similar in both groups (3.0% vs. 
2.8%, HR=1.02; 95%CI 0.64-1.60). In contrast, repeat revascularization procedures occurred 
more frequently in the coronary stenting as compared to the bypass surgery group (18% vs. 
4.4%, HR=4.4; 95%CI 3.3-5.9). In summary, coronary stenting could provide a similar on-
year clinical outcome for patients with multivessel coronary artery disease as bypass surgery, 
albeit at the cost of more repeat revascularization procedures. 
In Chapter 3 of this thesis, we described the evolutionary changes that have taken place in 
the field of coronary revascularization over the past decades. In the early days, both balloon 
angioplasty and bypass surgery were applied to patients who were significantly symptomatic, 
had documented myocardial ischemia and had predominantly single-vessel disease with 
discrete stenosis. By the late 1980s, a number of studies comparing balloon angioplasty to 
bypass surgery in patients with multivessel coronary artery disease were underway. The 
lessons learned from these trials are delineated in this chapter and complemented with the 
lessons from the second-generation trials that compared coronary stenting versus bypass 
surgery in patients with multivessel disease. In general, these studies found a similar 
prognosis and symptomatic relief for the two initial revascularization strategies (Balloon 
angioplasty or bypass surgery). Documented differences between the two procedures included 
a lower rate of repeat revascularization in patients initially treated with bypass surgery. 
However, the widespread use of coronary stenting had significantly decreased the need for 
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emergency bypass surgery to approximately 1% among patients treated with percutaneous 
coronary intervention. The observed gap between bypass surgery and percutaneous coronary 
intervention in terms of major adverse cardiac and cerebral events at one-year, has narrowed 
from 32% reported in the pre-stent era2 to 11% in the stent era. This gap could continue to 
narrow with the newly introduced drug-eluting stents that have been shown to remarkably 
reduce restenosis and repeat revascularization rates3. Preliminary data from the RESEARCH 
(Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) registry4 have shown 
a 91.2% 6-month major adverse cardiac and cerebral events free survival in 307 consecutive 
patients with multivessel disease treated with sirolimus-eluting stents compared to 81.4% in 
427 patients treated with bare metal stents (p<0.01). In this scenario, the adoption of measures 
aiming to modify the natural course of the atherosclerotic disease itself (i.e. non restenosis-
related complications) becomes the main focus of attention after percutaneous or surgical 
treatment of multi vessel disease. In this regard, statins could decrease peri operative mortality5 
and reduce the risk of coronary atherosclerotic events in patients undergoing percutaneous 
. . 6 
coronary rnterventwn . 
Results of randomized trials on the survival benefits of early revascularization after acute 
coronary syndromes have yielded inconsistent in regard to whether an early invasive strategy 
is associated with better clinical outcomes compared to a conservative non-invasive strategy. 
In Chapter 4, we describe the 6-month clinical outcome of patients with multivessel CAD 
presenting with an acute coronary syndrome and complete angiographic data enrolled in 
PURSUIT (Platelet Glycoprotein lib/Ilia in Unstable Angina: Receptor Supression Using 
Integrilin Therapy) stratified according to the treatment strategy applied early during 
hospitalization (Medical treatment- PCI (Balloon) - PCI (Stent) -CABO). The mortality rate 
at 30 days was 6.7%, 3.9%, 2.4% and 4.8% for medical treatment, PCI (Balloon), PCI (Stent) 
and CABO groups, respectively (p=0.002). Differences as observed at 30 days were still 
present at 6-month follow-up with 11.1 %, 5.8%, 5.5% and 6.5% mortality rates for the 
aforementioned groups (p=0.002). The 30-day MI rate was lower among medically than non-
medically treated patients, with the highest event rate observed in the CABO group (27.7%). 
Approximately half of the Mls in the PCI and CABO subgroups occurred within 48 hours 
after the procedure. Differences in event rates as observed at 30 days were still present at 6-
month follow-up. The differences in clinical outcomes in this study are in accordance to those 
from the FRISC-II7 trials, in which an early invasive strategy was associated with a survival 
benefit. On the other hand, in TACTICS-TIM! 188 and TIMI-IIIB9 studies, mortality was 
similar irrespective of whether revascularization was undertaken or not. The benefits of an 
invasive strategy may have been diluted in these studies by events occurring in patients 
allocated to an invasive strategy without or awaiting revascularization or by a crossover from 
the non-invasive to the invasive group, as in 36% in TACTICS-TIM! 18 and 37% in TIMI-
IIIB. 
Part 2: Predictors of adverse angiographic and clinical outcome 
In Chapter 5, we carried out a comprehensive comparative analysis from the balloon to the 
stent era on demographic, clinical and quantitative coronary angiographic predictors of 
coronary restenosis in a total of9,120 treated lesions in 8,156 patients. 
The restenosis rate was 35% after balloon angioplasty and 19% after angioplasty with 
additional stenting. 
There were no major differences in demographic and clinical predictors of coronary restenosis 
between balloon angioplasty and stent populations. In the modem (stent) era, a severe pre-
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procedural diameter stenosis is no longer an unfavorable predictor of restenosis. Still 
important, but more so in the stent population, is a large post-procedural minimal luminal 
diameter (optimal result). Finally, a larger pre-procedural reference diameter became a 
favorable predictor with the advent of stenting. Patients treated with drug-eluting stent 
represent a distinctive population in which the results of our analyses may not be applicable. 
In Chapter 6, we evaluated the clinical outcome of patients with in-stent restenosis treated 
with 6 different interventional devices (Stent-in-stent, rotational atherectomy, balloon 
angioplasty, laser angioplasty, directional atherectomy and vascular brachytherapy). In more 
detail, we specifically pooled all the data available from radiation therapy for the treatment of 
in-stent restenosis. A pooled analysis from the~ trials (Beta WRIST, START 30, START 40 
and INHIBIT) showed a 33% relative reduction (RR) in MACE favoring brachytherapy. 
Similarly, a pooled analysis from they trials (SCRIPPS-2, WRIST, GAMMA-I, GAMMA-2, 
long WRIST, long WRIST high-dose and SVG WRIST) demonstrated a 36% RR and finally, 
when pooling the ~ and y trials, altogether, a 35% RR was exhibited. Finally, we described 
the encouraging results (9.8% major adverse cardiac event rate at one-year) obtained in the 
first 41 patients treated with sirolimus-eluting stents for in-stent restenosis. 
Currently-available data suggests that stent deployment decreases restenosis and cardiac event 
rates in diabetic patients. However, there is little data regarding the differences between those 
diabetics who develop restenosis following stent deployment and those who do not; whether 
diabetics are at higher risk owing to longer lesions, smaller vessel calibre and therefore higher 
restenosis rates or whether simply being diabetic adds a constant increment to restenosis risk 
to all patients, is unclear. In chapter 7, we analyzed the clinical and angiographic variables 
associated with restenosis in diabetic patients from a large cohort of studies. Restenosis 
occurred in 20.6% of non-diabetic and 31.1% of diabetic patients. Multivariate predictors 
associated with restenosis included only vessel reference diameter, stented length and a lower 
body mass index. Moreover, we developed reference charts that demonstrated that the 
incremental risk of restenosis was dependent solely on vessel reference diameter. 
Part 3: Special subgroups on coronary revascularization 
The impact of body mass index on the outcomes after coronary artery revascularization 
remains controversiaL In Chapter 8, we describe the influence of body mass index on the 
long-term outcomes in patients with multivessel coronary artery disease randomized to either 
multiple coronary stenting or coronary artery bypass graft surgery. Patients were divided in 
three groups: normal body mass index between 18.5 and 24.9, overweight with a body mass 
index between 25 and 30 and obese with a body mass index greater than 30. At three-years 
follow-up, the incidence of death or cerebrovascular events or myocardial infarction was 
similar for each one of the three body mass index categories, regardless the revascularization 
technique employed. Repeat revascularization procedures were significantly higher among 
patients randomized to stenting, but similar among the different body mass index groups. For 
patients randomized to bypass surgery, there was a non-significant trend towards lower repeat 
revascularization procedures in obese patients. Among patients who underwent multiple 
stenting, body mass index had no impact on the three-year combined endpoint of major 
adverse cardiac or cerebrovascular event rates. However, among patients who underwent 
bypass surgery, major adverse cardiac or cerebrovascular event rates were significantly lower 
for obese (11 %) or overweight (15%) patients compared to patients with a normal body mass 
index (23%)(p=0.012). 
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Summary and Conclusions 
Chronic renal insufficiency is associated with adverse outcomes after bypass surgery and 
percutaneous coronary intervention. In Chapter 9, we evaluated the effect of chronic renal 
insufficiency on outcomes after coronary revascularization and we compared the outcomes of 
patients with chronic renal insufficiency who were randomly assigned to bypass surgery or 
percutaneous coronary intervention. Of 1205 patients enrolled in the Arterial 
Revascularization Therapies Study (ARTS), 1176 (97%) had baseline creatinine data, among 
whom 290 (25%) had chronic renal insufficiency, defined by creatinine clearance 60 mVmin 
estimated by the Cockroft-Gault equation. The primary clinical endpoint was the composite of 
death, non-fatal myocardial infarction, or stroke; and, a secondary outcome was repeat 
revascularization. The primary outcome occurred in 18% of patients with chronic renal 
insufficiency and 10% of patients without chronic renal insufficiency at 3-years of follow-up 
(HR=l.61; 95%CI 1.10-2.35). Within the chronic renal insufficiency subgroup, no difference 
was observed in the primary endpoint after bypass surgery vs. percutaneous coronary 
intervention (HR=0.93; 95%CI 0.54-1.60). However, bypass surgery was associated with a 
reduced risk for repeat revascularization. (HR=0.28; 95%CI 0.14-0.54). In patients with 
multivessel coronary artery disease, chronic renal insufficiency is a risk factor for death, non-
fatal myocardial infarction, or stroke after coronary revascularization. These outcomes 
occurred at equal rates among chronic renal insufficiency patients treated with bypass surgery 
or percutaneous coronary intervention, but bypass surgery was associated with decreased 
repeat revascularizations. 
In Chapter 10, we assessed the effect of fluvastatin on the outcome of patients with or 
without renal dysfunction in the Lescol Intervention Prevention Study (LIPS). We also 
evaluated the effect of fluvastatin treatment on renal function and the relation between 
changes in renal function over time on the incidence of adverse cardiovascular events. 
Complete data for creatinine clearance calculation were available in 93% of the total 
population, who were randomised to fluvastatin (normal renal function, n=631; impaired renal 
function, n=150), or placebo (normal, n=617; impaired, n=160) following successful 
completion of a first percutaneous coronary intervention. Follow-up time was 3-4 years. The 
primary endpoint was survival time free of coronary atherosclerotic events (cardiac death, 
non-fatal myocardial infarction, and coronary reinterventions not related to restenosis). Renal 
impairment significantly increased the incidence of coronary atherosclerotic events in 
placebo-treated patients (Relative Risk=l.42; 95% CI 1.00-2.01). Among those treated with 
fluvastatin, however, no differences were observed between patients with and without renal 
impairment (RR=0.97; 95% CI 0.61-1.56). No further deterioration in creatinine clearance 
was observed during follow-up, regardless of baseline renal function or allocated treatment. 
The occurrence of adverse events was not related to changes in renal function during follow-
up. Fluvastatin treatment reduced the risk of coronary atherosclerotic events after 
percutaneous intervention in patients with mild renal impairment and this benefit was 
unrelated to any effect on renal function. 
Finally, in Chapter 11 we assessed the incidence of cardiac atherosclerotic events (cardiac 
death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) 
in patients with single-vessel and multivessel disease randomized fluvastatin (40 mg bid) or 
placebo for at least 3 years following a first successful percutaneous coronary intervention in 
the Lescol Intervention Prevention Study (LIPS). In patients allocated to placebo, the presence 
of multivessel disease was associated with a significantly higher rate of cardiac atherosclerotic 
events compared with single-vessel disease (Relative Risk=l.67; 95% CI 1.24--2.25). 
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Summary and Conclusions 
However, patients with multivessel or single-vessel disease treated with fluvastatin presented 
similar long-term outcomes (RR=l.28; 95% CI 0.90-1.81). The long-term treatment with 
fluvastatin after percutaneous intervention reduced the risk of patients with multivessel 
disease to the level of those with single-vessel disease. 
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